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ABSTRACT 
 
As the HIV/AIDS epidemic has entered the third decade, a gap remains regarding the uniqueness 
of women with disease. Although the course of HIV disease management has changed with the 
development of antiretroviral medications women were not initially in these medication trials. 
Therefore, much of what is known regarding women’s adherence to these medications has been 
based upon research and clinical trials with HIV positive men. The purpose of this research was 
to examine selected psychological factors (depressive symptomatology, social support, and 
perceived stigma) and selected physiological factors (CD-4, viral load, HIV disease symptoms, 
and physical well-being) as predictors of self-reported adherence among women with HIV who 
were prescribed antiretroviral medications. In addition, this study examined the mediating effect 
of self-efficacy on the relationships between the selected psychological and physiological 
variables and self-reported adherence to antiretroviral medications.  
This convenience sample consisted of 44 HIV positive women. White subjects (55%) 
were women living in rural areas of eastern Ohio or western Pennsylvania. Approximately 80% 
of the women had a high school education or its equivalent; 30% of the women were married or 
in a significant relationship, 80% of the women reported their insurance as coming from public 
assistance, and most identified her disease exposure as being through heterosexual contact. 
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Standard measures were used for data collection and a demographic measure.  Within the 
larger study, a sample of ten women used the electronic event monitor (MEMS cap) for a period 
of 29 days. There were significant relationships between depressive symptomatology, perceived 
stigma, CD 4, HIV disease symptoms, and self-reported adherence. Self-efficacy beliefs had a 
mediating effect for depressive symptoms and CD 4 and self-reported adherence to antiretroviral 
medications.  This study is one of the first to explore the relationship between perceived stigma 
and self-reported adherence to antiretroviral medications in women. For this study, one’s self-
efficacy beliefs mediated self-reported adherence to antiretroviral medications for women with 
depressive symptomatology.  
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1.0  CHAPTER ONE 
1.1 SIGNIFICANCE 
As the Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome 
(AIDS) epidemic has entered the third decade, health care providers and researchers have not 
completely grasped the full impact of the disease for women or women’s unique issues in disease 
manifestation and disease management. Research has identified a lack of understanding among 
health care providers regarding the particular needs of women with HIV (Hudson, Kirksey, & 
Holzemer, 2004).  This is due in part to the failure of researchers to include women in clinical 
trials and the lack of funding to address unique and often-extreme conditions in which some of 
these women live (Bova, 2000; Liu et al., 2006).   
Research has shown that disease exposure is associated with risk taking behaviors, such 
as early sexual activity, multiple sex partners, unprotected sex, and drug and alcohol use 
(Diamond & Buskin, 2000; Lansky, Fleming, Byers, Karon, & Wortley, 2001). Females infected 
with HIV are three times more likely to engage in unprotected sex and to have had numerous sex 
partners compared to women who are not HIV-positive (Centers for Disease Control and 
Prevention [CDC], 2001a, 2004; Hader, Smith, Moore, & Holmberg, 2001).  Alcohol and/or 
drugs including intravenous drug use (IDU) have been identified as secondary causes of HIV 
through unprotected sex with a partner whose history includes IDU (Hader et al.; Israel, Romeis, 
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& Spitz, 2005). Approximately 79% of women with HIV report becoming infected from 
heterosexual contact or unknown exposure risk (CDC, 2004).  In addition, women are not always 
successful in negotiating safe-sex practices, which creates opportunities for infection (Israel et 
al.). Women who have HIV infected male partners are 17.5 times more likely to become infected 
from the disease than males who have HIV infected female partners (Abercrombie, 1996).  
Women may be more susceptible to HIV infection through heterosexual contact because there is 
a greater concentration of viral DNA in the semen of their male sex-partners (Hader et al.; 
Marlow, Ziskind, & Jones, 2000). 
The early manifestations of HIV infection occur within the first two weeks of exposure. 
During this time as the viral load is increasing, the person may complain of flu-like symptoms 
such as sore throat, fatigue, and nightsweats.  Women often ignore these symptoms because of 
more pressing issues including child care, home management, and meeting the basic needs of 
their children and themselves such as acquiring food, clothing, medication, and shelter 
(Abercrombie, 1996; Carey, Bratten, Jaworski, Durant, & Forsyth, 1999; Hudson et al., 2004 
Holzemer, 2004; Lehman-Trzynka & Erlen, 2004). Marginalized women with HIV often focus 
more on meeting their essential everyday needs rather than symptoms of illness (Abercrombie; 
Carey et al.; CDC, 2006; Greene, Frey, & Derlega, 2002; Hader et al., 2001; Simoni & 
Cooperman, 2000; Simoni & Ortiz, 2003). Regardless of the illness, women often ignore their 
symptoms and delay entry into treatment (Hader et al.). 
Late entry into treatment for  HIV  infection  may be  related  to  women’s  treatment for 
other infections such as candidiasis, human papillomavirus (HPV), or infections due to dramatic 
changes in CD 4. As candidiasis and/or HPV become more unmanageable, health care 
practitioners unfamiliar with the unique manifestations of HIV in women treat only the 
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candidiasis and not the underlying cause of the infection.  The result is that the CD 4 continues to 
decrease in these women and the risk of opportunistic infections increases; HIV disease 
progresses (Abercrombie, 1996; Tapper, Daar, Piliero, Smith, & Steinhart, 2005). 
Frequently women are not diagnosed with HIV until they require hospitalization  
or become pregnant (Abercrombie, 1996; Burpo, 2000; Hader et al., 2001; Hudson et al., 2004; 
Levine et al., 2001; Sowell, Moneyham, & Aranda-Naranjo, 1999).  The importance of 
diagnosing HIV in pregnant women became evident when in November 2001 the CDC made the 
following recommendations (CDC, 2001b, 2001c; 2002):   
• Provide HIV testing as a routine part of prenatal care for all pregnant women 
• Simplify the testing process so that pretest counseling is not a barrier to testing 
• Increase the flexibility of the consent process including oral and written informed 
consent 
• Explore and address reasons for refusal of testing 
• Emphasize HIV testing and treatment at the time of labor and delivery for women 
who have not received prenatal testing and prophylaxis (CDC, 2001b, 2001c). 
A 1999 CDC study examining the HIV testing practices of pregnant women in 14 states 
found the state-specific proportion of mothers who recalled discussing HIV testing with their 
prenatal health care provider ranged from 63.4% to 86.7%. The proportion of mothers who 
recalled being tested ranged from 58.0% to 80.7% (CDC, 1999a, 1999b).  In all 14 states Black 
women were significantly more likely than white or Latina expectant mothers to report that their 
provider discussed testing. In addition, in several states women with less than a high school 
education, less than 25 years of age, and receiving public health assistance (Medicaid) were more 
likely to have received some form of counseling for HIV testing during pregnancy (CDC, 
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1999b). While the issue of pregnancy and prenatal HIV disease management and care is beyond 
the scope of this study, the above information highlights some of the issues of sub-optimal 
medical management for women at risk for or diagnosed with HIV. 
Health care providers are aware of the factors causing lymphocyte depletion and  
HIV. Providers also are aware of the risk factors associated with disease exposure and the fact 
that the disease has no limitations or boundaries for men and women who are at risk. There are 
treatment regimens to manage and control disease; however, to enhance the effectiveness and 
efficacy of these regimens requires that treatment guidelines be followed (Yeni et al., 2004). 
Understanding the efficacy of the regimen requires monitoring individuals’ adherence to 
antiretroviral medications.  The focus on adherence to antiretrovirals centers around the fact that 
1) the virus has the potential to mutate and to change its genetic structure, 2) persons on 
antiretroviral medications may become resistant to current treatments due to viral mutation, and 
3) less than near perfect adherence increases the likelihood of both mutation and resistance. 
Although issues that may affect or predict medication adherence have been investigated for men 
with HIV, women, for the most part, have not been the focus in similar investigations. Findings 
from studies of antiretroviral medication adherence are providing some information about what 
issues contribute to non-adherence for men with HIV. Therefore, it is timely and important to 
investigate the issues that may influence antiretroviral adherence for women with HIV and to 
design interventions to address the identified predictors. 
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1.2 BACKGROUND OF THE PROBLEM 
Two  significant changes in  the  course of  HIV/AIDS since the  1990’s  are  the development of  
antiretroviral medications and the decrease in the rate of deaths from disease. There has been a 
14% decline in deaths from 1998 to 2002 and an 8% decline from 2000 to 2004 (CDC, 2004). 
There have been approximately 550,000 deaths of men, women, and children in the United 
States (US); 83,000 of those deaths have been women (CDC, 2004). HIV/AIDS is the fifth.  
 With the introduction of highly active antiretroviral therapy in 1995 there has been a 
marked decrease in morbidity and mortality related to HIV and AIDS disease.  Contrary to some 
beliefs, antiretroviral therapy does not promise a cure for HIV.  However, therapy does have the 
potential to reduce the plasma concentration of HIV RNA (or viral load) and increase the 
immune response as demonstrated by an improved CD 4 lymphocyte count (Yeni et al., 2002, 
2004).   The result of less HIV virus and an improved immune response decreases the 
individual’s risk of opportunistic infections and offers the hope and potential for disease survival 
(Liu et al., 2006). 
While the overall number of new cases of HIV/AIDS decreased in the US from  
2001 to 2003, there has been an increase of approximately 1% per year in new cases of HIV 
since that time (CDC, 2004). Women, especially Black (African American) and Latina (white 
Hispanic) continue to demonstrate a sizeable increase in number of newly diagnosed cases per 
year; 46% of all new cases of disease were among Black women (CDC, 2006).  The HIV 
surveillance report, which is now two years old, suggests that over one million people in the 
USA have been diagnosed with HIV and approximately 880,000 have been diagnosed with 
AIDS (CDC, 2004).  This same report estimates that approximately 41,000 new cases of HIV 
will be diagnosed annually in the USA with half of these newly diagnosed cases of disease being 
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persons (both males and females) under 25 years of age and from minority groups: Latinos, 
Blacks, and women (CDC, 2004).  
In 1999, the leading cause of death for men and  women ages 25 to 44  was AIDS (CDC,  
1999b). For Black women AIDS was the most frequent cause of death for persons 25 to 34 years 
of age.  Also, for Black women 21 to 24 and 35 to 44 years of age, AIDS is the fourth leading 
cause of death (CDC, 2006) and it is also the fourth leading cause of death for Latinas ages 35 to 
44 (CDC, 2006). Overall, AIDS is the most frequent cause of deaths in women (25 to 34 years of 
age). 
Of particular concern is the age of risk exposure of these women.  Females who are 13 to 
39 years of age continue to demonstrate the most significant increases of newly diagnosed cases 
of HIV (CDC, 2001a, 2006; Graham, 1997; Hader et al., 2001; Wortley & Fleming, 1997).  
Although white women remain in the majority of the female population in the USA, Black and 
Latina women account for approximately 80% of all cases of HIV/AIDS (CDC, 2006; Hader et 
al., 2001). A diagnosis of HIV/AIDS is 25 times more likely to occur in Black women than in 
their white peers and 4 times more likely for Latina women  than  white  women  (CDC, 2006).  
In  addition,  women  constitute  over  9,000 new  cases  of  HIV annually (CDC, 2004).  
Estimates are that approximately 100,000 women are currently living with the disease (CDC, 
2000, 2001a, 2004). The number of women with HIV has increased such that in 1987 only 
12.5% of all reported cases of HIV/AIDS were women (CDC, 1989). However, in 2000 women 
accounted for 22% of all new cases of disease (CDC, 2001a) and 27% of all cases by 2004 
(CDC, 2004). 
Summary of Medication Adherence. There is a paucity of research addressing adherence 
to antiretroviral medications among women with HIV especially in non-urban areas of the US. 
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The documented information regarding adherence to antiretroviral medications in women with 
HIV often has been generalized from previous research of men with disease and their medication 
adherence.  
In light of the potential for virus mutation, newly infected persons first need to have a 
virus resistance test prior to initiating an antiretroviral regimen (Little et al., 2002; Tapper et al., 
2005).  Tapper and colleagues (2005) recommend careful screening of the individual for life 
issues that may interfere with adherence. Screening should include assessment of the individual’s 
readiness to begin a life-long treatment plan, as well as the potential for side effects, the presence 
of co-morbidities such as diabetes, and consistent evaluation and monitoring of medication 
adherence.  
The measurement of one’s adherence to medications and/or treatment modalities, 
including lifestyle change is often subjectively approached using a variety of descriptive self-
report measures.  Although these self-report instruments are suggestive of one’s adherence, these 
measures are often subject to human error when reporting adherence.  Other more invasive 
methods of assessing adherence such as collecting blood samples increases the cost of the 
research and decreases subject participation (Paterson, Pitoski, & Capitano, 2002). Another 
method of evaluating medication adherence is through the use of electronic event monitors. 
However, these devices continue to have the potential for bias due to subject manipulation of 
their medications and/or the electronic equipment. 
Because HIV medication is pivotal to successful disease management there is a need for 
the individual to strive toward complete medication adherence. HIV medication regimens are 
continually being improved. These improvements are due to ongoing experimental research, 
introduction of new medications, patient use, side effects of medication use, the ability to 
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decrease dosing frequencies and the combination of medications into a single pill rather than 
multiple pills, and changes in disease management (Tapper et al., 2005). Designing appropriate 
interventions that will increase medication adherence in women with HIV requires an 
understanding of which factors influence adherence in this group of persons.  
1.3 PROBLEM STATEMENT 
The overall purpose of this research was to examine selected psychological factors (depressive 
symptomatology, social support, and perceived stigma) and selected physiological factors (CD 4, 
viral load, HIV disease symptoms, and physical well-being) that may be predictors of self-
reported adherence among women with HIV who were prescribed antiretroviral medications. 
The second purpose of this study was to examine the mediating effect of self-efficacy on the 
relationships between the selected psychological factors (depressive symptomatology, social 
support, and perceived stigma) and selected physiological factors (CD 4, viral load, HIV disease 
symptoms, and physical well-being) and self-reported adherence to antiretroviral medications. 
Therefore, the specific aims and hypotheses of this study were to: 
1. Describe overall patterns of self-reported adherence among women with HIV/AIDS 
prescribed antiretroviral medications.  
2. Describe the relationship between patterns of self-reported adherence and 
sociodemographic factors (age, education, race/ethnicity, marital status, and exposure 
risk category) among women with HIV/AIDS who were prescribed antiretroviral 
medications. 
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H2A: There is an association between patterns of self-reported adherence and 
sociodemographic factors (age, education, race/ethnicity, marital status, and 
exposure risk category) among women with HIV/AIDS who were prescribed 
antiretroviral medications. 
3. Examine the relationship between selected psychological factors (depressive 
symptomatology, social support, and perceived stigma) and self-reported adherence 
among women with HIV/AIDS who were prescribed antiretroviral medications. 
H3A: Women who report less depressive symptomatology will have better self- 
reported adherence to antiretroviral medications.   
H3B: Women who report strong social support will have better self-reported 
adherence to antiretroviral medications. 
H3C: Women who report less perceived stigma will have better self-reported 
adherence to antiretroviral medications. 
4. Examine the relationship between selected physiological factors (CD 4, viral load, 
HIV disease symptoms, and physical well-being) and self-reported adherence among 
women with HIV/AIDS who were prescribed antiretroviral medications. 
H4A: Women who report higher CD 4s and lower disease viral load will have better 
self-reported adherence to antiretroviral medications. 
H4B:  Women who report fewer HIV disease symptoms will have better self-reported 
adherence to antiretroviral medications. 
H4C: Women who report better physical well-being will have better self-reported 
adherence to antiretroviral medications. 
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5. Examine the mediating effect of self-efficacy on the relationships between selected 
psychological factors (depressive symptomatology, social support, and perceived 
stigma) and selected physiological factors (CD4, viral load, HIV disease symptoms, 
and physical well-being) and self-reported adherence among women with HIV/AIDS 
who were prescribed antiretroviral medications. 
H5A: Self-efficacy will mediate the relationship between selected psychological 
factors (depressive symptomatology, social support, and perceived stigma) and self-
reported adherence to antiretroviral medications among women with HIV/AIDS. 
H5B: Self-efficacy will mediate the relationship between selected physiological 
factors (CD 4, viral load, HIV disease symptoms, and physical well-being) and self-
reported adherence to antiretroviral medications among women with HIV/AIDS. 
6. Describe patterns of adherence in a subsample of women with HIV/AIDS who were 
prescribed antiretroviral medications as assessed by a self-reported instrument of 
adherence and as measured by the Medication Event Monitoring System (MEMS). 
1.4 DEFINITION OF TERMS 
1.4.1 Independent variables  
1.4.1.1 Depressive Symptomatology 
Depressive Symptomatology was the individual’s subjective perceptions of guilt and 
worthlessness, loss of appetite, sad mood, low energy, and sleep disturbances (Radloff, 1977). 
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The Center for Epidemiologic Studies-Depression Scale (CES-D) was used to measure 
depressive symptomatology (Radloff, 1977). 
1.4.1.2 Social Support 
Social Support was the resources that individuals have available to them through 
interpersonal relationships (Cohen & Syme, 1985). Social support was measured by using the 
Interpersonal Support Evaluation List (ISEL) that assesses the individual’s perceived available 
overall resources for social support (Cohen, Mermelstein, Kamarck, & Hoberman, 1995). 
1.4.1.3 Perceived Stigma 
Perceived Stigma was defined as the perceived interaction with and from others that 
makes the individual feel undesirable, tainted, flawed, and/or morally degenerated (Goffman, 
1963). Perceived stigma was measured using the HIV Social and Emotional Aspects 
Questionnaire (Berger, Ferrans, & Lashley, 2001). The measure examines the overall emotional 
and social issues relevant to living with HIV. 
1.4.1.4 CD 4 
CD 4 was defined as a lymphocyte that has circulated through the thymus gland and has 
differentiated to become thymocytes. The presence of CD 4 cells suggests the individual’s 
immune response is functioning and the potential to resist disease (Malarkey & McMorrow, 
1996).    
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1.4.1.5 Viral Load 
Viral Load was the plasma concentration of HIV RNA in the blood that suggests the 
presence of HIV disease. These data (CD 4 and viral load) were self-reported on the 
sociodemographic measure. 
1.4.1.6 HIV Disease Symptoms 
HIV Disease Symptoms were defined as the subjective changes in how one feels related 
to their HIV disease in the last 5-days. HIV disease symptoms were measured by using The 
Revised Sign and Symptom Check-List for HIV (SSC-HIV rev) (Holzemer, Hudson, Kirksey, 
Hamilton, & Bakken, 2001). 
1.4.1.7 Physical Well being 
Physical Well-being was defined as one’s current appraisal and satisfaction with their 
physical abilities and social functioning with others. Physical well-being was measured using the 
overall physical well-being score of the Medical Outcomes Study-HIV (MOS-HIV) that includes 
the subscales of physical functioning, bodily pain, general health, vitality/energy and fatigue, and 
social functioning (Wu et al., 1991).   
 
1.4.2 Dependent Variable  
1.4.2.1 Adherence 
Adherence was defined as the degree to which one follows a prescribed regimen. The 
AIDS Clinical Trial Group Assessment (ACTG) (Chesney et al., 2000) was used to assess 
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overall rates of self-reported adherence to antiretroviral medications. In addition, for a sub-
sample of women in the study the Medication Event Monitoring System (MEMS) cap was used 
to assess adherence rates over a 29-day period.    
1.4.3 Mediating Variable 
1.4.3.1 Perceived Self-efficacy Beliefs 
Perceived Self-efficacy was defined as the individual’s perceived ability to successfully 
manage their antiretroviral medications (Bandura, 1977, 1986, 1997). Perceived self-efficacy 
was measured using the HIV Medication Taking Self-efficacy Scale (Erlen, Cha, Sereika, 
Caruthers, unpublished manuscript).  
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2.0  SECOND CHAPTER 
INTRODUCTION 
Improved understanding of medication taking adherence and issues that affect one’s adherence 
are important topics to address among persons with HIV/AIDS.  Although there is considerable 
research literature focusing on medication adherence issues for men with HIV/AIDS, there 
remains a gap in the literature about medication adherence for women with this disease. Thus, 
women with HIV/AIDS and their adherence to antiretroviral medications are a timely and 
significant topic. Non-adherence to antiretroviral medications can lead to genetic changes in the 
virus and the altered viral RNA may become resistant to current medications. Thus, persons 
using antiretroviral medications may potentially exhaust their options for medications to manage 
their disease. The resistant genetically changed virus can also create a potential threat to public 
health as the resistant viral genome is passed on to others.  
2.1 OVERVIEW OF THEORETICAL FRAMEWORK 
This research examined selected psychological factors (depressive symptomatology, social 
support, and perceived stigma) and selected physiological factors (CD 4, viral load, HIV disease 
related symptoms, and physical well-being) as potential predictors of adherence among women 
with HIV prescribed and taking antiretroviral medications. Following an extensive investigation 
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of cognitive and social learning models: Theory of Reasoned Action (Fishbein & Ajzen, 1975), 
Health Belief Model (Becker, 1974; Rosenstock, 1966), Health Promotion Model (Pender, 
1982), and Social Cognitive Theory (Bandura, 1977), Self-efficacy Theory (Bandura, 1986, 
1997) was selected as the conceptual framework for this study. 
Self-efficacy Theory is rooted in Bandura’s Social Learning Theory (SLT) (1977), a 
framework for examining motivation, human thought, and action.  Social Learning Theory is 
based on the premise that behavior is influenced by environmental events, personal factors, and 
the interaction of these multiple dimensions. Bandura modified SLT resulting in Social 
Cognitive Theory (SCT). Social Cognitive Theory considers how patterns of behavior are 
learned and the cognitive process in learning. Once these patterns are learned, SCT considers 
how and why the behavior continues, changes, or ceases. Both SLT and SCT are based on the 
premise that behaviors are learned by modeling the actions (behaviors) of others. Learned 
behaviors begin at an early age through what Bandura refers to as observational modeling 
(1977).  Thus, the individual learns and perceives behaviors that will result in a favorable 
outcome or avoids behaviors that produce a negative result.  
A concept of SCT is self-reinforcement composed of efficacy expectation and outcome 
expectancies. Briefly, efficacy expectation is the conviction that one can successfully execute a 
behavior that produces the desired outcome (Bandura, 1977). Outcome expectation is one’s 
estimate that a given behavior will lead to the identified outcome (result). Efficacy expectation 
became the basis of perceived self-efficacy, which addresses one’s fear in attempting or not 
attempting a given behavior and forecasts the potential for eventual success in a behavior. Thus, 
self-efficacy is a cognitive process that is influenced by past behaviors, the successes and failures 
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of those behaviors, and the environment where the behaviors are attempted and performed, as 
well as the recognition for achieving the desired outcome.  
Bandura (1986) asserted that one’s perceived self-efficacy is a powerful predictor of the 
individual’s resulting behavior. Self-efficacy theory can be used to predict and explain an 
individual’s health behavior. The premise is that one’s expectation of personal mastery and 
success in a behavior determines whether an individual will engage in a select behavior(Bandura, 
1986). Self-efficacy is the individual’s expectation or perception of confidence in one’s ability to 
perform a specific task/behavior (Bandura, 1977).  Self-efficacy is not static; it changes from one 
behavior expectation to another. Self-efficacy evolves from previously learned positive and 
negative experiences (Bandura, 1977).  Thus, perceived self-efficacy, an indicator of the 
individual’s potential for success and expectations of self-efficacy, can affect one’s behavior 
(Bandura, 1986, 1997). 
Three principles underscore an individual’s efficacy expectation: 1) magnitude or degree 
of task difficulty, 2) generality or the degree to which the expectation can be implied to other 
situations, and 3) strength of the mastery of the expectation.  Persons who feel strongly that they 
can be successful with a task or behavior such as adherence to medication taking, even under 
complicated and stressful conditions, are more likely to adhere to the recommended regimes 
(Bandura, 1986). 
The importance of self-efficacy theory is becoming recognized within nursing literature. 
Washington (1999) reported that increased self-efficacy was important for chemically dependent 
women to be successful when re-entering the work force. Educational interventions were noted 
as increasing self-efficacy for men to request prostate screening (Boehm et al., 1995).  Kehoe 
and Katz (1998) reported self-efficacy to be a key component in adherence to pharmacotherapy, 
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as well as diet and exercise programs. Poor self-efficacy was associated with worker’s resistance 
to engage in use of protective hearing equipment (Lusk, Ronis, Kerr, & Atwood, 1994).  Finally, 
in a comprehensive review of the literature, Fitzgerald (1991) reported that self-efficacy was a 
predictor of an individual’s motivation for attempting, achieving, and maintaining behaviors to 
overcome unhealthy lifestyles. 
In this model using self-efficacy theory (Figure 1), the demographic variables (identified 
as age, race/ethnicity, education, marital status, and exposure risk category) are characteristics 
within the person/individual.  As identified in the model, demographic variables and exposure 
risk categories are believed to be characteristics of the person/individual.  There is a direct link 
between the person and self-reported adherence to antiretroviral medications. However, 
perceived self-efficacy may have a possible mediating effect on the relationship between person 
and self-reported adherence to antiretroviral medications. Perceived self-efficacy may influence 
the relationship between the psychological factors (depressive symptomatology, social support, 
and perceived stigma) and/or physiological factors (CD 4, viral load, HIV disease symptoms, and 
physical well-being,) and adherence to antiretroviral medication.  These psychological and/or 
physiological factors may moderate or mediate one’s perceived self-efficacy. 
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Figure 1 Theoretical Framework using a Modified Social Cognitive Theory. 
2.2 REVIEW OF SCIENTIFIC LITERATURE 
2.2.1 Adherence.  
There is extensive research on adherence and chronic disorders such as diabetes, hypertension, 
and heart disease (MacLean, & Lo, 1998; Metz et al., 1997; Wagner, Schnoll, & Gipson, 1998). 
Overall, the research suggests approximately 30 to 60% of persons with chronic 
disorders/diseases are non-adherent to their prescribed medication regimens (Berg, Dunbar-
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Jacob, & Rohay, 1998; Blackwell, 1992; Dunbar-Jacob & Mortimer-Stephens, 2001; Morisky, 
Green, & Levine, 1986; Sackett, Haynes, Gibson, Taylor, Roberts, & Johnson, 1978). Early 
studies of hypertension and adherence showed marked decreases in systolic and/or diastolic 
readings after adherence reached 80% or better (Blackwell; Morisky et al.; Sackett et al.). 
Sackett and colleagues (1978) in their early research noted patients were less adherent as their 
regimen became more complex; over time adherence continued to falter. In addition, researchers 
have found that when cueing and supportive strategies were curtailed, adherence decreased, and 
eventually ceased for many people (Blackwell; Burke & Dunbar-Jacob, 1995; Dunbar-Jacob & 
Mortimer-Stephens; Morisky et al.). 
Adherence  is  evident  when   patient   behaviors  are  congruent  with   medical  advice,  
including prescription management and lifestyle changes such as diet and exercise (Morisky et 
al., 1986). The goal of adherence is to produce the desired control and ultimately reduce the 
complications and risks associated with chronic disorders (Berg, Dunbar-Jacob, & Rohay, 1998), 
for example, increased morbidity and mortality (Hoffman, Rice, & Sung, 1997). Successful 
adherence is a function of positive attitudes (Blackwell, 1992), an acceptance of the challenges 
of illness (Erlen & Mellors, 1999), the capacity to incorporate others for support (Erlen & 
Mellors), and positive self-esteem (MacLean & Lo, 1998).  
2.2.1.1 Adherence and Antiretroviral Medications for Women with HIV. 
The concept of adherence to medications has a different meaning for each individual. 
However, for persons with HIV the key to their disease management frequently revolves around 
their pill-taking regimen.  The ability of persons with HIV to achieve adherence to antiretroviral 
medications thus results in their potential for survival with disease, as well as preventing 
opportunistic infections such as tuberculosis and preventing treatment failure.  Bangsberg 
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(2006a) stated that the goal of adherence assessment to antiretroviral medications for persons 
with HIV is to “detect specific levels and specific patterns of adherence that put a patient’s 
particular regimen at risk for resistance” (p. 250).  
Medication management of HIV has changed over the last several years. Initially, 
medications were prescribed early in the diagnosis of the disease (Bova, 2000; Hogg et al., 1998; 
Mellors et al., 1998; Valenti, 2004).  However, this practice was believed to be a contributing 
factor to increased reports of medication resistance. Medication resistance was also attributed to 
non-adherence. Poor adherence was often due to the complexity of the regimen, taking 
medications at inappropriate times or combining medications incorrectly, or patient initiated 
drug-holidays (planned break) in taking one’s medication (Aversa & Kimberlin, 1996), and 
numerous side effects (Catz, Kelly, Bogart, Benotsch, & McAuliffe, 2000; Hader et al., 2001; 
Ickovics et al., 2001; de Olalla et al., 2002).  
The recent change in antiretroviral medication use that may have the potential for 
improvement is the change in the dosing regimen, which includes combining of two or three 
different medications into one pill. These changes have decreased the patient’s pill burden but 
not necessarily the medication side effects (Hawkins, 2004; Portsmouth, Osorio, McCormick, 
Gazzard, & Moyle, 2005; Yeni et al., 2004). Portsmouth and colleagues (2005) reported an 
increase in adherence for subjects when their combination-medication regimen was changed 
from twice daily to once daily (97.7% vs. 99.4% adherence); however, this finding was not 
clinically significant (p = 0.2327). Nor was there a change in control of viremia or CD 4 levels 
(Portsmouth et al.). 
Hawkins (2004) in his review of clinical trials for once vs. twice daily dosing suggested 
that both a decrease in dosing of antiretroviral medications and a decrease a pill burden resulted 
 20 
in improved medication adherence. In most studies reviewed in this meta-analysis (Hawkins, 
2004), the use of a once-daily regimen did not produce an increase in viremia or medication 
failure. However, Hawkins (2004) stressed the necessity of individualizing the antiretroviral 
regimen to best fit the patient’s lifestyle and personal needs, and identifying a regimen that fits 
the experienced patient’s preference for medication use.  
The guidelines for use of antiretroviral medication were revised in 2002 (Yeni et al., 
2002). Following these recommendations, three new medications emerged from clinical trials. 
This has resulted in further revisions to the guidelines. The revisions take into consideration new 
information regarding side effects of all antiretrovirals, new information about medication 
resistance, and suggestions for improved therapeutic strategies for antiretroviral maintenance. 
The guidelines now focus on four major areas for overall improved antiretroviral medications 
use, which includes: when to initiate therapy, what antiretroviral medications to use when 
beginning therapy, when it is appropriate to make changes in therapy, and what changes in the 
therapeutic regimen best fit the patient’s specific needs (Yeni et al., 2004). 
Current recommendations for beginning pharmacological treatment are designed 
to reduce the plasma HIV RNA (viral load) and enhance the recovery potential for CD 4 cells. 
For patients with advanced disease or those symptomatic with opportunistic illness, therapy is 
recommended immediately, unless co-administration of medications to treat another illness such 
as with tuberculosis could potentially be toxic for the patient. This therapy has had an increased 
success in person’s naïve to previous antiretroviral therapy (Yeni et al., 2002, 2004). 
Antiretroviral medications should begin before the individual has a CD 4 (lymphocyte) below 
200 cell/ul (Yeni et al., 2002; 2004). However, research is inconclusive as to what specific 
parameters for a CD 4 above 200cell/ul will result in success (Yeni et al., 2002; 2004). Also, for 
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those individuals with a CD 4 greater than 200cell/ul but less than 350 cell/ul beginning 
antiretroviral medication is based on the patient’s symptoms of disease and potential for 
medication adherence. Individuals with a a CD 4 greater than 350cell/ul but less than 500 cells/ul 
and a viral load above 100,000 copies should be closely monitored because the CD 4 has been 
noted to rapidly decrease in the presence of increased viral loads (Yeni et al., 2002, 2004).  
Research also suggests that women with disease require close observation of their viral load. 
Even though women may have a CD 4 greater than the 250 to 350 cell/ul, their viral load may be 
elevated and they may quickly develop disease-related symptoms (Farzadegan et al., 1998; 
Fletcher et al., 2005; Junghans et al., 1999).  In addition, some antiretroviral medications, 
although effective, are not recommended for women contemplating pregnancy or those who are 
already pregnant due to the teratogenic effects of the drugs (Yeni et al., 2004).  
Prior to beginning any regimen patient centered issues such as other illnesses need to be 
carefully considered. The provider also needs to be mindful of the potential for issues of patient 
convenience, their knowledge of the importance of medication adherence, possible food/drug 
interactions, the potential for tolerability, the individual’s possible lifestyle, and their desire to 
commit to the HIV regimen (Yeni et al., 2004). HIV disease management continues to include a 
combination of medications. The standard treatment recommendations for initial therapy are: a 
non-nucleoside reverse transcriptase inhibitor (NNRTI); a protease inhibitor (PI) with Ritonavir; 
and two-nucleoside reverse transcriptase inhibitors (NRTI). The use of three NRTI is no longer 
recommended due to ineffective response of the CD 4 and viral load. Likewise, a regimen of four 
drugs with the addition of a PI is no longer recommended (Yeni et al., 2004).   
The patient needs to be monitored carefully for side effects during the first months of 
therapy and changes to the regimen are often made to produce the best results, decreased viral 
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load and improved CD 4 with the greatest comfort to the patient.  If the patient fails to 
demonstrate improved CD 4s and a decrease in viral load using the above recommendations, the 
care provider must carefully evaluate adherence and testing for medication resistance. When 
resistance testing confirms viral sensitivity to the current therapy then the issue of non-adherence 
may be the cause of treatment failure. If the issue is resistance, the care providers may consider 
an alternate regimen (Yeni et al., 2004).    
A regimen of antiretroviral medications will be life long and has the potential to  
result in non-adherence over time (Bova, 2001; Cochran & Wilson, 1999; Mellors et al., 1998; 
Paterson et al., 2000). Even 5% non-adherence can quickly lead to viral mutation, resistance to 
current medications, and development of medication resistant strains of the virus (Mellors et al.; 
Paterson et al.).  
Unfortunately, antiretroviral medications have numerous side effects such as chronic  
diarrhea, hyperlipidemia, abnormal fat distribution and type-2 diabetes, weight changes, fatigue, 
anemia, and peripheral neuropathy (Bova, 2000, 2001; Cochran & Wilson, 1999).  Although 
some medication combinations have changed to once or twice daily dosing, increasing the 
potential for adherence, the side effects of these toxic drugs remain a salient concern for the 
health care provider and the person with HIV disease. Despite the introduction of combination-
therapy, patients may continue to take many different medications daily, including antiretrovirals 
and medications to manage depression, anxiety, diabetes, high blood pressure, hyperlipidemia, 
and HIV related diseases, such as tuberculosis and Hepatitis C, as well as other opportunistic 
diseases (Murphy et al., 2000; Yeni et al., 2004). In addition, a regimen may require timing of 
each medication with and without food for maximum effectiveness (Bova, 2000, 2001; Yeni et 
al., 2002, 2004.). 
 23 
The importance of adherence cannot be understated. Lack of knowledge about one’s 
medications may also be a contributing factor to non-adherence. Catz et al. (2000) found that in 
their study of 72 HIV positive individuals, 18% could not correctly name all of their 
antiretroviral medications. In addition, 30% of participants could not recall the regimen 
requirements without cueing (Catz et al.).  When patients experience side effects from the 
medications this can lead to non-adherence. And as the viral load decreases and CD 4 increases, 
the individual may feel better and adherence may decline (Aversa, Kimberlin, & Segal, 1998; 
Mellors et al., 1998).   
Paterson et al. (2000) found a significant relationship between virologic failure and 
decreased adherence to participant’s antiretroviral regimen. Nieuwkert et al. (2001) in their 
investigation of antiretroviral medications adherence suggested a significant difference in viral 
load when patients achieved greater adherence; fully adherent (OR = 1.07; 95% CI, 0.64 - 1.35) 
and not fully adherent (OR = 0.81; 95% CI, 0.48 - 1.10) (Nieuwkert et al.).  
More recent studies suggest treatment failure and increased viremia are not only related 
to poor adherence but also to drug resistance (Bangsberg et al., 2006b; Bangsberg et al., 2004; 
Bangsberg et al., 2003, King, Burns, & Kempt 2004; Lange, Perriens, Kuretzher, & Zewdie, 
2004; Yeni et al., 2004). In addition, when compared with adherence rates of greater than 90% 
(Sethi, Celentano, Gange, Moore, & Gallant, 2003) reported that increased viremia (viral 
rebound) and medication resistance were significantly associated with adherence rates of 70 to 
89% (95% CI 1.61-7.20; p = 0.01) or less than 70% adherence.  
2.2.1.2 Overview Measurement of Adherence.     
The assessment of adherence to medications has been approached by both direct and 
indirect methods.  Direct methods include objective assessments, such as the clinician dispensing 
 24 
the medications and visually observing the individual taking each prescribed medications, and 
clinical or biological markers and assays, i.e., blood levels of specific medications. Indirect 
methods include subjective assessments such as self-report via questionnaires or diaries, pill 
counts, prescription refills, pill identification, clinical outcomes (i.e., CD 4 and viral load), and 
the use of electronic event monitors (Morse et al., 1991; Paterson et al, 2002; Samet, Sullivan, 
Traphagen, & Ickovics, 2001).  
Patient self-reports are the most frequently used method for assessing medication 
adherence.  Advantages of self-report are that it costs less to administer and requires a shorter 
time necessary for administration. However, self-report measures can be biased.  Regardless of 
the medication or treatment being measured, patients and study participants are prone to over-or-
under report their adherence. Diary data are also biased, with patients and research participants 
often having difficulty recalling their regimens and activities for longer than 24 hours (Erlen, 
Sereika, Cook, & Hunt, 2002). The pill count method does not clearly document when or if 
individuals took their medications, only the number of pills missing from the prescription bottle 
(Liu et al., 2001; Paterson et al., 2002).  There may also be an over-reporting of medications 
taken.  Bangsberg and colleagues (2001) reported 73% adherence using pill count with HIV 
infected patients. In their investigation of multiple measures of adherence, Liu and colleagues 
(2001) reported inconsistencies in adherence to antiretroviral medication when subjects used 
self-report, pill count, and use of the Medication Events Monitoring System (MEMS) cap. 
Fletcher and colleagues (2005) reported that their self-report measure, the ACTG, reflected a 
more accurate assessment of subject’s antiretroviral use than the daily diary, pill counts, or an 
electronic measure (MEMS).  Simoni and colleagues (2006) suggested self-report measures 
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especially those in longitudinal studies are a good predictor of subject’s adherence, changes in 
viral load, and the potential need for a medication treatment adjustment. 
In a longitudinal cohort study of women, Stone and colleagues (2001) reported an 
association between adherence and comprehension of correct medication dosing instruction. 
Adherence was measured using an interview format questionnaire. The questionnaire questioned 
the type of antiretroviral medication use, how it was prescribed, dosing frequency, and timing 
with food or beverages. There was a relationship between dose frequency with three or more 
daily doses and non-adherence (OR = 1.4; 95% CI, 0.9-2.3) and food/empty stomach 
requirements (OR = 1.5; 95% CI, 0.9-2.6) and three or more daily doses (OR = 1.4, 95% CI, 0.4-
4.3). In addition, participants with increased understanding of both medication use instructions 
and food restrictions had better adherence over the previous 3-day period (OR = 0.6; 95% CI, 
0.4-1.0) (Stone et al.). 
Erlen and colleagues (2002) refer to the absence of a “gold standard” in the measurement 
of adherence. However, there has been a movement toward use of electronic measures such as 
the MEMS. This device has a computer chip embedded in the cap of the medication bottle that 
records each time the cap is opened; thereby monitoring, in theory, the timing of pill removal. 
The limitations of the MEMS cap include the lack of quality control to assure that the medication 
has been taken, the patient requiring specific instructions on the use of the cap, the cost of the 
cap, the cost of the scanning device for cap data, and the time needed to evaluate patterns of 
adherence. In addition, it is important that an individual remain in the study and return the 
MEMS cap for evaluation. The importance placed on returning the MEMS cap cannot be 
devalued (Paterson et al., 2002). 
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The use of the MEMS cap had been considered to approach a standardized assessment of 
adherence (Paterson et al., 2002).  However, Samet and associates (2001) suggested when 
assessing adherence to antiretroviral medications, patient use of the MEMS may not be the 
“magic bullet” (p. 28) as previously envisioned by researchers. Investigations by others (Bova et 
al., 2005; Fletcher et al., 2005; Levine et al., 2006) suggest flaws with use of the MEMS cap. Liu 
and colleagues (2001) reported that the MEMS underestimated subject’s adherence to 
antiretroviral medications. Two additional studies suggested use of the MEMS may not be more 
accurate in assessing adherence to antiretroviral medications than self-report measures (Fletcher 
et al., 2005; Samet et al., 2001). Bova and colleagues (2005) in their investigation of adherence 
and use of the MEMS cap reported numerous pitfalls in using the device. These obstacles 
included problems with some medications such as use of liquid medication requiring 
refrigeration and individual issues including delays in refilling the bottle, failure to use the bottle 
vs. a pill box device, pocket dosing (removal of multiple doses at one time), patient incarceration 
and hospitalization, and frequent changes in available housing (Bova et al.).  The failure of the 
MEMS to accurately evaluate adherence in Bova and colleagues study was also due to need for 
multiple medications to be used for control and management of subject’s HIV disease as well as 
personal, social, and environmental dynamics unique to persons with HIV. 
Another indirect method of adherence is through pharmacy records. Laine et al., 2000) in 
their investigation from pharmacy records of 549 HIV-positive women reported that the presence 
of other chronic diseases in this sample of women was predictive of antiretroviral medication 
adherence (OR = 0.67; 95% CI, 0.44-1.0).  
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2.2.1.3 Adherence to Antiretroviral Medications 
Successful disease management requires a conscious commitment from the individual 
being treated as well as a supportive collaborative relationship with family, significant others, 
and care providers. As stated by Sorenson and colleagues (1998) “adherence reflects an attitude 
that a patient is empowered by a medication regimen, rather than simply complying with the 
wishes of medical staff” (p. 297). This section on adherence to antiretroviral medications 
addresses studies that have examined samples of men only or men and women.  
In a sample of 224 (201 men and 23 women) HIV-positive persons taking antiretroviral 
medications, Nieuwkert and colleagues (2001) reported a significant relationship between taking 
all medications as directed (correct timing of doses and food/beverage restrictions) and improved 
viral load (median concentration ratio, 0.81 vs. 1.07; p = 0.001). This study used a researcher 
developed self-report measure of adherence. Participants were divided into fully adherent, taking 
all medications as required and not fully adherent, not taking all medications on time including 
with food requirements (Nieuwkert et al., 2001).   
Two investigations used the AIDS Clinical Trail Group Assessment (ACTG) self- 
report measure of adherence. Chesney et al. (2000) reported non-adherence was associated with 
working outside the home, forgetting to take medications, and pill burden (X 2 [1] = 4.99, p = 
0.03). Murphy and colleagues (2002) reported improved adherence after 3 months with the 
intervention group more likely to follow their antiretroviral regimen than controls, p = 0.06 
(Murphy et al.). A study of 133 HIV-positive persons which was largely male (86%) and white 
(62%) used a modified self-report measured of adherence to antiretroviral medications from the 
HCSUS study (Gifford et al. 2000). The researchers reported an association between non-
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adherence and one’s antiretroviral medication regimen (adjusted OR = 5.3; 95% CI, 2.4-11.8). 
Adherence for women with disease was not analyzed separately (Gifford et al.).  
2.2.1.4 Women with HIV and Adherence to Antiretroviral Medications. 
Adherence to antiretroviral therapy in women began to be addressed later than men.  
Initially when pregnant women tested positive for HIV, the standard recommendation of 
physicians was to terminate the pregnancy, causing some women to postpone prenatal care until 
after 24-weeks gestation (Marlink, Kao, & Hsieh, 2001). The 1994 Pediatric AIDS Clinical 
Trails Group (PACTG) Protocol 076 served to significantly advance the treatment and 
prevention procedures for women with HIV. By July 1995, the PACTG 076 findings generated 
U. S. Public Health Service recommendations for universal prenatal HIV-1 counseling; HIV 
testing for all consenting pregnant women; and the use of a monotherapy (Zidovudine, ZVD) for 
reduction in perinatal transmission. The tide turned for inclusion of women in clinical trials 
following a 1997 Food and Drug Administration (FDA) ruling. The ruling revoked previous 
guidelines that placed restrictions on women of reproductive age from being included in any 
clinical trials (Marlink et al.). Subsequent epidemiological studies in the USA and France 
demonstrated a sharp decline in maternal to child, vertical transmission and opened the doors for 
inclusion of non-pregnant women in clinic trials (Marlink et al.; Shapiro et al., 1999, 2000).  
An early study of Zidovudine (ZVD), found women’s beliefs about treatment for HIV 
were influenced by their perceptions that health care is substandard for women in general and for 
socioeconomically disadvantaged non-white women in particular (Misener & Sowell, 1998).  
The failure to include minorities and women in clinical trials and related studies can adversely 
affect health promotion, health intervention strategies, and adherence to antiretroviral medication 
regimens (Hader et al., 2001). 
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Besides the failure to include women in clinical trials, research has identified several 
reasons for the lack of understanding among health care providers regarding women with HIV 
such as lack of funding and numerous psychosocial, psychological, physiological, and 
sociodemographic problems, including poverty (Bova, 2001, 2000; Catz, Gore-Felton, & 
McClure, 2002; Catz et al., 2000; Gardner et al., 2002; Greene et al., 2002; Hudson, Lee, 
Miramontes, & Portillo, 2001; Lehman-Trzynka & Erlen, 2004; Simoni & Ortiz, 2003).  
2.2.1.5 Summary of Women with HIV and Adherence to Antiretroviral Medications.  
There is little doubt that adherence to one’s medication regimen is important.  There 
remains a gap in the research regarding adherence to antiretroviral medications in women with 
HIV and AIDS.  There is also a gap in studies that investigate factors that may affect 
antiretroviral medication adherence such as stigma or social support in a sample of women with 
disease. And, there is limited research that explores adherence among HIV infected women in 
rural areas of the Northeastern United States.  In addition, there are inconsistencies in the 
measurement of adherence.  This investigation used two measures in an attempt to bridge this 
gap. The study used the self-report ACTG measure for all study participants and the “gold 
standard” MEMS for a select subsample. 
2.2.2 Self-Efficacy 
Self-efficacy has been identified as the theoretical framework, as well as a potential mediator of 
the relationship between the person (a woman with HIV) and her adherence to antiretroviral 
medications.  According to Bandura (1986), perceived self-efficacy affects the individual’s 
current and future behaviors. There is continual change throughout one’s life course and in one’s 
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perceived self-efficacy. Success or failure in one’s health behaviors is highly influenced by 
perceived self-efficacy and previous experiences (Bandura, 1997).  
2.2.2.1 Self-efficacy and Adherence to Antiretroviral Medications. 
An extensive review of computerized databases (CINAHL, Medline, and PsychInfo) 
identified few research studies focused on self-efficacy and adherence to antiretroviral 
medications for men and/or for women with HIV.   
Catz et al. (2000) examined 63 men and 9 women and their adherence self-efficacy to 
their antiretroviral treatment. Approximately 82% (59) of the participants were identified as 
adherent using an adapted 8-item instrument to measure treatment adherence self-efficacy. A 
paired t-test of adherent versus non-adherent participants suggested increased treatment 
adherence self-efficacy among adherent individuals [t (70) = 3.32, p = 0.001]. In addition long-
term treatment adherence was a significantly related to adherence self-efficacy, X 2 = (5, N = 72) 
= 15.2, p < 0.01 (Catz et al., 2000).  
Chesney and colleagues (2000) in a cross-sectional study of 60 men and 15 women 
reported a significant relationship between adherence and self-efficacy. This study used the 
AIDS Clinical Trials Group Assessment (ACTG) instrument with items to measure self-efficacy. 
In this sample, approximately 26 persons (36%) were identified as adherent to their antiretroviral 
medications. Non-adherent participants were less confident of their ability to take most or all of 
their medications (Mann-Whitney Z = 2.77, p = 0.006) (Chesney et al.).  
Murphy and colleagues (2002) used an investigator-modified measure of self-efficacy 
from the ACTG measure and investigated adherence at baseline, 7 weeks post intervention, and 3 
months following the intervention. Study participants included 29 men and 4 women. Those 
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subjects randomized to the intervention group demonstrated improved adherence from baseline 
to the 3-month follow-up period, t (31) = 2.13, p = 0.04. Subjects that demonstrated improved 
self-efficacy were more willing to continue antiretroviral medications despite negative responses 
from family and friends, t (31) = -2.10, p = .04, and reported the ability to better communicate 
problems with their medications to clinic personnel, t (31) =-2.13, p = 0.04 (Murphy et al.).   
A study of 133 HIV-positive persons, 86% male and 62% white, reported an association 
between non-adherence and one’s antiretroviral medication regimen (adjusted OR = 5.3; 95% CI, 
2.4-11.8) and between non-adherence and self-efficacy for use of HIV medications (adjusted OR 
= 9.0; 95% CI, 1.8-45.3). The study used a modified self-report measure of adherence to 
antiretroviral medications from the HCSUS study (Gifford et al., 2000). Reynolds and colleagues 
(2004) also reported that improved confidence in one’s ability to take their antiretroviral 
medications was related to more adherent behaviors. In this investigation of adherence self-
efficacy for 325 men and women adherence was reported at 89% (Reynolds et al.). 
A study of 136 Chinese men investigated self-efficacy as a predictor of adherence 
(Molassiotis et al., 2002). Using a stepwise regression for the overall model, self-efficacy was a 
significant predictor of adherence (Beta = 0.47, p = 0.002).  This study used a translated version 
of the ACTG self-efficacy measure. Gifford et al. (2000) reported in their study of 133 subjects a 
significant relationship between non-adherence and self-efficacy for use of HIV medications 
(adjusted OR = 9.0; 95% CI, 1.8 - 45.3).  
2.2.2.2 Women with HIV: Self-efficacy and Adherence to Antiretroviral Medications.   
Kalichman et al. (2001) in their investigation of 72 HIV-positive women reported that 
increased antiretroviral medication adherence was significantly related to increased self-efficacy, 
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t (70) = 2.4, p < 0.02.   Gifford and colleagues (1996) investigated behavioral skills self-efficacy 
using a 7-item instrument. The 39 women identified as “good adherers” also had significant 
differences in four of the seven self-efficacy items: medication schedule (t [70] = 2.8, p < 0.01), 
following one’s medications schedule when changes occur in their daily routine, (t [70] = 2.3, p 
< 0.02), following their medication schedule when not feeling well (t [70] = 2.6, p < 0.01), and 
taking medications even if it interfered with one’s day (t [70] = 2.1, p = 0.01) (Kalichman et al.). 
A study of 56 minority women reported a significant relationship between adherence and self-
efficacy and a decrease in viral load (r = -0.275, p < 0.05) (Ironson et al., 2005). 
2.2.2.3 Summary of Self-Efficacy and Adherence to Antiretroviral Medications. 
Despite the limited research focusing on self-efficacy and self-reported adherence to 
antiretroviral medications, there is some emerging recognition of this relationship.  Bandura 
(1986) acknowledges that perceived self-efficacy influences one’s successes and failures when 
attempting new behaviors.  The research focusing on studies of HIV/AIDS patients suggests that 
perceived self-efficacy affects one’s confidence and ability to achieve adherence to antiretroviral 
medications.  Few of the studies reviewed exclusively focused on women with disease. 
Therefore, at this juncture in HIV and AIDS research investigating the potential relationship 
between perceived self-efficacy and antiretroviral medications for women with this disease is 
important.   
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2.3 PREDICTORS OF ADHERENCE AMONG WOMEN WITH HIV/AIDS 
2.3.1 Socioeconomic Factors 
Socioeconomic status, poverty, and limited education have been identified as having an influence 
on adherence to antiretroviral medications for persons with HIV. Leenarts (1998) addresses these 
issues for white women. Moneyham and colleagues (2000), and Catz, Gore-Felton, and McClure 
(2002) discuss these issues for minority Black women. Simoni and Ortiz (2003) highlight these 
issues as well as the cultural dynamics for Latina women living in urban areas. These researchers 
and others (Bova, 2001; Gardner et al., 2002; Hudson et al., 2001) have found poverty (lower 
socioeconomic status) to be associated with receiving care or not receiving care, with care 
providers believing poor women are unable to maintain self-care, and unable to follow HIV 
medications adherence guidelines (Catz et al., 2000; Greene et al., 2002; Marlink et al., 2001).  
In addition, Hudson and colleagues (2001) found that limited economic resources contributed to 
women’s psychological distress and ability to manage disease or medication related symptoms.   
Simoni and Ortiz (2003) in their qualitative study discussed the issues of Puerto Rican 
women relocating to the USA mainland and the socioeconomic difficulties they may experience 
due to language barrier issues, discrimination, and poverty.  Likewise, Gardner et al. (2002) 
reported the disparity of care for impoverished women with HIV. These researchers found a 
relationship between having insurance (OR= 0.14; 95% CI, 0.04-0.5), less than an eighth-grade 
education (OR = 0.3, 95% CI, 0.1- 1.1), history or present illegal drug use (OR = 0.4; 95% CI, 
0.1–0.95), and depressive symptoms (OR = 2.8, 95% CI, 1.3-6.2). Women having Medicaid 
were more likely to receive care from an HIV specialist (OR = 2.1; 95% CI, 0.7- 6.5). Women 
without insurance or those having private insurance that did not reimburse for a specialist did not 
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receive care from a HIV specialist. Those women not receiving HIV specialist care were also 
less likely to be receiving antiretroviral therapy and to have abnormal clinical markers; increased 
viral load and decreased CD 4 (p = 0.009) (Gardner et al.).  
Greene and colleagues (2002) in their essay address various sociocultural, interpersonal, 
temporal, and situational contexts that influence HIV-positive women’s relationships and 
abilities to manage their disease. The authors reported that cultural and gender norms, social 
roles and sexual issues, life-stage development, and the impact of one’s environment contributed 
to the socioeconomic struggles of women with HIV (Greene et al.).   
2.3.1.1 Socioeconomic Factors and Adherence to Antiretroviral Medications. 
In a study of 85 men and 53 women, Kalichman et al. (1999) reported that low-literacy, 
less than 12 years of education (49% of the subjects) was associated with decreased adherence (X 
2. 1,138; 4.99; p = 0.05).  Another study of 52 men and 20 women found disease severity (F = 
7.72, p = 0.007), lack of appropriate education on medication use (i.e., doctor’s instructions) 
(Beta = - 0.33, t = -2.69, p = 0.009), insurance benefits and belief in the effectiveness of the 
medications (medication efficacy) (Beta = 0.36; t = 2.92, p < 0.01) were associated with 
decreased adherence (Gao, Nau, Rosenbluth, Scott, & Woodward, 2000). For this study, the final 
regression model showed that insurance benefits, medication efficacy, and education on 
medication use were significant predictors of HIV antiretroviral non-adherence, (F = 8.00, p < 
0.001) (Gao et al.). Reynolds et al. (2004) in their study of 325 men and women with HIV 
reported that improved adherence to antiretroviral medications were associated with achieving a 
better education (p = <. 007) and being older (p < .0001).  
Murphy and colleagues (2004) reported that older subjects were also more adherent to 
their antiretroviral medications. In this culturally diverse sample of 115 men and women using a 
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modified version of the ACTG for a 3-day recall of antiretroviral medication use, increased age 
was significantly associated with improved adherence (Wald Chi-sq. = 8.32; OR = 1.12 (95% CI, 
1.04 -1.22) (Murphy et al.). Other studies reported that improved adherence was related to being 
younger in age (O.R. = 2.47 (1.46-4.16, 95% C.I.; p = .001) (Ammassari et al., 2001; Stone et al., 
2001). Kleebeerger and colleagues (2001) in their multi-centered study of 5,622 men with HIV 
reported a significant relationship between non-adherence and an income of less than $50,000 
(OR = 2.6; 95% C.I.; p = .001) and African-American ethnicity (OR = 2.2; 95% C.I.; p = .005).  
Gifford and colleagues (2000) reported an association between non-adherence and ethnicity 
(African-American) (adjusted OR = 0.4; 95% CI, 0.2 – 1.0, p < 0.05).  The Ammassari et al. 
(2001) study of 358 Italian men and women also reported that non-adherence was significantly 
associated with unemployment (O.R. 3.29 (1.92-5.65, 95% C.I.; p < .001).  
Using an interview format, Wilson and colleagues (2002) reported a significant  
relationship between adherence and age, drug use, viral load, and health perception (X 2 = 55.4; p 
< .01).  However, they did not have a sufficient number of women to analyze those data 
separately. The regression model showed that less than 9% adherence was associated with a 
participant being younger (OR = 1.60; 95% CI, 1.30- 2.17, p < 0.01) and having a viral load at 
detectable levels (OR = 2.00; 95% CI, 1.37 –2.94, p < 0.01) (Wilson et al.) 
Socioeconomic status, poverty, and limited education have been identified as having an 
influence on adherence to antiretroviral medications for persons with HIV. Leenarts (1998) 
addresses these issues for white women. Moneyham and colleagues (2000), and Catz, Gore-
Felton, and McClure (2002) discuss these issues for minority Black women. Simoni and Ortiz 
(2003) highlight these issues as well as the cultural dynamics for Latina women living in urban 
areas. These researchers and others (Bova, 2001; Gardner et al., 2002; Hudson et al., 2001) have 
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found poverty (lower socioeconomic status) to be associated with receiving care or not receiving 
care, with care providers believing poor women are unable to maintain self-care, and unable to 
follow HIV medications adherence guidelines (Catz et al., 2000; Greene et al., 2002; Marlink et 
al., 2001).  In addition, Hudson and colleagues (2001) found that limited economic resources 
contributed to women’s psychological distress and ability to manage disease or medication 
related symptoms.   
Simoni and Ortiz (2003) in their qualitative study discussed the issues of Puerto Rican 
women relocating to the USA mainland and the socioeconomic difficulties they may experience 
due to language barrier issues, discrimination, and poverty.  Likewise, Gardner et al. (2002) 
reported the disparity of care for impoverished women with HIV. These researchers found a 
relationship between having insurance (OR= 0.14; 95% CI, 0.04-0.5), less than an eighth-grade 
education (OR = 0.3, 95% CI, 0.1- 1.1), history or present illegal drug use (OR = 0.4; 95% CI, 
0.1–0.95), and depressive symptoms (OR = 2.8, 95% CI, 1.3-6.2). Women having Medicaid 
were more likely to receive care from an HIV specialist (OR = 2.1; 95% CI, 0.7- 6.5). Women 
without insurance or those having private insurance that did not reimburse for a specialist did not 
receive care from a HIV specialist. Those women not receiving HIV specialist care were also 
less likely to be receiving antiretroviral therapy and to have abnormal clinical markers; increased 
viral load and decreased CD 4 (p = 0.009) (Gardner et al.).  
Greene and colleagues (2002) in their essay address various sociocultural, interpersonal, 
temporal, and situational contexts that influence HIV-positive women’s relationships and 
abilities to manage their disease. The authors reported that cultural and gender norms, social 
roles and sexual issues, life-stage development, and the impact of one’s environment contributed 
to the socioeconomic struggles of women with HIV (Greene et al.).   
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2.3.1.2 Socioeconomic Factors and Adherence to Antiretroviral Medications.       
In a study of 85 men and 53 women, Kalichman et al. (1999) reported that low-literacy, 
less than 12 years of education (49% of the subjects) was associated with decreased adherence (X 
2. 1,138; 4.99; p = 0.05).  Another study of 52 men and 20 women found disease severity (F = 
7.72, p = 0.007), lack of appropriate education on medication use (i.e., doctor’s instructions) 
(Beta = - 0.33, t = -2.69, p = 0.009), insurance benefits and belief in the effectiveness of the 
medications (medication efficacy) (Beta = 0.36; t = 2.92, p < 0.01) were associated with 
decreased adherence (Gao, Nau, Rosenbluth, Scott, & Woodward, 2000). For this study, the final 
regression model showed that insurance benefits, medication efficacy, and education on 
medication use were significant predictors of HIV antiretroviral non-adherence, (F = 8.00, p < 
0.001) (Gao et al.). Reynolds et al. (2004) in their study of 325 men and women with HIV 
reported that improved adherence to antiretroviral medications were associated with achieving a 
better education (p = <. 007) and being older (p < .0001).  
Murphy and colleagues (2004) reported that older subjects were also more adherent to 
their antiretroviral medications. In this culturally diverse sample of 115 men and women using a 
modified version of the ACTG for a 3-day recall of antiretroviral medication use, increased age 
was significantly associated with improved adherence (Wald Chi-sq. = 8.32; OR = 1.12 (95% CI, 
1.04 -1.22) (Murphy et al.). Other studies reported that improved adherence was related to being 
younger in age (O.R. = 2.47 (1.46-4.16, 95% C.I.; p = .001) (Ammassari et al., 2001; Stone et al., 
2001). Kleebeerger and colleagues (2001) in their multi-centered study of 5,622 men with HIV 
reported a significant relationship between non-adherence and an income of less than $50,000 
(OR = 2.6; 95% C.I.; p = .001) and African-American ethnicity (OR = 2.2; 95% C.I.; p = .005).  
Gifford and colleagues (2000) reported an association between non-adherence and ethnicity 
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(African-American) (adjusted OR = 0.4; 95% CI, 0.2 – 1.0, p < 0.05).  The Ammassari et al. 
(2001) study of 358 Italian men and women also reported that non-adherence was significantly 
associated with unemployment (O.R. 3.29 (1.92-5.65, 95% C.I.; p < .001).  
Using an interview format, Wilson and colleagues (2002) reported a significant  
relationship between adherence and age, drug use, viral load, and health perception (X 2 = 55.4; p 
< .01).  However, they did not have a sufficient number of women to analyze those data 
separately. The regression model showed that less than 9% adherence was associated with a 
participant being younger (OR = 1.60; 95% CI, 1.30- 2.17, p < 0.01) and having a viral load at 
detectable levels (OR = 2.00; 95% CI, 1.37 –2.94, p < 0.01) (Wilson et al.).  
2.3.1.3 Summary of Socioeconomic Factors and Adherence to Antiretroviral Medications. 
The burden of chronic disease can contribute to a decrease in one’s financial resources. 
Also one’s socioeconomic status may contribute to poor disease management and living with 
HIV (Ammassari et al., 2001; Kleebeerger et al., 2001; Stone et al., 2001). Poverty, less 
educational opportunities, and dissatisfaction with one’s life may be contributing factors in risk 
taking behaviors.  Age has also been identified in some investigations as being a factor 
contributing to one’s non-adherence but the results are inconclusive as to whether the younger or 
the older person is more likely be adherent. Perhaps the Greene et al. (2000) article best 
summarizes the plight of marginalized women and their risk for, as well as their struggle with 
HIV disease.  HIV disease knows no boundaries.  It, unlike sickle cell disease, is not restricted to 
a specific racial/ethnic group.  However, the proportion of Black and Latino men and women 
diagnosed with HIV is higher than the proportion among white men and women (CDC, 2000, 
2006).  Research suggests one’s environment: lack of education, poverty, and gender may make 
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living with HIV disease more complex. However, those findings cannot be generalized as to the 
degree these factors affect one’s adherence to antiretroviral medications (Bova, 2000, 2001; Catz 
et al., 2002; Catz et al., 2000; Gao et al., 2000; Greene et al., 2002; Hudson et al., 2001; 
Kalichman et al., 1999; Simoni & Ortiz, 2003). 
Transportation, prejudice, limited employment opportunities and workplace 
discrimination, low wages, and poor working conditions may contribute to financial issues for 
women with HIV living in rural areas (Lehman-Trzynka & Erlen, 2004). In addition, all of the 
above may be issues that limit women’s resources to health care (Lehman-Trzynka & Erlen, 
2004). Heckman and colleagues (1998) reported that lack of knowledge about HIV among health 
care providers, inaccessibility to appropriate services, and late diagnosis and delayed entry into 
treatment were more common among rural women with HIV.  The above studies suggest that the 
result of the impact of various socioeconomic variables on adherence to antiretroviral 
medications among women is inconclusive. 
2.4 PSYCHOLOGICAL PREDICTORS OF ADHERENCE AMONG WOMEN WITH 
HIV 
2.4.1 Depressive Symptomatology 
The advent and introduction of antiretroviral medications has placed HIV in the category of a 
chronic disorder. However, this chronic disease has multiple dynamic issues that perhaps makes 
living with the HIV more burdensome than living with many other chronic disorders (Greene et 
al., 2002; Jones, Beach, Forehand, & group, 2001). HIV is frequently accompanied with the co-
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morbid condition of depression, which has an impact on the individual’s behavior, mood, and 
ability to address and manage life expectations and navigate medication use (National Institute of 
Mental Health [NIMH], 1999). 
Depression is often a manifestation associated with ineffective coping from life  
situations, other diseases, and/or poor adaptation in living with chronic disease (Cabaj, 1996; 
Katon, 2000; NIMH, 1999). The NIMH has identified the diagnosis of depression as a primary 
co-morbid disorder and as the number one disease management problem in the USA (NIMH). 
Estimates are that approximately 19 million people in the USA suffer from some form of 
depression (NIMH). Depression is diagnosed correctly only 50% of the time; less than half of 
those persons receive appropriate medication and only 10% receive psychotherapy (Katon, 
2000). There are however no estimates of the percentage of persons with HIV who have the co-
morbidity of depression.   
Depression is a psychological entity that is treatable if diagnosed and properly managed 
with psychotherapy, counseling, medications, and often lifestyle changes. The symptoms 
associated with depression are often confused with other disease pathology and left untreated 
(Cabaj, 1996; Katon, 2000; NIMH, 1999). This investigation used depressive symptomatology 
over the previous two weeks as defined by The Center for Epidemiological Studies-Depression 
Scale (CES-D) (Radloff, 1977). The Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV) classification of depression (APA, 1994) includes the presence of a “depressed mood” 
for the majority of the day over a period of two years with a report of at least two of the 
following symptoms: feelings of hopelessness, inability to concentrate or make decisions, poor 
self-esteem, decreased energy or fatigue, sleep disorders, and appetite changes (APA, 1994). The 
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reader is referred to the DSM-IV for additional information of the classifications of depression 
and its various disorders in specific domains (APA, 1994).   
2.4.1.1 Depressive Symptomatology and Adherence to Antiretroviral Medications.    
HIV research has established associations between the individual being diagnosed with 
HIV and depressive symptomatology (Ickovics et al., 2001) and adherence to medications (Catz 
et al., 2000; Singh et al., 1996). Several investigations have addressed depressive 
symptomatology among men and women with HIV (Nott et al., 1995; Singh et al., 1996; 
Ickovics et al., 2001; Jones, Beach, Forehand, & Group, 2001; Laine et al. 2000; Morrison et al., 
2002; Simoni and Ortiz, 2003). Morrison and colleagues (2002) discussed the co-morbidity of 
depressive symptoms in women with disease and failure to take antiretroviral medications; 
however, adherence was not assessed in this study. Tostes, Chalub, and Botega (2004) reported 
that of the 76 HIV-positive women in their investigation almost all study participants had 
symptoms of psychiatric problems and/or mental health issues and were not receiving any health 
care to address this co-mobility.  
Singh and colleagues (1996) used the Profile of Mood States (POMS) in an early  
investigation of men with HIV and found an association between adherence and increased 
depression (M = 14.2 vs. M = 22.1, p = 0.04), decline in CD 4 (59% vs.41%, p < 0.25), and 
increased mortality (18% vs. 50%, p = 0.12). Simoni and Ortiz (2003) reported that in a sample 
of 12 Latina women depressive symptomatology was highly correlated with low self-esteem, 
cultural influences, education, and mastery of one’s life; the mean CES-D score was 22.75 (SD = 
12.34) approximately four times greater than community dwelling adults. 
 42 
Catz and colleagues (2000) in their research of HIV positive men and women compared 
CES-D scores between adherent and non-adherent participants (M = 17.39, SD = 12.48 vs. M = 
27.38, SD = 16.31; t [70] = 2.47, p = .016). Kalichman et al. (1999) also used the CES-D in a 
study of men and women and found that depressive symptomatology was significantly related to 
nonadherence (OR = 4.1; 95% CI, 1.6 -10.5). The participants’ CES-D depression score were not 
analyzed according to gender. 
Reynolds et al. (2004) used a modified 7-item CES-D measure to assess depressive 
symptomatology and the ACTG as the measure of adherence in their study of 325 subjects, 181 
women. Approximately one-half of the subjects had a “fairly high prevalence of depressive 
symptomatology” (p. 144). A standard mean for this measure was not available due to the 
author’s modification of items on the CES-D and changes in scoring. In this study depressive 
symptomatology was a statistically significant predictor for nonadherence (r = .33, p < .001) 
(Reynolds et al.).  Mannheim and colleagues (2005) did not assess the relationship of depressive 
symptoms and adherence but reported in their study of 412 men and 102 women an improved 
mental health score (using the SF-12) for 100% adherent vs. non-adherent subjects (45.8 vs. 
42.0; p < 0.005) over the 12 months of their investigation.  
2.4.1.2 Depressive Symptomatology and Adherence to Antiretroviral Medications for 
Women with HIV.         
A retrospective chart audit of 549 pregnant HIV-positive women found 22% of study 
participants were treated for depression (Laine et al., 2000). Research also suggests a connection 
between increased depressive symptomatology and use of protease inhibitor medications 
(Morrison et al., 2002). Seropositive women had significantly more depressive symptomatology, 
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as compared to the seronegative study participants (47% vs. 38.7%, p = 0.05). For women taking 
protease inhibitors their mean Hamilton Depression Scale scores were M = 10.6, SD = 9.1, while 
women taking other antiretroviral medications had lower scores (M = 7.8, SD = 7.3). However, 
this difference was not statistically significant (t (91) = 1.6, p = 0.10; Beta = 2.8, 95% CI, 0.6-
6.2). Adherence to the antiretroviral medication as a co-variate for increased depression was not 
explored in this study (Morrison et al.).   
Using the CES-D as a measure of depressive symptomatology in a large cohort study of 
765 women with HIV, Ickovics and colleagues (2001) suggested that the higher classification of 
depression [chronic (M = -0.35, SD = 0.54), intermittent (M = -0.27, SD = 0.60), or limited 
without symptoms (M = -0.13, SD = 0.60)] was related to changes in clinical indicators and 
disease progression. Based on levels of depression (Standardized Beta = -0.14, p < 0.001), the 
results suggested an association between declines in CD 4 (Beta = -0.12, p < 0.001) and 
increased mortality for participants with viral loads greater than 10,000 copies (48%, 31%, and 
21%) respectively by depression classifications. In the final model, women with CD 4s less than 
200ml/ul and increased viral loads were significantly related to increased mortality F (2, 111) = 
5.0; p = 0.009). The authors did not assess adherence to antiretroviral medications; however, 375 
(49%) of the women were prescribed and taking antiretroviral mediations. For this study, 
adherence to antiretroviral medications was documented through improved clinical markers 
(Ickovics et al.). 
Catz and colleagues (2002) in a study of 100 HIV-positive minority and low- income 
women assessed depressive symptoms, physiological distress, coping styles, stressors, and 
perceived social support. When fit into the multivariate regression model less social support, 
avoidance coping, less problem solving, and increased stressors contributed to increased 
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depressive symptoms (R2 = .46, F [7,89] = 10.04, p < 0.001) (Catz et al.). The CES-D mean 
score was extremely high (M = 24.9, SD = 12.5) with 75% of the women scoring in the range of 
mild to severe depression; half (n = 56) of the women had scores suggestive of major depression.  
A study that investigated 118 women with HIV reported only 29% were adherent o their 
antiretroviral regimen (Murphy et al., 2000). The researchers found that, depressed subjects were 
less likely to be adherent, X 2= 11.8; OR = 0.3, p < 0.03 (Murphy et al.). Phillips and colleagues 
(2005a) investigated sleep disturbance, depressive symptomatology, and adherence to 
antiretroviral medications in 173 women with HIV. Adherence was measured by the ACTG and 
depressive symptomatology by the CES-D.  The mean CES-D score for this sample was 24.1. In 
the last 3 months, 70% (121) of the women reported being nonadherent to their antiretroviral 
medications; 35% (61) reported missing at least one of their medications in the last 30-days. 
Women with severe depression (M = 1.8 + 3.9) were less adherent than those women with 
moderate depression (M = 6.1 + 10.1; (t, = 123) = df -3.8, p = 0.0002). Women with severe 
depression were also more likely to miss medications due to falling asleep, reported difficulty 
taking medications as prescribed such as with meals or on an empty stomach, and reported 
feeling ill from taking the medications. The authors predicted the mediating effect of sleep 
quality on depressive symptoms and reported that sleep quality significantly predicted depressive 
symptoms (p < 0.0001) and adherence, (p < 0. 0001). Depressive symptoms were the most 
significant predictor of women’s adherence (p = .032) (Phillips et al., 2005a).   
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2.4.1.3 Summary of Depressive Symptomatology and Adherence to Antiretroviral 
Medications. 
Research suggests depressive symptomatology and one’s mental health influences an 
individual’s ability to cope with disease and focus on managing one’s life, as well as adherence 
to antiretroviral medications.  This issue of depressive symptomatology and antiretroviral 
medication adherence for women with HIV has not been fully explored. Therefore, it is 
important that research continues to investigate the potential relationship between depressive 
symptomatology and adherence to antiretroviral medications in all persons with disease.  
Research is needed to clarify how depressive symptomatology affects women with HIV because 
they often must manage the lives of others, including children.  
2.4.2 Social Support and HIV  
Social support can come from many sources such as the provider-patient relationship, family, 
significant others, peers, and networks within one’s community.  All of these sources may be 
instrumental in a person’s ability to continue with a new and/or complicated long-term treatment 
(Erlen & Mellors, 1999; Mellors, Riley, & Erlen, 1997; Misener & Sowell, 1998).  Almost from 
the beginning of this disease, there was a tendency to blame the victim. In the early 1980s before 
HIV was identified, there was discrimination against men with gay related immunodeficiency 
disorder (GRID) and/or the related diseases (Shilts, 1987). Historical research on HIV 
underscores the importance of social support for gay males with HIV. These men networked and 
formed strong social and political organizations such as ACT UP (AIDS Coalition to Unleash 
Power; www.actupny.org) to study every aspect of the disease (Shilts.). ACT UP and other social 
support networks were largely responsible for changing the direction of HIV/AIDS research 
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leading to improved HIV disease management (Greene et al., 2002; Oppenheimer, 1988; Patton, 
1987; Shilts.). These same networks also allowed gay males to have the types of relationships 
needed to sustain the difficult times in managing and living with HIV/AIDS. Unfortunately, 
women lack these types of social networks.  Thus, women must negotiate personal issues such as 
social support, stigma, and other psychological issues alone or with minimal social support 
(Greene et al.; Patton; Treichler, 1988.).  
There are investigations, many with men or men and women that address the importance 
of social support from many sources and the individual’s physical well-being, depression, coping 
ability, and improved health.  Nott, Vedhara, and Power (1995) reported that social support from 
others outside the family including male-partner support and best friend support was important. 
However, for this sample of gay men, family members were more important than friend support; 
fathers were the poorest source of support (Nott, Vedhara, & Power). Other researchers have also 
reported the importance of friend and family support, which played a key role in managing the 
disease (Serovich, Brucker, & Kimberly, 2000; Derlega, Winisead, Oldfield, & Barbee, 2002). 
Murphy and colleague’s study (2002) also found that family, friends and children were the 
greatest sources of social support; medication cueing (38%) was shown to be the most frequent 
type of support. This study included 560 men and 44 women with disease. 
There are investigations, many with men or men and women that address the importance 
of social support from many sources and the individual’s physical well-being, depression, coping 
ability, and improved health.  Nott and colleagues (1995) reported that social support from others 
outside the family including male-partner support and best friend support was important. 
However, for this sample of gay men, family members were more important than friend support; 
fathers were the poorest source of support (Nott et al.). Other researchers have also reported the 
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importance of friend and family support, which played a key role in managing the disease 
(Serovich et al., 2000; Derlega et al., 2003). Murphy and colleague’s study (2002) also found 
that family, friends and children were the greatest sources of social support; medication cueing 
(38%) was shown to be the most frequent type of support. This study included 560 men and 44 
women with disease. 
Participants in the Erlen and Mellors (1999) study of men and women described a 
supportive relationship with care providers as important in their decision to begin antiretroviral 
medications.  Likewise, mistrust of one’s physician (OR = 0.21, 95% CI 0.074 –0.57) and feeling 
socially isolated (OR = 1.92, 95% CI 1.14-3.24) were predictors of subjects’ not taking 
antiretroviral medications (Schroeder et al., 2001). 
Eleven (73%) of the 15 HIV-positive Black women in a qualitative study identified their 
physician as being the most influential factor in their decision to take antiretroviral medications 
as prescribed (Sankar, Luborsky, Schuman,& Roberts, 2002). Women in another qualitative 
investigation identified the continued support of their health care providers as important 
(Metcalfe et al., 1998). However, these women felt a greater need for peer support from other 
women with disease (Metcalfe et al.). The women also identified a greater need for more social 
support from community agencies to cope with the unique struggles they had in managing their 
children, their lives, and their HIV disease. Yet women in another study reported their greatest 
and most important form of support from informal family (kin) networks; parents, spouses or 
significant other, and children (Ciamborone, 2002). 
Research on impoverished inner-city women with HIV showed that a lack of social 
support and social isolation contributed to participants’ psychological distress (Hudson et al., 
2001).  In this study, perceived tangible social support was significantly associated with HIV-
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positive women’s emotional and disease related distress (F [7, 61]; p = 042) and explained 14% 
of the variance in the regression model (Hudson et al.). 
Misener and Sowell (1998) found that woman’s negative attitudes regarding medications 
 for HIV were influenced by lack of information from providers, mistrust in the medical and 
social service agencies, and poor reinforcement from family and friends.  Martinez et al. (2000) 
also found that poor social support from providers and others (family and/or peers) influenced 
adherence in inner city young adults and adolescent males and females.  Ciambrone (2002) also 
addressed poor (negative) social support from family, friends, and children “invalidating the 
illness” (p. 888). 
Bova’s (2001) study of 101 HIV-positive Black, Latina, and white women showed that 
social support did not influence disease adjustment or symptoms; however, appraisal of illness 
appeared to act as a mediator of social support, disease adjustment, and symptom experience. 
African American women reported  better  perceived social support (F = 5.35, df = 2, p < 0.01) 
and fewer HIV symptoms (F = 5.02, df = 2, p < .01), including less pain (F = 3.66, df = 2, p < 
.05) and a more positive appraisal (F = 7.13, df = 2, p < .01) than did their white and Latina 
cohorts (Bova).   
Likewise, women participating in a qualitative study felt they lacked social support due to 
their failure to disclose their disease status (Johnston-Roberts & Mann, 2000). For the women in 
this study limited access to friend networks was due to other responsibilities, particularly 
childcare (Johnston-Robert & Mann, 2000). One participant in the research described the 
absence of social support resources as “being placed in an emotional prison” (p. 380).  Black and 
Miles (2002) in their qualitative investigation of women with HIV reported that it was the desire 
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for social support from family and friends that led some of the women to disclose their HIV 
status despite the perceived stigma of HIV disease.  
Simoni and Cooperman (2000) investigated social support among 373 ethnically diverse 
inner-city women.  The researchers found improved social support had a buffering effect on 
depressive symptomatology (R2 = -0.17, p < 0.001) and physical well-being (R2 = .11, p < 0.05).  
In addition, there was a difference between perceived social support among the women. In this 
study, lesbian women reported greater perceived social support than their heterosexual cohorts 
(R2 = 0.11, p < 0.05). 
2.4.2.1 Social Support and Adherence to Antiretroviral Medications. 
A study of 63 men and 9 women showed that there was a significant relationship between 
adherence and decreased perceived social support (t [70] = 2.63; p = 0.011), increased depressive 
symptomatology (t [70] = 2.47; p = 0.16), less adherence self-efficacy (t [70] = 3.32; p = 0.001), 
and more medication side effects (t [70] = 2.15; p = .035) (Catz et al., 2000).  The most 
significant independent predictors of adherence were social support and adherence self-efficacy. 
For each decrease in the standard deviation for perceived social support, participants were more 
than twice as likely to have reported missed doses of antiretroviral medication (OR = 2.27; 95% 
CI, 1.04 - 4.96) (Catz et al.).   
Power et al. (2003) reported 74% of 39 men and 34 women were 100% adherent to their 
antiretroviral medications. And having a satisfactory relationship or support from one’s partner 
was statistically significant with improved adherence to antiretroviral medications (Beta = 0.113, 
p = 0.040) (Power et al., 2003). Support from friends and family was not statistically related to 
improved adherence.   
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A study of 39 female and 19 male urban inner-city Blacks and Latinos, demonstrated that 
poor social support was significantly associated with non-adherence (Beta = 0.24, p = 0.04) 
(Simoni, Frick, Lockhart, & Liebovitz, (2002). However, in the final regression model, social 
support was not statistically significant when integrated with social support and self-efficacy 
(Beta = -.32, p = 0.04) and self-efficacy and poor adherence (Beta = -0.49, p < 0.01). The authors 
identified social support as having a mediating effect on adherence (Simoni et al.).  
Simoni, Frick and Haung (2006) recently explored the potential mediating effect of social 
support on adherence to antiretroviral medications. They followed 75 men and 61 women were 
for a period of 6 months. Using modified structure equation modeling there were statistically 
significant paths for social support, negative affect, greater spirituality, self-efficacy to adhere, 
adherence at 3 months, and viral load at 6 months [X 2 (113, N = 136) = 152.78, p = .008, CFI = 
.95, TLI = .94, RMSEA = .05 (.03, .07)]. There was no direct relationship between social support 
and adherence. There was an indirect relationship for adherence and social support through 
negativity (Beta = -.422, p <. 001), spirituality (Beta = .53, p < .01), self-efficacy (Beta = .40, p < 
.001), and negative affect (Beta = -.26, p < .01). In addition, using this model explained the 8% 
of the variance for adherence after 3 months and 8% of the variance in the viral load (Simoni Et 
al.). The authors suggest that interventions to increase and maintain social support for persons 
with HIV and taking medications might improve their self-efficacy to adhere, spirituality, 
decrease their negativity, and thus, result in better adherence (Simoni et al., 2006).    
2.4.2.2 Social Support and Adherence to Antiretroviral Medications fo Women with HIV. 
Gardner et al. (2002) reported a relationship between increased support from HIV 
specialist care providers and more education about medication use and better medication 
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adherence (relative risk [RR] = 2.4; 95% CI, 1.3 - 4.6). The relationship did not exist for women 
in the study receiving care from a generalist. In another study, the support and positive 
reinforcement of an HIV specialist contributed to women accepting antiretroviral treatment (OR 
= 2.8; 95% CI, 1.0 - 7.5) and improved clinical indictors, specifically an improved CD 4 and 
lower viral load (OR = 1.4; 95% CI, 0.5 - 4.0) (Mostashari, Riley, Selwyn, & Altice, 1998). 
Findings from a qualitative study with 20 ethnically diverse women showed a relationship 
between positive social support and improved adherence to antiretroviral medications in women 
with HIV (Johnston-Roberts & Mann, 2000).   
The type of social support received and from whom also appears to impact women’s 
decisions to take antiretroviral medications and their adherence to the regimen (Misener & 
Sowell, 1998). Results from a study of 24 HIV-positive women demonstrated a relationship 
between perceived family support and fewer depressive symptoms (r = -0.560; p < 0.01), anxiety 
(r = -0.455; p < 0.05), stress (r = -0.731; p < 0.01), and feelings of loneliness (r = -0.748; p < 
0.001) (Serovich, Kimberly, Mosack & Lewis, 2001). Although support from friends was 
important, it was the perception of the sustaining support from family members that had a greater 
impact on mental health for this sample of women with HIV (Serovich et al.).  However, other 
researchers failed to find a relationship between social support and/or social networks and 
adherence to antiretroviral medications for adolescent females with HIV (Murphy et al., 2000). 
The authors explained that these phenomena might be related to the increased sociability during 
this time in adolescent development and/or other adherence behaviors. 
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2.4.2.3 Summary of Social Support and Adherence to Antiretroviral Medications.   
Research suggests that positive as well as negative social support and interaction influences 
one’s perception of their disease and consequent life stressors such as depressive 
symptomatology.   In addition, some research suggests from whom the social support comes 
(i.e., family, friends, or physician) and the amount of social support provided may affect one’s 
adherence to their antiretroviral regimen.   
There is little research that has specifically reported a relationship between social support and 
adherence to antiretroviral medications for women with HIV.  There is anecdotal evidence, such 
as in the Misener and Sowell (1998) study, to suggest social support has an affect on the use of 
antiretroviral medications. Therefore, there is a need to examine the potential affect social 
support may have on women taking antiretroviral medications and achieving optimal, 95% 
adherence to these medications.  
2.4.3 Perceived Stigma and HIV 
Stigma comes from the Greek language and is associated with the tattoo and mark of shame or 
disgrace (Goffman, 1996). Social interaction occurs between persons who perceive themselves 
as normal (the unstigmatized) and the non-normal (the stigmatized). The stigmatized are labeled 
and/or identified as flawed, undesirable, and morally corrupt. Thus, a diagnosis of HIV is 
potentially stigmatizing, as it often labels the woman as unworthy, prejudges her moral values 
and lifestyle, and devalues her as a mother, sister, and wife (Leenarts, 1998). Disclosure of one’s 
disease to others is often regulated by the perceived stigma attached to a diagnosis of HIV 
(Greene et al., 2002). In fact, Greene and colleagues suggested that the perceived stigma 
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associated with HIV might play a pivotal role in delayed testing for disease and seeking health 
care.  
Perceived stigma occurs because of how the disease was acquired through sexual contact 
or IDU and by being diagnosed as HIV-positive.  There is no doubt that from the time the new 
gay related immune disease (GRID) was recognized, there was a stigma attached to how the 
disease was acquired and who were affected; gay males and drug users (Crandall & Coleman, 
1992; Oppenheimer, 1988; Shilts, 1987). Crandall and Coleman address the perceived and actual 
stigma and discrimination associated with GRID and/or HIV. This early study of 40 men and 8 
women reported perceived stigma was highly correlated with depression, negative affect, distrust 
of others, and anxiety about their disease. In addition, the study reported an association between 
loss of social support due to the associated perceived stigma of the HIV diagnosis; however, the 
researchers did not analyze the variable separately for women.  
Bunting (1996) acknowledged that women with HIV are often stigmatized because of 
their sexuality, gender, minority status, poor socioeconomic status, and the diagnosis of their 
disease. Women with HIV are blamed for their disease, which enables those without disease to 
place themselves on a higher moral plain (Bunting.). Women with HIV fear prejudice and 
discrimination and perceive a risk that includes losing custody of one’s children if their disease 
status is known (Simoni & Ortiz, 2003).  
Black and Miles (2002) in their qualitative research of perceived stigma identified three 
patterns of disclosers of women with HIV: secretive, selective, and full-disclosers. Each category 
presented the women with both risks and benefits of revealing their HIV-positive status. 
Secretive-disclosers usually concealed their HIV status from all but one or two trusted 
individuals, usually a partner/husband or mother like-figure. For this category, the fear of 
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shunning and the resulting consequence often resulted in feelings of anger, isolation, and loss of 
social relationships. Selective-disclosers expanded their network of others aware of their 
diagnosis on a “needs to know basis” (p. 693). Women in this category closely linked their 
disclosure choice to their need for increased social support (child-care or transportations to 
health care service) versus a willingness to risk the perceived stigma associated with HIV. Only 
three of the 48 women in the study were identified as full-disclosers. Each of these women 
identified a different reason for fully disclosing their disease status but all withheld the 
information from their children.  This latter group appeared able to withstand the perceived 
stigma associated with the disease for themselves but did not want the effects of stigma 
transferred to their children (Black & Miles).  
A qualitative study of eight HIV-positive women reported that aside from the trauma of 
learning their diagnosis, all participants expressed unknown fear of societal reactions to women 
with HIV (Metcalfe et al., 1998). However, the greatest fear for these women did not focus 
around their diagnosis of disease but the uncertain implications their disease would have for their 
children and the resulting stigmatization associated with their HIV disease. 
Berger and colleagues (2001) used the HIV Stigma Scale with a sample of 310 men 
(80.6%) and women (19.4%) and reported Pearson r correlations between stigma and low self-
esteem (r = -.60, p < .001), depressive symptomatology using the CES-D (r = .63, p < .001), 
social support (r = .54, p < .001), and social conflict (r = .59, p < .001). In addition, stigma as 
related to negative self image was negatively correlated with low self esteem (r = -.68), 
depressive symptomatology (r = - .66), and subjective social interaction (r = -.62) (Berger, 
Ferrans, & Lashley). 
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2.4.3.1 Perceived Stigma and Adherence to Antiretroviral Medications.    
There were no investigations assessing perceived stigma or stigma and any direct 
relationship of stigma on one’s self-reported adherence to antiretroviral medications for either 
men or women with disease following an extensive search of Medline, Pub Med, CINAHL, and 
Psych Info. There were several publications that addressed stigma such as: disclosure and 
antiretroviral medication use (Klitzman et al., 2004), coping, disclosure and women’s use of 
antiretroviral medications (Siegel & Schrimshaw, 2005), stigma and depression(Abel, Rew, 
Gortner, & Delville, 2003), disease associated stigma and use of medications and reports of non-
adherence related to stigma (Schrimshaw & Siegel, 2003).  
2.4.3.2  Summary of Perceived Stigma and Adherence to Antiretroviral Medications.      
The above articles briefly review the importance of perceived stigma in living with and 
managing one’s HIV disease. The stigmatizing impact of HIV is not in question. There is 
sufficient research that addresses the perceived stigma of a diagnosis of HIV. For many persons 
with HIV, particularly women, they must also struggle with the perceived stigma of poverty, 
race, poor education, single parenting, and limited opportunities for themselves and their 
children. Most research that addresses the perceived stigma attached with HIV has been of a 
qualitative nature. The Berger et al. study (2001), although extensive and diverse, does not 
explore the issue for a large sample of women. Moreover, there is little research investigating the 
relationship between perceived stigma and adherence to antiretroviral medications in women 
with HIV. 
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2.5 PSYCHOLOGCIAL PREDICTORS OF ADHERENCE TO ANTIRETROVIRAL 
MEDICATONS 
As shown in the framework for this study, four concepts of physiological predictors will be 
examined. The first two, CD 4s and viral load and their significance and relationship to disease 
progression and adherence have been addressed in earlier sections of this and the previous 
chapter. Although an increase in one’s viral load and a decrease in CD 4 is often suggestive of 
non-adherence, there may be other reasons for a change in the CD 4 and viral load.  HIV disease 
symptoms will be reviewed within the context of the various symptoms that may have an affect 
on women’s adherence to antiretroviral medications. Physical well-being as it is reviewed is a 
function of one’s abilities for social and role functioning, general perception of health, and one’s 
quality of life. 
2.5.1 CD 4 and Viral Load and HIV 
Catz et al. (2000) in their study of 63 men and 9 women used self-reported medication adherence 
to assess their antiretroviral medications, complete a calendar of activities, and report the total 
number of medications missed over the previous 5 days. Thirteen participants (18%) were 
identified as non-adherent.  There was a significant relationship between number of missed doses 
and increased viral loads, Mantel-Hanszel X 2 (1, N = 72) = 5.3, p < 0.05 (Catz et al.). 
2.5.1.1 Summary of CD 4 and Viral Load and Adherence to Antiretroviral Medications.  
 CD 4 and viral load is no longer considered a method of assessing one’s adherence to 
antiretroviral medications. An individual may be 100% adherent but yet there may be changes in 
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their CD 4 and viral load; suggesting the possibility of medication resistance. Or, an individual 
be less than 95% adherent and yet reflect adequate CD 4 and viral load laboratory values. 
Therefore, CD 4 and viral load, if known, are no longer appropriate for assessment of adherence.  
2.5.2 HIV Disease Symptoms and HIV 
Nurses and health care providers often group the physical manifestations of disease, signs and 
symptoms together as one.  Dodd et al. (2001)using the University of California, San Francisco 
(SCSF) School of Nursing Center for Symptom Management model defines symptoms as “ a 
subjective experience reflecting changes in the biophysical functioning, sensation, or cognition 
of an individual” (p. 669). A sign is a part of the physical assessment process for evaluating 
“disease status and to evaluate and verify the effectiveness of management strategies” (p. 669).  
Dodd et al. (2001) reported that both signs and symptoms are important and both can be 
significant indicators of abnormal health and possible pathology associated with illness.  For 
example, fever (a symptom) reflects a temperature (a sign) either of which is not an expected 
clinical finding during a physical assessment or which may prompt a person call to their health 
care provider.  An elevated temperature is suggestive of an infection, dehydration, or many 
illnesses; viral or bacterial. On the other hand, the lack of a symptom or sign does not suggest an 
individual is in optimal health, nor does it suggest they do not require the interventions of a 
health care provider.  
Persons with HIV may or may not have symptoms. The presence of symptoms may be 
suggestive of disease progress; a change in the CD 4 or viral load (Holzemer, 2002). To further 
complicate the assessment of symptoms, it is sometimes difficult to separate the symptoms 
associated with HIV from those symptoms associated with the use of antiretroviral medications. 
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In fact, the use of antiretroviral medications may exacerbate the symptoms already associated 
with the presence of HIV disease (Chesney et al., 1999; Gifford et al., 2000; Hudson et al., 2004; 
Johnson, Stallworth, & Neilands, 2003).   As Mannheimer and colleagues (2005) suggest, these 
symptoms can and often do interfere with one’s quality of life (QoL) for persons with HIV and 
limit their abilities to care for themselves and others (Hudson et al., 2004; Holzemer et al., 1999; 
Holzemer et al., 2001; Holzemer, 2002; Johnson et al.; Justice et al., 2001; Spirig, Moody, 
Battegay, & DeGeest, 2005; Reynolds et al., 2004).    
2.5.2.1 Symptoms and HIV.  
Dodd and colleagues report it is not only the presence of the symptoms that are important 
but how the individual responds to the symptoms. Researchers address the complexity of the 
symptom experience, the behavioral implications, physical and psychological, which may further 
affect one’s social relationships. For example, for women with HIV the presence of fatigue may 
result in the inability to work outside their home. The inability to financially provide for their 
children and themselves may contribute to feelings of sadness, depressive symptomatology, fear, 
and anxiety, and may result in social isolation from family, friends, and peers (Holzemer, et al., 
1999; Hudson et al., 2004; Reynolds et al., 2004). 
Holzemer (2002) explains it is not just the presence or absence of symptoms but how the 
person responds to their array of symptoms that may ultimately affect their adherence to 
medication, social and role function, and overall ability to live with and manage their HIV 
disease. In fact, the presence of an increased number of symptoms, especially depressive 
symptomatology, was associated with non-adherence (Holzemer et al., 1999). Other research 
suggests that increased symptoms result in a change in health behaviors such as increased use of 
alcohol and poor quality of life (Hudson et al., 2004; Johnson et al., 2003; Mannheimer et al., 
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2005; Phillips et al., 2004; Phillips et al., 2005a; Phillips et al., 2005b; Spirig et al., 2005; 
Valenti, 2004).    
Numerous symptoms have been associated with HIV disease. Justice et al. (2001) and 
Holzemer (1999, 2001, 2002) have done extensive research to identify the following symptoms: 
shortness of breathe, fever, fatigue, night sweats, gastrointestinal complaints (diarrhea, nausea, 
vomiting, and constipation), weight loss, tender and swollen lymph glands, decreased strength, 
anxiety, fear, and depression. Holzemer et al. (2001) revised the self-reported symptoms list to 
include changes in body fat distribution (lipodystrophy) and women’s unique gynecological 
related symptoms: vaginal discharge, itching, odor, irregular or heavy menstrual cycles, break-
through bleeding (between menstrual cycles), and pelvic pain. The symptoms or side effects of 
antiretroviral medication include abdominal complaints (gas and bloating, upset stomach, 
nausea, vomiting, diarrhea, and constipation), fatigue/malaise, headache, muscle and joint pain, 
dry mouth, changes in taste, anemia, hair loss, and physical changes to one’s body fat 
distribution (Johnson et al., 2002). 
A multi-site study of 336 men and 84 women used a modified 4-item self-report measure 
to assess adherence to antiretroviral medications (Holzemer et al., 1999).  The participants also 
completed additional measures for depression (CES-D), functional status (13 items from the 
MOS-SF 36), quality of life (7 items from the MOS-SF 36), living with disease, and 
environmental/interpersonal resources.  Using hierarchical multiple regression analysis to 
identify predictors of non-adherence, the researchers found that symptoms of disease was the 
strongest predictor of adherence (R2 = 0. a predictor of adherence, X 2 (420) = 38.521; df 10, p < 
0.00. In this model, nausea and vomiting (OR = 0.68; p = 0.06) and depression (OR = 1.05; p = 
0.01) were significant predictors of adherence.  In addition, environmental/interpersonal factors 
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and poor social support were the strongest predictors of subjects’ non-adherence to their 
antiretroviral medications (OR = 0.46; p = 0.00) (Holzemer et al.).  
Hudson and colleagues (2001) reported issues of symptom control for women; however, 
did not assess adherence. In another study, 420 men and women reported that the presence of 
symptoms explained 11% of the variance in their multi-factor model with subjects reporting 
greater symptoms also reporting being less adherent to their medications (Holzemer et al., 2001).  
111, p = 0.004). Logistic regression analysis of the nine symptom predictors also supported 
symptoms as  
2.5.2.2 Summary of HIV Disease Symptoms and Adherence to Antiretroviral 
Medications.  
There is anecdotal evidence to suggest that symptoms impact adherence. There is also 
some connection between the presence and absence of symptoms and changes in the patient’s 
CD 4 and viral load. Numerous studies address the effect of HIV disease related symptoms on 
one’s quality of life, role and social function as cited above (Dodd et al., 2001; Holzemer, 2002; 
Hudson et al., 2004). However, there remains a gap in the literature for HIV disease symptoms 
and the possible relationship they may have on one’s self-reported adherence to antiretroviral 
medications. This gap is true for literature relating to men and women living with and trying to 
manage their HIV disease.  
2.5.3 Physical Well being and HIV 
The perception of one’s quality of life is often centered on one’s abilities to be physically well 
and engage in multiple physical and social activities.  An individual who is acutely ill often has 
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limited capacity and desire to engage in physical activity. However, once the acute phase has 
past and their illness becomes chronic, one’s physical and social activities may continue to be 
adversely influenced.  
As discussed in the section on depressive symptomatology, one’s mental well-being 
interacts with one’s physical wellness and influences one’s overall quality of life. The HIV 
disease related symptoms are often manifested as one or more physical signs and/or symptoms of 
disease.  However, for persons with HIV it is often difficult to discern disease related symptoms 
from antiretroviral medication related symptoms and both appear to influence one’s physical, 
role, and social functioning (Holzemer et al., 1999, 2001; Hudson et al., 2004; Johnson et al., 
2003; Justice et al., 2001). 
2.5.3.1 Physical Well-being and Adherence to Antiretroviral Medications.      
Liu and colleagues (2006) reported that despite the use of antiretroviral medications to 
manage disease, women reported negative feelings, which interfered with their social, role and 
physical functioning. In their research, van Servellen and colleagues (2002) investigated the 
gender differences in physical well-being as a function of health related physical well-being.  
This study of 44 women and 82 men reported that regardless of ethnicity, women had more HIV-
related symptoms and impaired physical function than men. Women had more HIV-related 
symptoms (women, M = 2.4, SD = 1.1; men, M = 1.7, SD 1.3, p < 0.01), more functional 
limitations (women, M = 10.4, SD 2.2; men, M = 11.8, SD = 2.6, p < 0.01), and decreased 
physical well being (women, M = 1.5, SD = 0.6; men M = 0.9, SD = 0.7, p < 0.001) (van 
Servellen et al.).   
Tate and colleagues (2003) reported a relationship between mood and decreased physical 
functioning (r = - 0.355, p < 0.05), mental health (r = - 0.613, p < 0.01), social functioning (r = - 
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0.556, p < 0.01), emotional role functioning (r = -0.411, p < 0.01), vitality (r = - 0.443, p < 0.01), 
pain (r = - 0.481, p < 0.01), and general health perception (r = - 0.468, p < 0.01.  There was also a 
trend toward lower scores for all components of physical function for the MOS-HIV (F [1, 61] = 
3 .9, p = 0.051) (Tate et al.).   Likewise, Mrus et al. (2005) in their comparison study of 976 men 
and 202 women with HIV reported that women had lower physical functioning scores than their 
male cohort (women 6.7 points lower; p < 0.001). The authors used the ACTG Quality of Life 
Health Survey, which is a modified version of the MOS SF-20.  
Mannheimer and associates (2005) investigated the relationship between physical and 
mental well being and adherence to antiretroviral medications in a study of 412 men and 102 
women with HIV over a period of 1 year. The SF-12 Health Survey instrument was used for this 
study, a version of the MOS-HIV (Wu et al., 1991); scores were categorized into physical and 
mental component summary scores. Adherence was self-reported using a 7-day recall measure 
with subjects’ adherence rates identified as 100%, 99-80%, and less than 80% adherent.   Over 
the 1-year, adherent vs. non-adherent subjects had better physical scores (49.20 vs. 46.15, p 
<0.001).  Subjects identified as 100% adherent had significantly better physical scores (48.7 vs. 
43.9, p < 0.001) than subjects with 80% adherence.  In addition, as subjects’ adherence improved 
over the 12-month period their physical component score increased; those with < 80% adherence 
had a decrease in their physical component score (Mannheimer et al.). 
In a clinical trial of antiretroviral medications, 967 men and 189 women reported 
improved physical and mental well-being as the CD 4 values increased and viral load decreased 
(Weinfurt, Wilke, Glick, Freimuth, & Schulman, 2000). These changes in physical health (PH) 
and mental health (MH) were more noticeable 12 weeks into the study for viral load (PH, R2 = 
0.23, p < 0.05; MH, R2 = 0.23, p < 0.05) than changes in the CD 4 (PH, R2 = 0.32, p < 0.05; MH, 
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R2 = 0.38; p < 0.05). The CD 4 and viral load were used as indicators of adherence to 
antiretroviral medications  
An investigation of 114 men and 28 women hospitalized with AIDS explored the 
relationship between functional status, symptoms, and clinical indicators (Sousa, Holzemer, 
Henry, & Slaughter, 1999). Findings from the four-tiered multiple linear regression analysis 
suggested statistical significance for general health perception (R2 = .107, p < 0.001), functional 
status (R2 = 0.158, p < 0.001), symptom status (R2 = 0.202, p < 0.001), and clinical markers (R2 = 
0.201, p < 0.05) (Sousa et al.). Antiretroviral medications were not measured. 
Reynolds et al. (2004) in their study of men and women reported significant relationships 
between non-adherence and role function (r = 0.16; p = 0.005), non-adherence and health 
perception (r = 0.19; p = 0.001), and non-adherence and social emotional-cognitive functioning 
(r = 0.25; p = 0.001).  
Although adherence to antiretroviral medications was not assessed, another large 
investigation explored health related quality of life (HRQoL) for 2,864 persons with HIV, 49% 
men (Hays et al., 2000). Men and women with HIV/AIDS had more disease-related symptoms, 
less functional ability, and poorer physical well-being than was demonstrated in studies of 
persons with other chronic disorders (difference [USA population] = HIV disease of 14 points; 
95% CI, 11-18; p <0.001). In addition, for persons with AIDS the differences were more 
pronounced than for people with other chronic disorders (difference, 32 points; 95% CI, 28-35; p 
< 0.001) (Hays et al.).   
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2.5.3.2 Physical well-being and adherence to antiretroviral medications for women with 
HIV.   
Liu and colleagues (2006)) in their longitudinal study investigated women naïve to 
antiretroviral treatment and women using antiretroviral medications.  For this sample of 458 
matched pairs of women, the use of antiretroviral medications demonstrated significant 
improvements in four-domains; role function (mean change: 5.08; p = 0.01), social function 
(4.33; p = 0.01), pain  (4.53; p = 0.01), and perceived health index (4.53, p = 0.01).  Over time, 
there was only a small decline in these domains; role function (2.17; p < 0.01), social function 
(0.11; p < 0.02), pain (1.57; p < 0.01), and perceived health index (0.24, p < 0.01).   Simoni and 
Cooperman (2000) in their research of inner city women with HIV reported a relationship 
between three domains: general health (r = 0.15; p < 0.01), physical symptoms (r = -.25; p < 
.001), and CD 4 (r = .11; p < .05).  
An adherence investigation of 766 women with HIV reported statistically significant 
relationships between participants with greater than 95% adherence (585) and women with less 
than 95% adherence (181) using the MOS-HIV (Wilson et al., 2002).  Differences between non-
adherent and adherent women for the domains specific to the physical well-being subscore were: 
physical functioning (M = 64.5, SD = 29.4 vs. M = 69.2, SD = 28.3; p < .05), pain (M = 66.4, SD 
= 26.9 vs. M = 72.9, SD = 27.3; p < .01), energy/fatigue (M = 51.1, SD = 24.2 vs. M = 57.3, SD = 
24.6; p < .01), and health perception (M = 48.5, SD = 23.1 vs. M = 56.9, SD = 24.3; p < .01), 
social function and role function were not statistically significant (Wilson et al.).  
Cowdery and Pesa (2002) in their investigation of 82 HIV-positive women reported 
statistically significant relationships between independent variables, demographics (age, 
ethnicity, education, and employment), social support, and time since HIV diagnosis, CD 4, 
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symptoms and Karnofsky performance score (KPS).  Based on six multiple regression models 
there were predictors for each of the six domains of the MOS-SF-20.  Age and KPS was 
correlated with physical functioning (R2 = 0.442, p = 0.009). Employment status was correlated 
with role function (R2 = 0.394, p = 0.005). Age, employment status, and KPS were correlated 
with social functioning (R2 = 0.391, p = 0.005). Social support was correlated with mental health 
(R2 = 0.389, p = 0.005).  KPS and social support were correlated with health perception (R2 = 
0.348, p = 0.020), and KPS, social support, and discrimination were correlated with pain (R2 = 
0.413, p = 0.002) (Cowdery & Pesa). 
2.5.3.3 Summary of Physical Well-being and Adherence to Antiretroviral Medications.  
Research would suggest that one’s physical functioning has a relationship with social and 
role function and overall ability to interact with others. Research would suggest that one’s 
physical functioning has a relationship with social and role function and overall ability to interact 
with others. There is limited research that has investigated the relationship between physical 
well-being and adherence to antiretroviral medications. Although researchers reported poor 
physical function greatly affected women with HIV (Remplle, Hilton, Ratner, & Burdge, 2004; 
Tostes et al., 2004; Weaver et al., 2004), there is a gap for how this relates to their adherence to 
antiretroviral medications.  
2.6 SUMMARY 
HIV as a chronic disease is an open field for nursing research due to the recent  
advances in disease management and late entry of women with disease into clinical trials. 
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The course has been set for pursuing such research with the suggestion of potential psychological 
and physiological variables, as findings suggest from previous research.  This investigation of 
psychological and physiological factors may influence future research for adherence to 
antiretroviral medications in women with HIV disease. For research to contribute to the body of 
knowledge regarding women with HIV, it must focus on specific variables/factors that affect 
adherence to antiretroviral medications. The factors that were explored for this study were 
selected psychological factors (depressive symptomatology, social support, and perceived 
stigma) and selected physiological factors (CD 4, viral load, HIV disease symptoms, and 
physical well-being) and if or how these factors predicted self-reported adherence to 
antiretroviral medications use in women with HIV.  In addition, selected sociodemographic 
variables (age, education, race/ethnicity, marital status, and exposure risk category) were 
examined for their potential relationships on self-reported adherence to antiretroviral medication 
use in women with HIV. 
Guided by theory, self-efficacy was examined for its potential mediating effect on the 
relationships between the selected psychological factors, selected physiological factors, and 
demographic variables and self-reported adherence to antiretroviral medication use in women 
with HIV.  Because women with HIV often have less education, poor financial resources, and are 
from minority groups, their perceived self-efficacy may already be less than others. It was 
important that research of perceived self-efficacy for women with HIV be investigated. 
Addressing the identified gaps in the literature is needed prior to designing adherence strategies 
for optimal success with HIV antiretroviral medication management in the future.  
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3.0  CHAPTER THREE 
3.1 METHODOLOGY 
Conducting research, similar to conducting a literature review of the concepts of interest, can be 
approached from many perspectives. However, both processes require a plan, albeit a method. 
Polit and Hungler (1994) refer to the research design as an “overall plan for obtaining answers to 
research questions and testing the research hypothesis” (p. 225).  The method selected for one’s 
inquiry is the “formal, systematic, and rigorous process” that Fawcett describes in her work 
(1998, p. 8). The design of the research lays out strategies for the researcher to implement and 
conduct the study. Indeed, if the theoretical or conceptual framework drives one’s study, the 
methodology provides the mechanics and components of the engine. 
3.2 DESIGN 
This descriptive cross-sectional study was conducted to examine selected psychological factors 
(depressive symptomatology, social support, and perceived stigma) and selected physiological 
factors (CD 4, viral load, HIV disease symptoms, and physical well-being) that were considered 
to be potential predictors of self-reported adherence among women with HIV who were 
prescribed antiretroviral medications. In addition, this study examined the mediating effect of 
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self-efficacy on the relationships of the selected psychological factors (depressive 
symptomatology, social support, and perceived stigma) and selected physiological factors (CD 4, 
viral load, HIV disease symptoms, and physical well-being) and self-reported adherence to 
antiretroviral medications among women with HIV who were prescribed antiretroviral 
medications.  Standardized research measures were used to collect data on each of the study 
variables in a convenience sample of women with HIV living in the tri-state area of western 
Pennsylvania (Ohio and Pennsylvania, and West Virginia). No women were recruited from West 
Virginia. 
3.3 POPULATION AND SAMPLE 
The population of interest was English speaking women who were 18 years of age or older and 
diagnosed with HIV or AIDS. Specifically, the sample was recruited from an urban university 
primary care clinic, a community-based center, and rural clinics only in Western Pennsylvania. 
3.3.1 Setting 
Women who received HIV care at a university primary care clinic, community-based center, and 
rural clinics in the tri-state areas of western Pennsylvania were asked to participate in the study. 
The multiple sites for recruitment and data collection were selected to increase the diversity of 
the sample. However, as data collection progressed there was limited diversity as western 
Pennsylvania has primarily white, non-Hispanic and African American populations. The 
projected sample from the university and rural clinics consisted of white and Black participants. 
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The original plan was to include women from a clinic in Lancaster County, Pennsylvania. This 
site was selected because of the HIV health care provided to Latina women, primarily women 
who had migrated from Puerto Rico. However, this site became unavailable. The western 
Pennsylvania university-based clinic had approximately 900 clients with an estimated 25% being 
women. The rural clinics of northwestern PA had approximately 200 clients with an estimated 
35% being women. 
3.3.2 Eligibility Criteria 
Women who were 18 years or older, diagnosed with HIV/AIDS for a period of at least six 
months or longer, and prescribed antiretroviral medications were invited to participate in the 
study.  Participants needed to be free of neurocognitive impairment and mental health disorder 
based on self-report. Participants were required to read and write English.  The inclusion criteria, 
speaking English, did not discriminate in any way toward a non-English speaking person.  Health 
care agencies in the tri-state area of western Pennsylvania serve primarily Black and white 
patients with less than 1% of the population being non-English speaking. Females of 
childbearing age and pregnant women were not excluded from the study provided they met the 
other inclusion criteria.  Participants were required to have access to a telephone for the 
researcher to contact them to schedule an appointment to obtain informed consent, screen, and 
collect data.  
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3.3.3 Sampling Procedure 
The study was originally projected to include a convenience sample of 75 women.  At that time, 
the sample size was configured by considering the feasibility of recruiting the desired sample and 
having adequate power (.90) when evaluating the primary aims of the study. A secondary 
analysis of baseline data from an intervention study (R01NR04749, J. Erlen, Principal 
Investigator) at the University of Pittsburgh, School of Nursing, assisted in estimating the 
number of subjects needed for the greatest power. Multiple linear regression analysis of 
depressive symptoms, social support, perceived stigma, and physical well-being on self-reported 
adherence, explained 44.7% of the variance in adherence. Given this finding, a sample size of 75 
women would have had at least .90 power to detect an R-squared of .447 based on eight 
predictor variables (using total scale scores) when using multiple linear regression analysis with 
an alpha of .05, two-tailed test (PASS, version 2002, Kaysville, UT).  With 0.80 power this study 
would have be able to detect R-squared as small as .183 based on eight predictor variables with 
an alpha of .05, two-tailed test (PASS, version 2002, Kaysville, UT).  
 
Table 1. Multiple Regression Power Analysis 
Power N Alpha Beta Count Ind. 
Variables 
Tested R2
Count Ind. Variables 
Controlled R2
0.9999 75 0.0500 0.0000 8 0.447 0 0.0000 
0.9000 75 0.0500 0.1000 8 0.222 0 0.0000 
0.8000 75 0.0500 0.2000 8 0.183 0 0.0000 
 
Because of problems with recruitment the sample size was re-calculated using the above-
described procedures. A more complete discussion of the changes in the power analysis and 
sample recruitment will be addressed later in this chapter under the heading, Difficulties and 
Limitations.   
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3.4 PROCEDURES 
3.4.1 Recruitment 
Following approval from the Institutional Review Board at the University of Pittsburgh, the 
researcher began to recruit, enroll, and screen participants, and collect data.  Women who met 
the inclusion criteria were invited to participate in the research study. Nurses, physicians, social 
workers, and case managers at the recruitment locations assisted the researcher in identifying 
potential participants by informing the women about the study. In addition, self-referral materials 
(a bi-fold handout and “pull-off” posters) were available for staff at all recruitment sites to 
distribute to interested and potential participants.  The “pull-off” was a standard 8 by 10 colored 
piece of paper, which included a brief description of the study and had pre-cut sections at the 
bottom of the sheet with the study contact number. Potential participants were able to self-refer 
by contacting the researcher at a toll-free telephone number or an email address. Both the 
telephone number and email address were included on the self-referral handout and “pull-off 
poster”. The researcher made telephone contact with each potential participant to screen for 
appropriateness, query for permission to ask personal information, determine if the potential 
participant was interested, and arrange an appointment to obtain informed consent and collect 
data.  Recruitment for the study occurred at multiple sites including the rural clinics and public 
areas of convenience for the potential participants from the rural areas and the university clinic. 
A brief description of the study was provided to each potential participant during initial 
contact.  In addition, the researcher assured the potential participant of her confidentiality and 
discussed the need for written informed consent.  The researcher screened for inclusion criteria 
during the initial telephone call or personal contact.  At that time, the researcher made an 
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appointment with the participant at a mutually agreed upon time and place.  Numerous subjects 
at the rural clinics elected to meet immediately and continued with the informed consent and data 
collection. When potential participants made appointments through telephone contact, they 
received a telephone reminder call the day of the scheduled appointment.  If contact was not 
established, a second reminder call was made; a message was left on an answering machine, if 
possible and the researcher continued to the recruitment site at the designated time.  Use of a 
mobile telephone made it possible for potential participants to contact the researcher while 
traveling to the recruitment site to cancel and/or reschedule the appointment. 
The preferred location for data collection at recruitment sites was a private conference 
room. However, due to issues of convenience for potential subjects, recruitment occurred in their 
home or at a designated location near their home. This strategy greatly increased recruitment for 
women who received health care from the rural clinics. Most of these rural dwelling women 
lived 30 to 60 miles or more from their respective clinic. The dates and times for their next clinic 
appointment occurred on a rotating or variable monthly schedule meaning they did not attend a 
clinic again for 1 to 3 months. Regardless of recruitment site, following discussion of the 
informed consent and summary of the key points of study participation, the potential participant 
was asked to sign the informed consent document.  Each participant received a signed copy of 
the informed consent. The researcher kept a copy of the informed consent in a locked file in her 
office that was separate from the data files. 
3.4.2 Data Collection 
Following informed consent and using an interview format, the researcher screened the 
participant. Two screening measures were used. The Rapid Estimate of Adult Literacy in 
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Medicine (REALM) was used to briefly assess the ability of the participant to read and 
understand medical terminology (Davis et al., 1993).  Possible neurocognitive impairment was 
assessed using the 4-item HIV Dementia Scale [HDS] (Powers, Selnes, Grim, & McArthur, 
1995).  These measures took approximately 10 minutes to complete. If any subject stated that she 
was unable to read or the researcher suspected a reading or mental handicap that limited the 
participant’s ability to read and understand the informed consent process, she was informed she 
was ineligible for the study at this time. 
The AIDS Clinical Trial Group Assessment (ACTG) measure of self-reported adherence 
(Chesney et al., 2000) required a brief interview to identify the prescribed antiretroviral 
medications and the regimen, frequency of dosing, and number of pills taken at each time 
interval. The remainder of the ACTG and all other instruments were self-administered. The 
participants answered all questionnaires only one time. Completing the questionnaires took 
approximately 45-60 minutes. The researcher reviewed each questionnaire for completeness 
prior to the participant’s leaving the site. A token of appreciation ($15.00) was provided to assist 
with the recruitment of subjects and was given to women immediately after completing the 
questionnaires. 
Subjects who had not previously used the electronic Medication Event Monitor system 
(MEMS) cap or had not used the MEMS cap in a previous study for at least a period of 90 days, 
and were agreeable, were asked to use the MEMS cap for one antiretroviral medication for a 29-
day-period. A convenience subsample of 12 women was recruited to use the MEMS cap.  
Participants were instructed in the purpose of the MEMS for the selected antiretroviral 
medication during the next 29 days. When a participant took more than one antiretroviral 
medication, the researcher assigned a number to each medication. Each number (for example 1, 
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2, 3, 4) was written on a small piece of paper and placed in an envelope. The subject then 
selected one number from the envelope and the number corresponding to a specific medication 
was identified as the medication for use with the MEMS cap. The identified medication, dosing, 
and frequency were recorded in the participant’s adherence and research record and written on 
the label of the pill bottle. Each subject was provided an instruction sheet for using the cap, 
refilling the bottle, beginning date for using the cap/pill bottle, date to return the cap, and a self-
addressed stamped envelop to return the cap and bottle to the researcher.  Dosage of the 
identified medication was verified using the instructions as written on the subject’s medication-
prescription bottle. Subjects began using the cap and pill bottle the day following enrollment in 
the study for the 29-day period.  
The use of the MEMS cap began the day after enrollment into the study. Participants 
were instructed to return the MEMS cap 30 days from enrollment in the researcher-addressed 
mailing envelope.  As a reminder, each participant using the MEMS cap received a telephone 
call from the researcher at least two days before the scheduled MEMS cap return date. If a 
subject no longer had a working telephone number, a note and an additional envelope were 
mailed to the participant.  When the MEMS cap was not returned within 10 days after the end 
date, the researcher made an additional reminder telephone call or sent a note and envelope, if 
telephone service had been discontinued. All MEMS caps were distributed with an anticipation 
attrition of 20% (loss of two subjects). Once the cap was returned, the subject received a $5.00 
gift card to a store of her choice such as a regional grocer or a discount store. A thank you note 
was included with the gift card.   A record was maintained for caps returned and those not 
returned. 
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3.5 INSTRUMENTATION 
As diagrammed in the theoretical framework, the following psychological variables (depressive 
symptomatology, social support, and perceived stigma) and physiological variables (CD 4, viral 
load, HIV disease symptoms, and physical well-being) were identified for this investigation. In 
addition, demographic attributes (age, education, race/ethnicity, marital status, and exposure risk 
category) of the woman were identified as possible covariates within the model.  
3.5.1       Psychological Variables 
3.5.1.1     Depressive Symptomatology 
Depressive symptomatology was defined as the individual’s subjective perceptions of 
guilt and worthlessness, loss of appetite, sad mood, low energy, and sleep disturbances (Radloff, 
1977). The Center for Epidemiological Studies - Depression Scale (CES-D) was used to assess 
depressive symptomatology.  This 20-item self-report measure uses a Likert-response format 
from 0 (rarely or none) to 3 (most or all of the time). The CES-D measures depressive symptoms 
over the previous week for community dwelling adults and adolescents (Radloff, 1977; Radloff 
& Lock, 1986) with summary scores that range from 0 to 60.  The CES-D has been used widely 
in samples of persons with HIV and has acceptable internal consistency reliability, test-retest 
reliability, and discriminate validity (Catz et al., 2000; Chesney et al., 2000; Ickovics el al., 2001; 
Lyon & Munro, 2001; Murphy et al., 2000). Chesney and colleagues (2000) reported a 
coefficient alpha of .85 in their study of 75 (60 men and 15 women) HIV patients.  Numerous 
studies using the CES-D in community dwelling persons with HIV were addressed in the 
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literature review.  In addition, the measure has been used in HIV adherence clinical trials and in 
conjunction with studies within the AIDS Clinical Trials Group.  
For this study, the total score on the Center for Epidemiological Studies -Depression 
Scale (CES-D) was used to measure depressive symptomatology (Radloff, 1977). A score of 16 
or greater is suggestive of depressive symptomatology; a score of 25 or greater indicates severe 
mental distress (Radloff, 1977).  
3.5.1.2 Social Support.    
Social support was defined as the resources individuals have available to them through 
interpersonal relationships (Cohen & Syme, 1985) including family, friends, peers within the 
community, and health care providers. Social support was assessed by the Interpersonal Support 
Evaluation List (ISEL) a 40-item Likert scale with responses from 0 “definitely false” to 3 
“definitely true”. Negative items are reverse coded. This measure appraises the individual’s 
perceived available resources for social support using four-domains: tangible support, appraisal 
support, self-esteem support, and belonging support.  The total scores range from 0 to 120 with 
higher overall scores suggestive of greater perceived potential availability of social support. The 
ISEL has been used to assess social support as a buffer or mediator of distress and disease in 
numerous samples (Cohen & Herbert, 1996) including cancer (Helgeson & Cohen, 1996), 
women’s immunity and depression (Miller, Cohen, & Herbert, 1999), infectious disease (Glaser, 
Rabin, Chesney, Cohen, & Natelson, 1999), smoking cessation (Mermelstein, Cohen, & 
Lichtenstein, 1983) and HIV (Catz, Gore-Felton, & McClure, 2002).  The measure has shown a 
total score internal consistency reliability coefficient alpha from .88 to .90 (Cohen, Mermelstein, 
Kamarch, & Hoberman, 1995). 
There is limited research with HIV patients reported using the ISEL.  Catz and colleagues 
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 (2002) in their study of 100 minority and low-income HIV-positive women reported a total 
mean score of 106.8 (SD = 27.4) indicating a moderate degree of perceived social support. 
Findings from this study (Catz et al.) showed that less social support contributed independently 
to increased depressive symptoms (R2 = .46, p = <.001).  Psychometric properties for the ISEL 
were not reported. Although the ISEL has the potential for four subscores within the measure, for 
purposes of this investigation only the total support score was used for analysis. 
3.5.1.3 Perceived Stigma 
Perceived stigma was defined as the perceived interaction with and from others that 
makes the individual feel undesirable, tainted, flawed, and/or morally degenerated (Goffman, 
1963). The total score of the HIV Social and Emotional Aspects Questionnaire was used to 
access the overall emotional and social issues relevant to living with HIV (Berger, Ferrans, & 
Lashley, 2001). The measure is composed of 40-items. The measure uses a 4-point Likert-type 
format with responses from strongly disagree (1) to strongly agree (4) with higher values 
indicating more item agreement. Using exploratory and confirmatory factor analysis, the authors 
of the measure identified a four-factor model for stigma. Each of the four factors addresses 
aspects of perceived stigma for persons with HIV: personalized stigma, disclosure concerns, 
negative self-image, and public attitudes. Total scores on the measure can range from 40 to 160. 
Two items were reverse coded and raw scores for each subscore are then totaled. Sixteen items 
are associated with more than one subscore reflecting the intercorrelation of the factors.   
Construct validity of the subscales and total measure are excellent.  Pearson r correlations  
for the total HIV Stigma Scale and other measures are: Rosenburg self-esteem (-.60), CES-D 
depressive symptoms (.63), social support availability (-.54), social support validation (-.54), 
subjective social integration (-.65), and social conflict (.59), p = < .001 for all correlations 
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(Berger, Ferrans, & Lashley, 2001). Internal consistency reliability of the total measure (N = 
318) is reported as 0.96. Internal consistency reliability of the subscores ranged from 0.90 to 
0.96.  Test-retest reliability (N =139) has been reported as 0.87 to 0.92 for the subscales and 0.92 
for the overall score (Berger et al.)The total score of the measure was used in the data analysis. 
Higher scores suggest greater item agreement and less perceived stigma (Berger et al.).   
3.5.2 Physiological Variables 
3.5.2.1  Clinical Indicators.     
The two clinical indictors for evaluation of HIV disease progression were the CD 4 and 
viral load. CD 4 is the lymphocyte count and measures the individual’s immune response and 
ability to resist disease. Viral load refers to the amount of HIV-RNA copy present in the HIV-
infected individual. As a part of the sociodemographic measure, participates self-reported, if 
known, their CD 4 and viral load. 
3.5.2.2 HIV Disease Symptoms.  
HIV disease symptoms were defined as the subjective changes in how one feels related to 
their HIV disease in the last 5 day period. HIV disease symptoms were measured by using The 
Revised Sign and Symptom Check-List for HIV (SSC-HIV rev) (Holzemer, Hudson, Kirksey, 
Hamilton, & Bakken, 2001). Eleven factors explained 73.3% of the variance in this sample of 
women with HIV disease related symptoms (Hudson, Kirksey, & Holzemer, 2004) Each of the 
symptoms is scored based upon intensity for the present day. Items are scored from 0 not present 
today, mild (1), moderate (2), or severe (3). The mean score for HIV disease symptoms present 
the day data were collected was 20.82 (SD = 16.50). HIV symptoms ranged from 0 (none present 
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today) to 56. Hudson and colleagues (2004) reported a Cronbach’s alpha coefficient of .97 in a 
sample of 118 women. 
3.5.2.3 Physical Well being 
Physical well-being was defined as one’s current appraisal and satisfaction with their 
physical abilities and social functioning with others (Wu et al., 1991). Physical well-being was 
operationalized using the overall physical well-being score of the Medical Outcomes Study-HIV 
(MOS-HIV) (Wu et al., 1991). The SF-20 measure assessed general health perceptions, physical 
function, role function, social function, mental health, and cognitive function. The MOS-HIV 
includes domains specific to persons with HIV that have the potential to impact their quality of 
life (QOL), pain, energy/vitality, health distress, and health transition. The MOS-HIV appraises 
the individual’s physical and mental health through their perceived well-being; functional 
behaviors, disability, and overall perception of health.  The measure has excellent reliability and 
validity with coefficient alpha for all subscales ranging from .62 to .96 (McHorney, Ware, Lu, & 
Sherbourne, 1994). The MOS-HIV health survey has been given to more than 15,000 men and 
women with HIV (Wu, Hays, Kelly, Malitz, & Bozzette, 1997a). The measure has two summary 
scores: physical well-being and mental well-being. Exploratory and confirmatory factor analysis 
identified physical function, pain, and role function with the physical well-being summary score 
(Revicki, Sorenson, & Wu, 1998).  
The mental well-being summary score includes mental health distress, QOL, and 
cognitive function. The domains of general health, energy/vitality, and social function contribute 
to both factors. The internal consistency for the physical health summary score has shown 
Cronbach’s alpha coefficients ranging from 0.90 to 0.92. The Cronbach’s alpha for mental health 
score ranged from 0.91 to 0.94 (Wu et al., 1997b). Wu and colleagues (1997a, 1997b) reported 
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good construct validity of the total measure, as well as the physical and mental health summary 
scores.   
There is some suggestion of a potential for a ceiling effect for subscores of role, social, 
and physical functioning for persons with less severe disease and a floor effect for role function 
in persons with more disease related symptoms (Wu, Hays, Kelly, Malitz, & Bozzette, 1997a; 
Wu, Revicki, Jacobson, & Malitz, 1997b).  In addition, Badia et al. (2000) found that the MOS-
HIV had improved test-retest treatment change of 86.4% when compared to the 
Multidimensional Quality of Life. 
3.5.3 Sociodemographic Data  
Demographic data were collected on the subjects using an investigator-modified version of a 
demographic measure currently used by the University of Pittsburgh, School of Nursing, Center 
for Research in Chronic Disorders. Questions on the self-report sociodemographic form included 
race/ethnicity, education, age, martial status, employment, income, number of children and 
children living at home, living arrangements, number of persons living in the home, exposure 
risk category, drug and alcohol use, health care coverage, CD 4, and viral load. Five of these 
attributes (race/ethnicity, age, education, marital status, and exposure risk category) were 
considered possible covariates of adherence.   
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3.5.4 Adherence to Antiretroviral Medications         
Adherence was defined as the degree to which one follows a prescribed regimen.      
3.5.4.1 Self-reported Adherence.           
Overall rates of self-reported adherence to antiretroviral medications were assessed using  
the AIDS Clinical Trial Group Assessment (ACTG) measure (Chesney et al., 2000). The ACTG 
is composed of three subsections with a total of 40 items.  Section A of the measure requires the 
researcher to interview the subject and list all antiretroviral medications, dosing frequency, and 
number of pills per dose. Section B is a daily diary to summarize missed “pills” for the previous 
4 days. Section C is composed of single to multiple questions with Likert-type responses, graded 
from low (0) to high (4) (Chesney et al.). This section explores possible reasons for not taking 
one’s medications as per the required regimen. The ACTG has been used in clinical trials 
(Chesney et al.; Ickovics et al., 2001; Murphy et al., 2000); however, reports of the psychometric 
properties have not been included.  The measure does distinguish adherent from non-adherent 
participants in independent t-test and Mann-Whitney statistical analysis (Chesney et al.; Ickovics 
et al.).  
3.5.4.2 MEMS Cap. 
A subsample of 12 participants agreed to use the MEMS cap (AARDEX Corp, Aug, 
Switzerland) for a period of 29 days.  This electronic device is designed to record each time the 
subject opens the bottle cap. This device consists of a standard plastic medication bottle and a 
cap containing a microchip circuit that records the time and date when the cap is removed. The 
cap is sealed and is water proof. The subject uses the cap in the same manner as any screw-type 
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medication bottle cap. The cap has sufficient memory capacity to record and store information 
far beyond the required 29 day period. The battery within the cap has a 2-year life capacity.  The 
MEMS cap can be used with any dosing schedule. 
Three adherence rates were calculated in the following manner: First, dividing the actual 
number of cap openings by the prescribed number of openings during a designated 29 day period 
and multiplying by 100 for percent of adherence.  Second, rates of adherence were calculated 
computing the percent of days in which the subject opened the MEMS cap and third removed the 
medication at the correct time of day. A subject was identified as adherent if she scored a 95% or 
greater adherence rate and patterns. A subject was identified as moderately adherent with a score 
of 80 to 94% for both rate and patterns of adherence. A subject was identified as non-adherent if 
she scored less than 95% in her adherence rate and patterns.  Data housed in the microchip of the 
cap were retrieved using a communicator and software package and downloaded into a 
Windows-based computer.     
3.5.5 Potential Mediator of Adherence 
3.5.5.1 Perceived Self Efficacy Beliefs. 
Perceived self-efficacy was defined as the individual’s perceived ability to successfully 
manage their antiretroviral medications (Bandura, 1977, 1986, 1997).  Perceived self-efficacy 
was measured using the total score of the HIV Medication Taking Self-Efficacy Scale (Erlen et 
al., unpublished manuscript). Erlen and colleagues developed this 26-item measure. A total score 
and two subscales scores can be calculated. The subscores are self-efficacy beliefs with 17 items 
and outcome expectancies with 9 items. The instrument uses a Likert-type response format to 
appraise the individual’s perceived confidence in the management of their HIV/AIDS 
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medications. The measure is scaled from 1 (not at all confident) to 10 (totally confident).  Pilot 
data with 26 subjects reported a Cronbach’s alpha of .96 for the total scale with a test-retest 
correlation (r = .45, p = .02) (Erlen et al, 2001).  The subscales also show good reliability with a 
Cronbach’s alpha of .96 for self-efficacy beliefs with a test-retest correlation (r = .47, p = .01) 
and a Cronbach’s alpha of .95 for outcome expectancies with a test-retest value (r = .42, p = .03) 
(Erlen et al., 2001). Additional examination of the psychometric properties of the measure is 
currently underway (personal communication, J. Erlen, September, August, 2006). 
3.6 PILOT STUDY 
The pilot study was undertaken for two reasons: 1) to develop and implement a data analyses 
plan and 2) to assist the researcher in identifying possible measures that would be appropriate for 
the dissertation. The data set used for the secondary analysis was part of a larger on going study 
(R01 NR04749, J. Erlen, Principal Investigator). The larger study enrolled both men and women; 
however, the data used included only women enrolled into the study at the time the pilot study 
was conducted in spring of 2003. 
The pilot study instruments differed from this dissertation in respect to the use of the 
subscale of the MOS-HIV, mental well-being for assessment of depressive symptomatology, the 
Modified Morisky Self-Report Measure (Morisky et al., 1986) for measurement of self-reported 
adherence, Berger’s earlier measure to assess perceived stigma (Berger, Cohen, Ferrans, & Patel, 
1995), and the Revised Sign and Symptom Check-List for HIV (SSC-HIV rev) (Holzemer, 
Hudson, Kirksey, Hamilton, & Bakken, 2001). In addition, only the demographic attributes of 
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age, race (Black and white), highest level of education, and marital status were included in the 
secondary analysis. The exposure risk category was not included in the secondary analysis.  
3.6.1 Discussion of Pilot Specific Aims.   
Five specific aims were explored in the pilot study. The specific aims of the dissertation were 
expanded and the reader is referred to Chapter One for more detailed information.  
 
3.6.1.1 Specific Aims 1. 
Describe rates of self-reported adherence among women with HIV who were taking 
antiretroviral medications. 
3.6.1.2 Specific Aims 2. 
 Describe the associations between rates of self-reported adherence and 
sociodemographic factors (age, highest level of education, race/ethnicity, and marital status) 
among women with HIV who were taking antiretroviral medications. 
3.6.1.3 Specific Aims 3. 
Examine selected psychological factors (social support, mental well-being, and perceived 
stigma) and a selected physiological factor (physical well-being) that may be predictors of self-
reported adherence among women with HIV who were taking antiretroviral medications. 
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3.6.1.4 Specific Aims 4. 
Examine the relationships among selected demographic variables (age, education, 
race/ethnicity, and marital status) and selected psychological predictors (social support, mental 
well-being, and perceived stigma) and a physiological predictor (physical well-being) and self-
reported adherence to antiretroviral among women with HIV/AIDS who were taking 
antiretroviral medications. 
3.6.1.5 Specific Aim 5. 
Examine the mediating effect of self-efficacy on the relationship of selected 
psychological factors (social support, mental well-being, and perceived stigma) and a selected 
physiological factor (physical well-being) that may be predictors of self-reported adherence 
among women with HIV who were taking antiretroviral medications. 
3.6.2 Data Analysis of the Pilot Study.     
A detailed descriptive analysis of all data was done, involving the summarization and the use of 
exploratory analytic techniques.  The information obtained from this preliminary analysis was 
used to describe the univariate and bivariate sample distributions of the data, ascertain the 
interrelationships between and among the variables, and check for violations of assumptions 
necessary for statistical techniques.  Means, percentiles, dispersions, and standard deviations of 
each variable were computed.  The distributions of important covariates at baseline (e.g., race 
and age) were compared among the levels of key predictors of interest to ascertain possible 
confounding.  From these preliminary investigations, the level of significance was established at 
0.05 (two-tailed).  When strong relationships existed, the variables were treated as covariates in 
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the preliminary analysis. Initially, the bivariate relationships were investigated for the specific 
aims using simple linear regression to obtained crude (unadjusted) estimates of the effect of each 
predictor variable. Stepwise linear regression was then used to further define the selection of 
variables into the predictive model.  Lastly, higher order effects and interactions of the predictor 
variables were considered for possible inclusion in the predictive model.   
3.6.3 Description of the Pilot Sample 
There were 71 women in the pilot study. The mean age was 39.38 (SD = 7.713) with ages 
ranging from 24 to 55 years. Three categories for highest level of education were created (N = 
69): less than high school education (N =18, 25.4%), high school education (N = 26, 36.6%), and 
greater than a high school education (N = 27, 38%). Marital status (N = 71) was grouped into 
never married (N = 22, 31%), currently married/living with partner (N = 22, 31%), no longer 
married (N = 25, 35.2%), and other (N = 2, 2%). Race included 36 (51%) subjects identified as 
white and 35 (49%) subjects identified as Black (N = 71). 
3.6.4 Discussion of the Findings 
3.6.4.1 Specific Aims 1 
Describe rates of self-reported adherence among women with HIV  
who were taking antiretroviral medications. Using the Modified Morisky Self-report Measure of 
Adherence (Morisky et al., 1986), most women reported being adherent to their antiretroviral 
medications (M = 9.24, SD = 2.192). However, there was considerable variability in self-
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reported adherence (Var. = 4.806). The skewness of the data was -.255 and kurtosis was -.515. 
Two subjects had missing data (n = 69). 
3.6.4.2 Specific Aims 2 
Describe the associations between rates of self-reported adherence and 
sociodemographic factors (age, highest level of education, race, and marital status) among 
women with HIV who were taking antiretroviral medications.  There was no significant 
relationship between age and adherence using a bivariate correlation, Pearson r. There was no 
significant relationship between adherence to antiretroviral medications and age, educational 
group, racial group, or martial status using a nonparametric approach, Kendall’s Tau (Table 2).  
Table 2. Sociodemographic Associations with Adherence  
 Age Highest Level of 
Education 
Race Marital Status 
Adherence r =.180, p =.139 r = .106, p = .286 r = -.073, p =.486  
(white) 
r = .041, p = .694 
(Black)  
r = -0.19, p = .851 
3.6.4.3 Specific Aims 3 
Examine selected psychological factors (social support, mental well-being, and perceived 
stigma) and a selected physiological factor (physical well-being) that may be predictors of self-
reported adherence among women with HIV who were taking antiretroviral medications.  Using 
the Pearson r to examine the possible associations between selected variables and adherence, a 
significant relationship between social support and adherence to antiretroviral medications was 
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found (r = .262, p = .029).  There was no relationship between the subscales of perceived stigma 
and self-reported adherence for this sample of HIV positive women. The findings for each 
subscale included: personalized stigma (r = -.220, p = .072), disclosure stigma (r = -.018, p = 
.885), negative self-image (r = - .208, p = .086), and perceptions of public attitudes (r = -.090, p 
= .463). Using the mental well-being sub-score of the MOS-HIV, women who reported a better 
state of mental well-being had improved adherence to antiretroviral medications (r = .332, p = 
.005). Using the physical well-being subscale from the MOS-HIV, women who reported better 
physical well-being also had improved adherence to antiretroviral medications (r = .256, p = 
.033) (Table 3). 
As described, due to the strong relationships between social support, mental well-being, 
and physical well-being and self-reported adherence these variables were fit into a multiple 
regression model. Although significant relationships were found between these variables and 
self-reported adherence to antiretroviral medications (R2 = .112, p = 0.036), additional stepwise 
regression entering social support, mental well-being, and physical well-being in one of three 
blocks suggested only social support contributed to the model (R2 = .069, p = .029).   
 
Table 3.   Relationships between predictor variables and adherence to antiretroviral medications. 
 Social Support Mental well-being Stigma Physical well-
being 
Adherence r  = .262, p = .029 r = .332, p = .005 personalized stigma 
 (r = -.220, p = .072) 
disclosure stigma  
(r = -.018, p = .885), 
negative self-image  
(r = - .208, p = 
.086), and 
perceptions of 
public attitudes  
(r = -.090, p = .463) 
r = .256, p = .033 
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3.6.4.4 Specific Aims 4 
Examine the relationships between selected demographic variables (age, education, race, 
and marital status) and selected psychological predictors (social support, mental well-being, and 
perceived stigma) and a physiological predictor (physical well-being) and self-reported 
adherence to antiretroviral medications) among women with HIV/AIDS who were taking 
antiretroviral medications.  Using a Kendall Tau association for all analyses, a significant 
negative relationship was found between one’s race and personalized stigma: white subjects (r = 
-.240, p = .018) and Black subjects (r =. 257, p = 0.11).  There was a significant relationship 
found between race and social support: white subjects (r = .229, p = .020) and Black subjects (r 
= .229, p = 0.19). Likewise, there was a significant negative relationship between race and 
physical well-being for Black subjects (r = -.230, p = .020). There was also a significant 
relationship between highest level of education and negative self-image (r = .205, p = .030).  The 
variables of race (white and Black), personalized stigma, social support, physical well-being, 
highest level of education, negative self-image, and self-reported adherence were fit into a 
multiple regression model to further test the relationships. No relationship was found between 
these variables and self-reported adherence to antiretroviral medications (R2 = .174, p = .104). 
3.6.4.5 Specific Aims 5 
       Examine the mediating effect of self-efficacy on the relationship of selected psychological 
factors (social support, mental well-being, and perceived stigma) and a selected physiological 
factor (physical well-being) that may be predictors of self-reported adherence among women 
with HIV who were taking antiretroviral medications.    Bivariate correlations of self-efficacy 
and the demographic variables did not demonstrate a relationship among any of the attributes. 
Pearson r correlations showed a significant relationship between self-efficacy and social support 
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(r = .473, p = .000). There were significant negative relationships between self-efficacy and 
personalized stigma (r = -.316, p = .008) and between self-efficacy and negative self-image (r = -
.393, p = .001). There were significant relationships between self-efficacy and physical well-
being (r = .380, p = .001) and between self-efficacy and mental well- being (r = .545, p =.000). 
Fitting a multiple regression model suggested self-efficacy had a significant direct effect on 
adherence (Beta coefficient = .620, p = .0001; R2 = .38) and self- Efficacy mediated mental well 
being and self-reported adherence (Beta coefficient = .601, p = .000; R2 = .299 (See Figure 2).  
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Figure 2.   Path Analysis of the Mediating Effect of Self-efficacy and Adherence to Antiretroviral 
Medications using Subscales of the MOS HIV.     
 
Furthermore, fitting a model for all variables (social support, mental well-being, physical well-
being, personalized stigma, disclosure stigma, negative self-image, perceptions of public 
attributes, and self-efficacy resulted in self-efficacy significantly mediating social support (R2 = 
.223) and mental health (R2 = .392).  No other significant relationships were found within the 
model.  
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Additional stepwise regression analysis for all variables was conducted. This consisted of 
seven variables within the model, each was entered as a block: 1) self-reported adherence, 2) all 
demographic variables (age, race-white, race-Black, highest level of education, and marital 
status), 3) social support, 4) all stigma sub-scores (personalized stigma, disclosure stigma, 
negative self-image, and public attitudes), 5) self-efficacy, 6) physical well-being, and 7) mental 
well-being. Only two models, the second and the fourth, demonstrated significant findings (See 
Table 4). 
Table 4. Regression Model Summary 
Model Variables R Square Beta Coefficient Significance 
1 Demographic Variables 
(Marital status, race-white, 
race-Black, age, 
highest level of education) 
.097 2.171 .260 
2 Demographic Variables 
Social Support 
.176 2.091 .019* 
3 Demographic Variables 
Social Support 
Perceived Stigma Subscales 
(Personalized Stigma, 
Disclosure Stigma, Negative 
Self-Image, & Public Attitudes) 
.235 2.084 .360 
4 Demographic Variables 
Social Support 
Perceived Stigma Subscales 
Self-efficacy 
.444 1.792 .000* 
5 Demographic Variables 
Social Support 
Perceived Stigma Subscales 
Self-efficacy 
Physical Well-being 
.447 1.805 .628 
6 Demographic Variables 
Social Support 
Perceived Stigma Subscales 
Self-efficacy 
Physical Well-being 
Mental Well-being 
.447 1.821 .854 
 
Findings from the second model suggested that social support contributed to adherence (R2 = 
.176, p = .019). Model four suggested that self-efficacy contributed the most to adherence (R2 = 
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.444, p = .0001). Fitting all variables (self-reported adherence, demographic factors, social 
support, perceived stigma subscales, self-efficacy, physical well-being, and mental well-being) 
into the final sixth model, suggested that only self-efficacy significantly contributed to self-
reported medication adherence for women with HIV (Beta coefficient = .580, p = .0001).   
3.6.5 Summary of the Pilot Study 
For this sample of women (N = 71) there was little covariance within the model for demographic 
attributes (age, highest level of education, race, or marital status). Improved social support and 
physical well-being influenced adherence to antiretroviral medications. Increased mental well-
being had a positive relationship with adherence to medications among women with HIV. These 
findings are important for designing interventions to improve adherence. Including interventions 
that may improve social support, physical well-being, and mental well-being may potentially 
lead to better adherence. 
This pilot study was used to subsequently guide the dissertation study. A review of these 
pilot study data suggested self-efficacy had a mediating effect on self-reported adherence to 
medications among women with HIV/AIDS who were taking antiretroviral medications. There 
was a significant relationship between self-efficacy and mental well-being and self-efficacy and 
social support.  This pilot study did not use the same measure of self-reported adherence as the 
dissertation study. The dissertation used the CES-D as the measure of depressive 
symptomatology. Several additional measures were also used for assessment of variables in the 
dissertations study. The HIV Social and Emotional Aspects Questionnaire (Berger, Ferrans, & 
Lashley, 2001) for assessed of perceived stigma, CD 4 and viral load were self-reported, and 
HIV disease symptoms was assessed using the revised Sign and Symptoms Check-list for HIV 
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(SSC-HIV rev (Holzemer et al., 2001). The MEMS cap adherence was also included to assess 
adherence in the dissertation study for a subsample of women.     
3.7 DATA MANAGEMENT AND ANALYSIS 
3.7.1 Data Screening 
Before data entry, all forms were checked for completeness as described in the procedure 
section. If categorical data were missing an asterisk was substituted. Some personal information, 
such as income is sensitive and subjects may have chosen not to include this information. Data 
were screened for the type of missingness. If the data were missing at random and were 
continuous, the mean value was substituted for the missing value. If data were missing at random 
for a categorical value, these data were retained for analysis. If data were not missing at random 
for a subject’s questionnaire and more than 20% of the data were missing for a given measure, 
that subject’s data set was removed from the study.  
3.7.2 Data Entry 
Instrument forms were created using the TeleformTM Designer.  All forms were scanned using 
TeleformTM optical reader and converted into a data file for each instrument.  In addition, all 
forms were pre-coded to help minimize errors when processing data.  Once the format (i.e., 
layout, naming and coding of variables, settings of valid ranges, verification standards, etc.) was 
finalized, the form was activated for use in data collection.  Data entry and verification were 
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conducted using Teleform Windows-based software for automated data entry/verification. SPSS 
for Windows was used for data management (SPSS, 2006, Version 13, SPSS UK LTD, Surrey, 
Great Britain). A data dictionary was generated and the associated database table was initialized 
and readied for data entry.  Database tables were formatted for use in SPSS for Windows.  Data 
were backed up on a continual basis as they were entered in the data base, archived on compact-
disc (CD) for future use, and stored in the researcher’s office.  
Preliminary Data Analysis 
A detailed descriptive analysis of all data was done involving the summarization and the 
use of exploratory analytic techniques.  The information obtained from this preliminary data 
analysis was used to: 1) describe univariate and bivariate sample distributions of the data, 2) 
ascertain the interrelationships between and among variables, and 3) check for violations of 
assumptions necessary for statistical techniques.  Statistics describing the means, percentiles, 
dispersions, and standard deviations of each variable were computed.  The distribution of 
important covariates at baseline (e.g., ethnicity, age) was compared among the levels of key 
predictors of interest to check for possible confounding.  For these preliminary analyses, the 
level of significance was established at 0.05 (two-tailed). When strong relationships existed, 
these variables were treated as covariates in the primary analysis.  
3.7.3 Primary Data Analysis 
Bivariate relationships were investigated for the aims using simple linear regression to obtain 
crude (unadjusted) estimates of the effect of each predictor variable. Stepwise linear regression 
was then used to further define the selection of variables into the predictive model. Lastly, higher 
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order effects and interactions of the predictor variables were considered for possible inclusion in 
the predictive model. The level of significance was set at 0.05. 
 
 
3.7.4 Procedure for the Protection of Human Subjects 
3.7.4.1 Confidentiality 
The proposal was submitted to the University of Pittsburgh Institutional Review Board 
(IRB) and approval was received. Each participant was assigned a three-digit code number.  A 
master list of participants’ names, addresses, and telephone numbers was kept in the event that 
further contact was required.  All personal identification and completed instruments were filed 
separately from the assigned codes to protect anonymity.  This confidential identifying 
information was kept under double lock accessible only by the researcher and will be destroyed 
upon completion of the study, or as per University policy, at 5 years following study completion, 
whichever occurs last.  A computerized tracking system was developed, which captured 
information regarding participant eligibility and study completion.   
3.7.4.2 Risk and Benefits Ratio 
Participants were assured there was minimal risk if they agreed to participate in the 
research study.  One possible risk was that women might become embarrassed when asked to 
report personal matters.  There was also a risk that participants may become fatigued during the 
data collection session.  No subject reported fatigue; however, if fatigue had occurred, the 
researcher would have allowed time for rest or rescheduled the data collection at another agreed 
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upon time. Participants were assured there was no retribution if they decided not to participate in 
the study or withdraw from the research study at any time.  If a participant decided not to take 
part in this research study, she continued to receive her usual care from her health care provider.  
Participation in the study did not replace the usual treatment from the subject’s health care 
provider.   
3.7.4.3 Potential  Benefits to Patient 
There were no benefits to the participant from taking part in this research study.  For 
future subjects, there is the possibility that the results of this study may benefit women as more 
investigations are undertaken that explore issues of adherence to medications for women with 
HIV. This study may also guide a future study to improve adherence to antiretroviral 
medications for women with HIV.  
3.7.4.4 Competency to Consent to Research 
Adult participants (i.e., women 18 years and older) diagnosed with HIV/AIDS for at least 
a period of six months or more and prescribed antiretroviral medications, and receiving health 
care for their HIV infection in a hospital or university affiliated primary care clinic or rural clinic 
were recruited for this study.  All persons involved in the study were required to be able to read 
and write English, as well as to vocalize their feelings and acknowledge an understanding of 
their disease and medication use. The clinic and hospital liaisons were instructed to provide 
brochures about the study to potential subjects.  Women who were able to read and discuss and 
sign the consent form were assumed mentally competent to participate in this study. 
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3.7.4.5 Cost and Payments 
Neither the participant nor her insurance provider was charged for costs of any 
procedures performed for the purpose of this study.  In the unlikely event that an injury would 
occur as a result of the research procedures the participant was informed to contact the Principal 
Investigator on the first page of the Informed Consent Form (Medication Management for 
Women).  No injuries were reported. 
 
3.7.5 Difficulties and Limitations 
As with any research investigation there were potential difficulties identified prior to the 
initiation of a study; the researcher had planned for many of these problems in advance. There 
was considerable difficulty in recruiting the original sample of 75 HIV-positive women. The 
researcher had planned for this possibility by establishing relationships with three HIV care 
centers (see Setting) and commitment of key personnel at the facilities to assist in the 
identification of potential participants. This plan, although well designed, was not successful. 
Many obstacles occurred including inability to secure support from the HIV clinic in Lancaster 
County, PA; this site would have increased the potential for recruiting minority Latina women. 
Other obstacles were a long delay in receiving a physician letter of support and slow recruitment 
at all rural and urban sites. These limitations are further addressed in Chapter 5 of this report. 
Anticipating difficulties with recruitment and as an incentive, a token of appreciation ($15.00) 
was provided to enhance recruitment of potential participants.   
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Due to the difficulty in recruitment the power analysis for the study was recalculated for 
the potential of 35 and 45 subjects recruited into the study. Using the same power analysis 
technique as described previously the following demonstrates the changes in power. 
 
Power N Alpha Beta Count Ind.Variables 
Tested R2
Count Ind. 
Variables 
Controlled 
R2
0.9999 45 0.05 0.0001 8 0.57413 0 0.0000 
0.9500 45 0.05 0.05 8 0.38362 0 0.0000 
0.9000 45 0.05 0.1 8 0.34276 0 0.0000 
0.8000 45 0.05 0.2 8 0.29072 0 0.0000 
 
Power N Alpha Beta Count Ind. 
Variables 
Tested R2
Count Ind. 
Variables 
Controlled 
R2
0.9999 35 0.05 0.0001 8 0.65307 0 0.0000 
0.9500 35 0.05 0.05 8 0.46352 0 0.0000 
0.9000 35 0.05 0.1 8 0.41969 0 0.0000 
0.8000 35 0.05 0.2 8 0.36212 0 0.0000 
Original Power Analysis  
Power N Alpha Beta Count Ind. 
Variables 
Tested R2
Count Ind. 
Variables 
Controlled 
R2
0.9999 75 0.0500 0.0000 8 0.447 0 0.0000 
0.9000 75 0.0500 0.1000 8 0.222 0 0.0000 
0.8000 75 0.0500 0.2000 8 0.183 0 0.0000 
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It was anticipated that women in the subsample using the MEMS cap might misplace or 
lose the MEMS cap and/or the return-mailing envelope and/or forget to forward the MEMS cap. 
Therefore, the researcher contacted each participant using the MEMS cap as described. In 
addition, participants who completed use of the MEMS cap for 29 days were provided with an 
additional token of a $5.00 gift card following return of the MEMS cap. 
It was also anticipated that childcare might be an issue and deter some women from 
participating in the study. To assist women accompanied by children to participate in the study, 
the researcher was present and available to assist with childcare as needed.  There were only two 
recruitment situations that required supervision of children. 
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4.0  CHAPTER FOUR 
4.1 RESULTS 
Two identified overall purposes guided this descriptive cross-sectional study. The first purpose 
was to examine the psychological factors (depressive symptomatology, social support, and 
perceived stigma) and physiological factors (CD 4, viral load, HIV disease symptoms, and 
physical well-being) that may be predictors of adherence among women with HIV/AIDS who 
were prescribed antiretroviral medications. The second purpose was to examine the potential 
mediating effect of self-efficacy on the relationships between the psychological factors 
(depressive symptomatology, social support, and perceived stigma) and physiological factors 
(CD 4, viral load, HIV disease symptoms, and physical well-being) and self-reported adherence 
to antiretroviral medications for women with HIV. 
The specific aims were to: (1) describe overall patterns of self-reported adherence among 
women with HIV/AIDS prescribed antiretroviral medications, (2) describe the relationships 
between patterns of self-reported adherence and age, education, race/ethnicity, marital status, and 
exposure risk category among women with HIV/AIDS prescribed antiretroviral medications, (3) 
examine the relationships between the selected psychological factors (depressive 
symptomatology, social support, and perceived stigma) and self-reported adherence among 
women with HIV/AIDS prescribed antiretroviral medications, (4) examine the relationships 
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between the selected physiological factors (CD 4, viral load, HIV disease symptoms, and 
physical well-being) and self-reported adherence among women with HIV/AIDS prescribed 
antiretroviral medications, (5) examine the mediating effect of self-efficacy on the relationships 
between selected psychological factors (depressive symptomatology, social support, and 
perceived stigma) and selected physiological factors (CD 4, viral load, HIV disease symptoms, 
and physical well-being) and self-reported adherence among women with HIV/AIDS prescribed 
antiretroviral medications, and (6) describe patterns of adherence in a subsample of women with 
HIV/AIDS who were prescribed antiretroviral medications using a self-reported measure of 
adherence and the Medication Event Monitoring System (MEMS). 
4.1.1 Screening 
Forty-five women were recruited into the study. Following informed consent each subject was 
screened for inclusion through the use of standardized tests and one self-report questionnaire. 
Two standardized screening measures were used. The Rapid Estimate of Adult Literacy in 
Medicine (REALM) was used to briefly assess the ability of the participant to read and 
understand medical terminology (Davis et al., 1993). One subject was excluded due to her 
inability to read and understand medical terminology. The remaining subjects (N = 44) had 
acceptable scores on the REALM and were included in the sample. Possible neurocognitive 
impairment was assessed using the 4-item HIV Dementia Scale [HDS] (Powers, Selnes, Grim, & 
McArthur, 1995). No subject was excluded based upon her HDS score (<10). No potential 
subject self-reported a history of mental illness; therefore, this criterion did not exclude anyone 
from participation. 
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4.1.2 Data Analysis of the Study 
A detailed descriptive analysis of all data was done, involving the summarization and the use of 
exploratory analytic techniques. Scatter plots were run for each of the five socio-demographic 
variables and independent variables. There were no outliers for any of the variables. Using a 
scatter plot and/or stem and leaf graphs for each of the ACTG adherence items and each socio-
demographic variable showed that there were no outliers. In addition, using a scatter plot and 
stem and leaf graphs for each of the ACTG adherence items and the independent variables 
showed no outliers. The possibilities of indirect effects of the independent variables on the 
dependent variable for the ACTG items were explored; no indirect effects were identified.  
The information obtained from this preliminary analysis was used to: 1) describe the 
univariate and bivariate sample distributions of the data and 2) ascertain the interrelationships 
between and among the variables and check for violations of assumptions necessary for 
statistical techniques. The means, percentiles, dispersions, and standard deviations of each 
variable were computed. The distributions of important covariates at baseline (e.g., race and age) 
were compared among the levels of key predictors of interest to ascertain possible confounding. 
When strong relationships existed, the variables were treated as covariates in the preliminary 
analysis. Initially, the bivariate relationships were examined relevant to the specific aims using 
simple linear regression to obtained crude (unadjusted) estimates of the effect of each predictor 
variable. Stepwise linear regression was then used to further define the selection of variables to 
be entered into the predictive model. Lastly, higher order effects and interactions of the predictor 
variables were considered for possible inclusion in the predictive model.  
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4.2 SAMPLE 
After cleaning the data, descriptive statistics were used to describe the sample. The 44 women in 
this convenience sample ranged in age from 29 to 60 years with a mean age of 42.89 (SD = 7.97) 
years. Of this sample 28 (64%) were women over 40 years of age.  In addition, nine of these 28 
women were 50 years of age or older and one women 60 years of age, which equals 20% of the 
total sample.  More than half of the sample was white or non-Hispanic (n = 23, 55%). Thirty-six 
percent (n = 18) of the women were Black/African American. Three (7%) of the women 
identified themselves as Latina, specifically Puerto Rican. Three women indicated that their 
race/ethnicity was biracial. These latter three groups were classified as non-white for data 
analysis purposes. 
Years of education reflected a range from 6 through 18 years of education. The mean 
number of years of education was 12.34 (SD = 2.07). Twenty-seven (62%) of the women had 
either a high school education or general education degree (GED). Eleven women (25%) 
reported to have never been married; thirteen (30%) were currently either married or living with 
a partner/significant other. Twenty women (46%) were divorced, separated, or widowed.  
The women were recruited from western Pennsylvania and eastern Ohio. Using mailing 
zip codes as indicators of area of residence, 18 women (41%) resided in small towns/rural areas 
throughout Western PA. An additional eleven women (25%) resided in a large urban city and 15 
women (34%) resided in suburban areas or moderately sized towns in western PA and eastern 
Ohio. Other demographic information is included in Table 5 below.  
Twenty-eight (64%) of the women did not respond to the question on income. However, 
all 44 responded to the question regarding income meeting their basic needs; 27 (61%) reported 
that their income met their basic needs. The majority of subjects (75%) reported that their main 
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source of income came from social security, supplemental security or retirement/survivor 
benefits. Only five women reported being employed 35 hours per week or more. Forty women 
(91%) reported their exposure risk as being through heterosexual sex with a man who was HIV 
positive. Other socio-demographic information is included in Table 5.  
In addition, for the subsample of women who participated in the monitored adherence 
substudy (n =10) the socio-demographic and variable data were compared with the total sample 
(N = 44). The ten women were equally divided with five white and five non-white participants. 
Five women had a high school education or general education degree (GED). One woman had 
less than a high school education and four women had more than a high school education. Six 
women were between ages 29 and 39. Three women were between the ages of 40 and 49 and one 
woman was age 50 or older. All ten women reported their HIV exposure risk as being through 
heterosexual contact. 
 
Table 5  Socio-demographic Characteristics (N =44). 
Variable Frequency Percent 
Age    
Less than 30 1 2 
30 – 39 15 34 
40 – 49 19 43 
50 – 59 8 18 
60 and over 1  2 
   
Race   
White 23 52 
Black/African American 16 36 
Latina/Hispanic  3 7 
Biracial    2 5 
   
Education                     
< High School 9 20 
 GED 10 23 
 High School  17 39 
 > High School 8 18 
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Table 5 (continued)    
   
Martial Status    
Never married  11 25 
Married 5 11 
Living with partner 8 18 
Widowed 4   9 
Separated/divorced 16 37 
   
Area of Residence    
Urban 11 25 
Suburban 15 34 
Rural/Small towns 18 41 
   
Income    
< 10,000 8 18 
10,000 – 14,999 3   7 
15,000 – 19,999 1   2 
20,000 – 29,999 3   7 
30,000 – 39,999  1   2 
Not reported 28 59 
   
Employment     
Employed full-time 5 11 
Employed part-time 3   7 
Retired/laid-off  2 4.5 
Disabled 28 64 
Homemaker full-time  5 11 
Seasonal worker 1   2 
   
Exposure Risk Category 
Multiple Selections possible  
  
Heterosexual Contact 40 91 
Intravenous drug use  2 4.5 
Blood  2 4.5 
   
Children    
Yes 35 80 
No 9 20 
   
Insurance   
Private Insurance  9 20 
Medicare 16 36 
Medicaid/SSI 19 44 
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Table 5 (continued)   
   
Insurance to Cover Meds   
Yes, all 25 57 
Yes, some  15 34 
No 3 7 
Unknown 1 2 
 
4.3 DESCRIPTION OF THE MEASURES 
The psychological variables included depressive symptomatology, social support, and perceived 
stigma. The Center for Epidemiological Studies - Depression Scale (CES-D) was used to assess 
depressive symptomatology (Radloff, 1977). A score of 16 or greater suggests depressive 
symptomatology; a score of 25 or greater is suggestive of severe depressive symptomatology. 
The mean CES-D score was 22.4 (SD = 8.80). CES-D scores ranged from 8 to 41. Social support 
was measured by the Interpersonal Support Evaluation List (ISEL) (Cohen & Syme, 1985). 
Scores on this measure can range from 0 to 120 with higher overall scores suggestive of greater 
perceived potential availability of social support (Cohen & Syme.). The mean score for this 
sample was 79.33 (SD = 19.07). Social support scores ranged from 45 to 115. Perceived stigma 
was measured using the total score of the HIV Social and Emotional Aspects Questionnaire 
(Berger et al., 2001). The scores on this measure can range from 40 to 160. For the women in 
this study, the mean score for perceived stigma was 100.43 (SD = 21.14); scores ranged from 56 
to 155. Higher scores suggest greater item agreement and less perceived social support (Berger et 
al.) 
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The physiological variables included self-reported CD 4 and viral load, HIV disease 
symptoms, and physical well-being. CD 4 and viral load were self-reported by the subjects as a 
part of the socio-demographic measure. Eighteen (41%) subjects did not know their CD 4. 
Twenty-six (59%) reported their CD 4; the range for CD 4 was 0 to 1400 (M = 338.45, SD = 
429.91). Thirty-two women (75%) did not know their viral load.  
The Revised Sign and Symptom Check-list measured HIV Disease Symptoms for HIV 
(SSC-HIV rev) (Holzemer et al., 2001). This measure assesses symptoms associated with HIV 
disease, treatments, and medications. The revised measure includes eight gynecological 
symptoms for women with HIV disease.  The total score reflects a sum of 72 items. The mean 
score for HIV disease symptoms present the day of data collection was 20.82 (SD = 16.50). HIV 
symptoms ranged from 0 (none present today) to 56. The higher the score the more symptoms 
present and the greater the intensity of the symptoms. The most frequently reported symptoms 
(present today) were: fatigue, fear/worries, joint pain, weight gain, muscle aches, shortness of 
breath, abdominal complaints (gas, bloating, diarrhea, nausea) headache, dizziness, and night 
sweats.  
Physical well-being was measured using the subscale of the Medical Outcomes Study-
HIV (MOS-HIV) measure (Wu et al., 1991). The subscale includes the domains of physical 
function, pain, role function, overall health, energy/vitality, and social function. The mean score 
was 44.24 (SD = 12.33) with scores ranging from 22.34 to 63.95. Scores are summated from 0 to 
100 with higerh scores suggestive of better health (Wu et al.). 
The mediating variable, perceived self-efficacy, was assessed using the HIV Medication 
Taking Self-efficacy Scale (Erlen, 1999). This 26-item measure includes an overall score for 
self-efficacy and two subscales, self-efficacy beliefs and outcome expectancies. The overall 
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score ranges from 26 to 260 with higher scores suggestive of greater perceived confidence in 
management of their HIV/AIDS medications. The self-efficacy beliefs subscale was used for data 
analysis. The mean score was 151.43 (SD = 21.51) with scores ranging from 17 to 170.  
The dependent variable, self-reported adherence, was assessed for all 44 women in the 
study using the AIDS Clinical Trial Group Assessment (ACTG) measure (Chesney et al., 2000). 
The ACTG is composed of three subsections with a total of 40 items. In addition, a subsample of 
10 women used an electronic event medication system (MEMS). This electronic device is 
designed to record each time the subject opens the bottle cap and can be used with any dosing 
schedule. Following selection of the medication to be monitored (see Chapter Three for further 
descriptions of medication selection) each subject was instructed on the filling and use of the pill 
bottle. The mean, standard deviation, range of scores, and Cronbach’s alpha for the measures are 
presented in Table 6.  
 
Table 6.  Psychometric properties of the measures (N = 42).        
 
Measure   Mean Score     Standard Deviation Range          Cronbach’s 
Alpha 
CES-D   22.42   8.80   8 -  41 .79 
ISEL   79.33 19.07 45 - 115 .94 
Perceived 
Stigma 
100.43 21.14 56 - 155 .95 
Self-efficacy 
Belief 
151.43 21.51 17 - 170 .93 
HIV symptoms   20.82 16.59  0 - 88 .93 
MOS-HIV 
Physical Well-
being  
  44.24 12.33 22.34 - 
63.95 
.90 
 
There were differences in the mean score for two measures for the women who used the MEMS 
cap and those that did not use the MEMS cap in regard to HIV disease symptoms and physical 
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well-being, neither of the differences were significant. The women using the MEMS cap had 
better physical well being, yet more HIV disease symptoms. (See Table 7).  
 
Table 7  Comparison of measures for the total sample and subsample using the MEMS cap. 
Measure        Sample (N = 42)                                 Cap Subsample (n = 10)  
 Mean SD Mean SD 
CES-D 22.42   8.80 20.40 7.29 
ISEL 79.33 19.07 81.80                   21.07 
Perceived 
stigma  
100.43                 21.14                   99.00                   19.22 
HIV symptoms 20.82                 16.59                   27.64                   24.12 
MOS-HIV 
Physical  
well-being  
44.24                   12.33                   40.74                   18.25 
 
Self-efficacy 
Beliefs 
231.39                 27.51                   233.20                 26.85 
 
4.4 SPECIFIC AIMS 
4.4.1 Specific Aims 1 
Describe the overall patterns of self-reported adherence among women with HIV/AIDS 
prescribed antiretroviral medications. The ACTG measure of adherence (Chesney et al., 2000) 
contains six questions. Each question/item was examined separately. (See Table 8). For this 
sample of 44 women with HIV/AIDS who were prescribed antiretroviral medications, 34 women 
(77%) reported they never missed taking their medications on any of the last 4 days. However, 
the ten (23%) remaining women reported missing doses of medications at least one to four days 
over that last 4-day period. When responding to a question regarding following a specific 
schedule for their medications, such as 2 to 3 times a day, 28 women reported that they follow 
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this regime all of the time; six women followed the regimen some to half of the time. 
Approximately 59% of the women (n =26) reported taking their medications according to the 
special instructions, such as with or without food or on an empty stomach; ten women (22.7%) 
reported following these special instructions all of the time. Most of the women (82%) reported 
that they were not forgetful about taking their medications on the weekends. Nine women (21%) 
reported that they “never skip medications”, 13 (30%) reported skipping their medications more 
than 3 months ago, 15 (34%) missed their medication during the last 3 months, and 7 (16%) 
missed medications within the last week. (Table 8).  
The most frequently identified reasons for missing medications were: being away from 
home (n =16), busy with other things (n =15), simply forgot (n = 12), feeling sick (n = 11), 
change in routine (n = 9), falling asleep or slept through the dosing time (n = 9), and not wanting 
others to notice taking medications (n = 6). Only two women reported missing medications due 
to running out of their medication.  
4.4.2 Specific Aims 2 
Describe the relationships between patterns of self-reported adherence and socio-demographic 
factors (age, education, race/ethnicity, marital status, and exposure risk category) among women 
with HIV/AIDS who were prescribed antiretroviral medications. 
H2A: There is an association between self-reported adherence and socio-demographic 
factors (age, education, race/ethnicity, marital status, and exposure risk category) among 
women with HIV/AIDS who are prescribed antiretroviral medications.  
The ACTG self-report adherence questionnaire does not use a composite score, rather 
there are five separate items/questions addressing aspects of medication adherence. For these 
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analyses, items 1 and 6 were considered as continuous variables. Items 2, 4, and 5 were either 
categorical or dichotomous variables. Item 3 does not assess adherence, rather it inquires about 
special instruction (medications have special instructions, i.e., with food).   
 
Table 8  Self-reported medication adherence as assessed using the ACTG (N = 44). 
 
 Possible Responses Frequency Percentage 
Missed taking all of 
your doses in the 
last 4 days 
0 None 
1 One day 
2 Two days 
3 Three days 
4 Four days 
 34 
  5 
  3 
  0 
  2 
77.3 
11.4 
 6.8 
 0.0 
 4.5 
    
Following dose 
instructions (i.e., 2 
to 3 times a day). 
0 Never 
1 Some of the time 
2 About half the time 
3 Most of the time 
4 All of the time 
  0   
  2 
   
  4 
10 
 28 
 0.0 
 4.5     
  
9.1 
22.7 
63.5 
    
Medications have 
special instructions 
(i.e., with food). 
 
Yes 
No 
 
26 
18 
 
59 
41 
    
Follow special 
instructions 
N = 26 
 
0 Never 
1 Some of the time 
2 About half of the time 
3 Most of the time 
4 All of the time 
0 
3 
  
1 
12 
10 
0.0 
6.8 
 
2.3 
27.3 
22.7 
    
Missed pills on the 
weekend 
Yes 
No 
36 
 8 
81.8 
18.2 
    
Last time you 
missed medications. 
Within past week 
Between1-2 weeks ago 
Between 2-4 weeks ago 
Between 1-3 months ago 
More than 3 months ago 
Never 
 7 
 4 
 4 
 7 
13 
9 
15.9 
  9.1 
  9.1 
15.9 
29.5 
20.5 
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Age was treated as a continuous variable in the analyses. The Pearson r correlation was 
used to examine the associations between age (range was 29 to 60 years) and self-reported 
adherence questions (1 and 6). There were no significant relationships between these items and 
the subject’s age. Kendall’s Tau correlation was used for the other three questions (2, 4, and 5). 
There were no significant relationships between these self-reported adherence items and the 
subject’s age.  (See Table 9).  
Three categories for highest level of education were created: less than high school 
education (n = 9), high school education or GED (n = 27), and greater than a high school 
education (n = 8). Marital status was grouped as follows: never married (n = 11), married or in a 
relationship (n = 13), and no longer married, divorced, separated, or widowed (n = 20). Race was 
grouped into two categories: white (n = 23) and non-white (n = 21). The latter group included 
those women who self-reported their race as Black/African-American, Hispanic, and biracial.    
Significant relationships were identified when using Kendall’s Tau to examine 
race/ethnicity groups, education, and marital status (Table 9). There was a moderately significant 
relationship between race/ethnicity and “missed taking any of your doses in the last 4 days” (r = 
.340, p = .021). There was a significant moderate relationship between education and “following 
dose instructions (i.e., 2 to 3 times a day)” (r = .346, p = .013) and a significant moderate 
relationship between education and “follow special instructions” (r = .420, p = .025). There was 
a significant moderate negative relationship between marital status and “following dose 
instructions (i.e., 2 to 3 times a day)” (r = -.333, p =. 017). There were no associations between 
exposure risk category and the five items of self-reported adherence. Therefore, hypothesis 2A 
was partially supported.  
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Table 9  Associations between socio-demographic variables and self-reported adherence (N =44) 
Self-reported Adherence  Age Education   Race  Marital 
Status 
Exposure 
Risk 
1.  Missed taking all of 
your doses in the last 4 
days. 
r = .003,  
p =.982 
r = -.257, 
p = .069 
r = .340,  
p = .021* 
r = .112,  
p =.426 
r = -.045, 
p = .759 
2.  Following dose 
instructions (i.e. 2 to 3 
times a day). 
r = -.077, 
p = .528  
r = .346,  
p = .013* 
r = .160, 
p = .271 
r = -.333, 
p =.017* 
r = .110,  
p = .445 
4. Follow special 
instructions. 
n = 26 
r = -.157, 
p =  .346 
r = .420, 
p = .025* 
r = .206,  
p = .290 
r = .000, 
p = .100 
r = .162,  
p = .400 
5. Missed pills on the 
weekend.  
 
r = .037, 
p = .772 
r = .188, 
p = .200 
r = -.257,  
p = .091 
r = -.276, 
p = .058 
r = .263, 
p = .082 
6. Last time you missed 
meds. 
r = .194,  
p = .208 
r = -.111,  
p = .395 
r = .024,  
p = .857 
r = .133,  
p = .304 
r = - 191, 
p = .156 
 
4.4.3 Specific Aim 3 
Examine the relationship between selected psychological factors (depressive symptomatology, 
social support, and perceived stigma) and self-reported adherence among women with 
HIV/AIDS who were prescribed antiretroviral medications. 
H3A: Women who report less depressive symptomatology will have better 
self-reported adherence to antiretroviral medications.  A Pearson r correlation for assessing self-
reported adherence “missed taking any of your doses in the last 4 days” and depressive 
symptomatology showed a weak significant association between these two variables (r = .315, 
p =. 040). There were no associations between the other self-reported adherence items using 
either the Pearson r correlation or Kendall’s Tau non-parametric procedure. Thus, this hypothesis 
was partially supported.  
H3B: Women who report strong social support will have better self-reported adherence 
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to antiretroviral medications. There were no significant associations between adherence and 
social support using either the Pearson r or Kendall’s Tau. This hypothesis was not supported.  
H3C: Women who report less perceived stigma will have better self-reported adherence 
to antiretroviral medications. The Pearson r correlation for self-reported adherence (questions1 
and 6) and perceived stigma demonstrated no significant relationships. Using Kendall’s Tau to 
examine self-reported adherence to questions 2, 4, and 5 and perceived stigma, resulted in one 
significant association was shown. Perceived stigma was significantly negatively associated with 
“following dose instructions” (r = -.275, p = .023).  There were no other significant associations 
between self-reported adherence and perceived stigma. Therefore, this hypothesis was partially 
supported. 
4.4.4 Specific Aim 4  
Examine the relationship between selected physiological factors (CD 4, viral load, HIV disease 
symptoms, and physical well-being) and self-reported adherence among women with HIV/AIDS 
who were prescribed antiretroviral medications. 
H4A: Women who report higher CD 4s and lower disease viral load will have better self  
reported adherence to antiretroviral medications. Only 26 women were aware of their CD 4. 
Self-reported adherence assessing “last time you missed meds” and CD 4 was significantly 
negatively associated (r = -.256, p = .031) using the Pearson r procedure. Self-reported 
adherence “following dose instructions (i.e., 2 to 3 times a day)” was significantly associated 
with CD 4 (r = .317, p = 0.12) using Kendall’s Tau. Of the 44 women, fifteen (34%) self-
reported their viral load and three (6%) self-reported their viral load as undetectable. There were 
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no significant correlations between self-reported viral load and self-reported adherence using the 
Pearson r or Kendall’s Tau. Thus, this hypothesis was partially supported. 
 H4B:  Women who report fewer HIV disease symptoms will have better self-reported 
adherence to antiretroviral medications. Using a Pearson r correlation for self-reported 
adherence and HIV disease symptoms there were no significant associations. There was a strong 
significant negative association between HIV symptoms and “following dose instructions (i.e., 2 
to 3 times a day)” (r = -.427, p = .009), using a Kendall’s Tau non-parametric procedure.  
Therefore, this hypothesis was partially supported. 
H4C: Women who report better physical well-being will have better self-reported  
 adherence to antiretroviral medications. Using Pearson r and Kendall’s Tau there were no 
significant associations between physical well being and self-reported adherence. Therefore, this 
hypothesis was not supported.  
The Pearson r correlation was used to explore the possible relationships between the 
selected psychological factors or physiological factors. There were significant associations 
between depressive symptomatology and two variables, perceived stigma (r =. 482, p = .001), HIV 
disease symptoms r = .585, p = .000), and a trend for a negative relationship with CD 4 (r = -
.294, p =.056). Social support was significantly negatively associated with perceived stigma (r = 
-.497, p = .001) and HIV disease symptoms (r = -.316, p = .036). Perceived stigma was 
significantly negatively associated with CD 4 (r -.310, p = .041) and physical well being (r = -
.358, p = .018) with a trend for a relationship with HIV disease symptoms (r = .291, p = .055).  
In addition, there was a significant negative relationship between HIV disease symptoms and 
physical well-being (r = -.358, p = .018). These associations are represented in Table 10. 
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Table 10  Associations between variables (N =42) 
Variable Depressive  
Symptom-
atology 
Social 
Support 
Perceived 
Stigma 
CD 4 Viral load HIV 
Disease 
Symptom 
Physical 
Well -
Being 
Depressive  
Symptomatology 
1 r = -.272, 
p =  .078  
r =. 482,  
p = .001 
r = -.294, 
p =.056 
r = -.075, 
p = .632 
r = .585, 
p = .000 
r = .002, 
p = .990 
 
Social Support  1 r = -.497, 
p = .001 
r =. 267, 
p = .080 
r = -.119, 
p = .440 
r = -.316, 
p = .036 
r = .199,  
p = .201 
 
Perceived 
Stigma 
  1 r -.310, 
p = .041 
r = .090, 
p = .561 
r = .291, 
p = .055 
r = -.358, 
p = .018 
 
CD 4    1 r = -.014, 
p = .928 
r = -.78, 
p = .617 
r = -.212, 
p = .172 
 
Viral load     1 r = .117, 
p = .448 
r = -.261, 
p = .091 
 
HIV Symptoms      1 r = -.358, 
p = .018 
 
Physical Well –
Being 
      1 
 
4.4.5 Specific Aim 5 
Examine the mediating effect of self-efficacy on the relationship between selected psychological 
factors (depressive symptomatology, social support, and perceived stigma) and selected 
physiological factors (CD 4, viral load, HIV disease symptoms, and physical well-being) and 
self-reported adherence among women with HIV/AIDS who were prescribed antiretroviral 
medications.  
H5A: Self-efficacy will mediate the relationship between selected psychological  
factors (depressive symptomatology, social support, and perceived stigma) and self-reported 
adherence to antiretroviral among women with HIV/AIDS.  
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H5B: Self-efficacy will mediate the relationship between selected physiological   
factors (CD 4, viral load, HIV disease symptoms, and physical well-being) and self-reported 
adherence to antiretroviral medications among women with HIV/AIDS.  
The self-efficacy measure includes a total score and two subscales scores: self-efficacy 
beliefs and outcome expectancies. The relationships between self-efficacy beliefs and self-
reported adherence for the five ACTG items were investigated prior to examining the possible 
mediating effect of self-efficacy.  
Using the Pearson r, there was a significant negative association between the self-efficacy 
beliefs and self-reported adherence “last time you missed meds” (r = -.310, p = .041). Using 
Kendall’s Tau, there was a significant association between the self-efficacy beliefs subscale 
score and self-reported adherence “missed pills on the weekend” (r = .257, p = .047).   
The Pearson r was used to examine possible associations between self-efficacy beliefs 
and the psychological predictor variables (depressive symptomatology, social support, and 
perceived stigma). The self-efficacy beliefs subscale was significantly associated with social 
support (r = .394, p = .008).  The Pearson r was used to examine possible associations between 
self-efficacy beliefs and the physiological predictor variables (CD 4, viral load, HIV disease 
symptoms, and physical well-being). There were no significant associations between self-
efficacy beliefs and the physiological predictor variables. Associations are presented in Table 11 
for self-efficacy beliefs subscale score and psychological and physiological predictor variables.  
The potential mediating effects of self-efficacy beliefs the variables were examined using 
the regression analyses techniques as identified by Baron and Kenny (1986). In this article, the 
authors describe a mediating variable as influencing the relationship between the independent 
variables and the dependent variables. Thus, the mediating variable, self-efficacy beliefs, has the 
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Table 11  Correlations between Self-efficacy Beliefs and Predictor Variables (N = 42) 
Variable Depressive  
Symptomatology 
Social  
Support 
Perceived 
Stigma 
CD 4 
 
Viral 
Load 
HIV  
Symptoms 
Physical 
Well- 
Being 
Self -
efficacy 
beliefs 
subscale  
r = -.045,  
p = .776 
r = .394,  
p = .008* 
r = -.243,  
p = .112 
r = .208, 
p = .175 
r = -.054, 
p = .727 
r = -.159, 
p =  .301 
r = .164, 
p = .292 
 
potential to provide additional insight about the relationships between the independent variables 
(depressive symptomatology, social support, perceived stigma, CD 4, viral load, HIV disease 
symptoms, and physical well-being) and the dependent variables of the ACTG self-reported 
adherence measure.  
The tests for mediation include the following steps (Baron & Kenny, 1986): Step 1, 
regress the mediator on the independent variables, Step 2, regress the dependent variables on the 
independent variables, which includes the five dependent variables of the ACTG and the seven 
independent variables, and Step 3, regress the dependent variables (ACTG items) on both the 
mediator (self-efficacy beliefs) and the seven independent variables. These analyses included 
linear regression with continuous dependent variables, items 1, 2, 4, and 6 and logistic regression 
with dichotomous dependent variables, items 3 and 5. Item 3, is concerned with the medications 
having special instruction, such as taking the medication with food. Twenty-six women 
responded yes to this answer; therefore, this item was explored in the logistic regression as this 
approach is used for dichotomous variables, such as a yes and no response. 
Step 1. The possible relationships between self-efficacy beliefs and depressive 
symptomatology, social support, perceived stigma, CD 4, viral load, HIV disease symptoms, and 
physical well-being were fit into a linear regression model using the SPSS default of enter (N= 
42). There were no significant relationships. However, using a step-wise approach yielded 
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significant results for a relationship between self-efficacy beliefs and social support 
(Unstandardized Beta = .431, R2 = .145, p = .013).  
Step 2. To explore the possible relationships between the ACTG continuous dependent 
variables, items 1,2 ,4, and 6 and seven independent variable each were fit into separate linear 
regression models (N= 42). There were significant associations as follows: a significant positive 
association between self-reported adherence (item 1) “missed taking any of your doses in the last 
4 days” and depressive symptomatology (Unstandardized Beta .035; R2 = .095, p = .047), a 
significant positive association between self-reported adherence (item 2) “following dose 
instructions, i.e., 2 to 3 times a day” and CD 4 (Unstandardized Beta .001; R2 = .138, p = .015), a 
significant negative association between self-report adherence “last time you missed meds” and 
CD 4 (Unstandardized Beta = - .001; R2 = .358,  p = .020).  The logistic model for items 3 and 5 
of the ACTG and the independent variables did not yield significant results.  
Step 3. The possible relationships between the dependent variables, self-reported 
adherence items 1, 2, 4, and 6 and self-efficacy beliefs, depressive symptomatology, social 
support, perceived stigma, CD 4, viral load, HIV disease symptoms, and physical well-being 
were further tested by fitting these variables into a linear regression model (N= 42).  The enter 
default mode was used for the analyses. There were significant associations between item 2 
“follow special instructions, i.e., taking medications 2 or 3 times a day” and CD 4 
(Unstandardized Beta = .001, t = 2.181, p = .036) and item 4 “following special instructions, i.e., 
taking with food” and perceived stigma (Unstandardized Beta = -.038, t = -2.360, p = .032. 
Using a step-wise linear approach yielded the following results: a significant positive 
association between self-reported adherence (item 1) “missed taking any of your doses in the last 
4 days” and CD 4 (Unstandardized Beta .035; R2 = .095, t = 2.046,  p = .047), a significant 
 120 
positive association between self-reported adherence (item 2) “following dose instructions, i.e., 2 
to 3 times a day” and CD 4 (Unstandardized Beta .001; R2 = .138, t = 2.530, p = .015), and a 
significant negative association between self-reported adherence “last time you missed meds” 
and CD 4 (Unstandardized Beta = - .001; R2 = .358, t = -2.423, p = .020).  These data are the 
same as above with self-efficacy beliefs entered into the regression model with all of the 
independent variables in step two.  
Due to the limited responses from the subjects for their CD 4 and viral load these 
independent variables were removed from the model and the data again explored. As in the 
previous analyses, there was a significant positive association between self-reported adherence 
(for item 1) “missed taking any of your doses in the last 4 days” and depressive symptomatology 
with the results the same as step two (Unstandardized Beta .035; R2 = .095, p = .047).  However, 
with CD 4 and viral load removed from the linear regression there was a significant negative 
association between self-reported adherence “last time you missed meds” and self-efficacy 
beliefs (Unstandardized Beta = - .026; R2 = .102, p = .040).  Using a logistic regression approach 
for categorical data of the self-report measure of adherence (ACTG) items 3 and 5 did not yield 
significant results. 
Additional regression analysis for all variables was conducted. This consisted of eight 
variables within the model, each variable was entered one at a time into the block in the 
following sequence: each self-reported adherence item as the dependent variable and 1) self-
efficacy beliefs, 2) depressive symptomatology, 3) social support, 4) perceived stigma, 5) CD 4, 
6) viral load, 7) HIV disease symptoms, and 8) physical well-being.  There was a significant 
association between self-reported adherence “missed taking any of your doses in the last 4 days” 
and depressive symptomatology. (See Table 12).  
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Table 12  Regression Model Summary (Missed taking any of your doses in the last 4 days).   
Model Variables R 
Square 
Unstandardized 
Beta Coefficient
Significance 
1 Self-efficacy Beliefs .073 -.012 .083 
 
2 Self-efficacy Beliefs 
Depressive Symptomatology 
.165 .034 .046 
 
3 Self-efficacy Beliefs 
Depressive Symptomatology 
Social Support 
 
 
.165 
 
 
.001 
 
 
.927 
4 Self-efficacy Beliefs 
Depressive Symptomatology 
Social Support 
Perceived Stigma 
 
 
 
.169 
 
 
 
-.004 
 
 
 
.667 
 
5 Self-efficacy Beliefs 
Depressive Symptomatology 
Social Support 
Perceived Stigma 
CD 4 
 
 
 
 
.194 
 
 
 
 
.000 
 
 
 
 
.299 
 
6 Self-efficacy Beliefs 
Depressive Symptomatology 
Social Support 
Perceived Stigma 
CD 4 
Viral load 
 
 
 
 
 
.201 
 
 
 
 
 
.000 
 
 
 
 
 
.581 
 
7 Self-efficacy Beliefs 
Depressive Symptomatology 
Social Support 
Perceived Stigma 
CD 4 
Viral load 
HIV Disease Symptoms 
 
 
 
 
 
 
.211 
 
 
 
 
 
 
.009 
 
 
 
 
 
 
.567 
 
8 Self-efficacy Beliefs 
Depressive Symptomatology 
Social Support 
Perceived Stigma 
CD 4 
Viral load 
HIV Disease Symptoms 
Physical Well-being 
 
 
 
 
 
 
 
.222 
 
 
 
 
 
 
 
.010 
 
 
 
 
 
 
 
.429 
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There was a significant association for self-reported adherence “last time you missed 
meds” and self-efficacy beliefs. (See Table 13). In fact, self-efficacy beliefs remained significant 
for several blocks in the overall model. Figure 3 represents the mediating effect of self-efficacy 
beliefs and the independent variable, depressive symptomatology and one ACTG adherence item 
“missed taking any of your doses in the last four days”.   
There were no other significant associations in the models using linear or logistic 
regression. Using a logistic regression approach for categorical data responses of the self-report 
measure of adherence (ACTG) items 3 and 5 did not yield significant results. Therefore, 
hypothesis 5A was partially supported. Hypothesis 5B was not supported; however, there is a 
strong trend for self-efficacy beliefs to mediate HIV disease symptoms and physical well-being.   
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Table 13  Regression Model Summary (Last time you missed your medications). 
Model Variables R 
Square 
Unstandardized 
Beta Coefficient
Significance 
1 Self-efficacy Beliefs .102 -.026 .040 
     
2 Self-efficacy Beliefs 
Depressive Symptomatology 
 
.046 
-.025 
 .046 
.039 
.128 
     
3 Self-efficacy Beliefs 
Depressive Symptomatology 
Social Support 
 
 
.156 
-.027 
 
 .005 
.046 
 
.750 
     
4 Self-efficacy Beliefs 
Depressive Symptomatology 
Social Support 
Perceived Stigma 
 
 
 
.156 
-.027 
 
 
-.001 
.049 
 
 
.939 
     
5 Self-efficacy Beliefs 
Depressive Symptomatology 
Social Support 
Perceived Stigma 
CD 4 
 
 
 
 
.225 
-.024 
 
 
 
-.001 
.070 
 
 
 
.083 
     
6 Self-efficacy Beliefs 
Depressive Symptomatology 
Social Support 
Perceived Stigma 
CD 4  
Viral load 
 
 
 
 
 
.225 
-.024 
 
 
 
 
-000 
.074 
 
 
 
 
.936 
     
7 Self-efficacy Beliefs 
Depressive Symptomatology 
Social Support 
Perceived Stigma 
CD 4 
Viral load 
HIV Disease Symptoms 
 
 
 
 
 
 
.260 
-.026 
 
 
 
 
 
-.029 
.055 
 
 
 
 
 
.212 
 Table 13 (continued)    
8 Self-efficacy Beliefs 
Depressive Symptomatology 
Social Support 
Perceived Stigma 
CD 4 
Viral load 
HIV Disease Symptoms 
Physical Well-being 
 
 
 
 
 
 
 
.260 
-.026 
 
 
 
 
 
 
.000 
.059 
 
 
 
 
 
 
.993 
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 R2 = .165, p = .046             
 
 
 
Depressive 
Symptomatology 
Missed taking any of 
your doses in the last 
4 days 
Self-efficacy 
Beliefs 
Figure 3  Path analysis of the mediating effect of self-efficacy beliefs on adherence 
4.4.6 Specific Aim 6  
Describe patterns of adherence in a subsample of women with HIV/AIDS who were prescribed 
antiretroviral medications using self-reported adherence and the Medication Event Monitoring 
System (MEMS). 
Using the ACTG, subject’s medications and self-reported adherence were assessed for the 4 days 
prior to the data collection. Subjects took from 2 to 5 different antiretroviral medications. Six 
subjects reported having special instructions for taking their medications (i.e., taken with food or 
on an empty stomach); two reported not following these instruction all of the time. One subject 
reported missing medications on the weekend (last Saturday or Sunday). Two of the ten subjects 
reported having missed their medications in the last one to two weeks.  One subject missed all of 
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one prescription for the last 4-day period. See Table 14 for antiretroviral medications information 
and self-reported adherence responses. Subjects are listed according to their specific medication, 
dosing regimen, and response to the ACTG items for the medication used with the cap.  
MEMS caps were distributed to a convenience sample of twelve women (23%). One cap 
was not returned. Eleven caps were returned and downloaded. One cap could not be read and the 
data were lost. Data were retrieved from 10 caps. Data were computed for 29 days for the ten 
subjects.  
Using the cap data, a subject was identified as adherent if she attained a 95% or greater 
adherence rate. A subject was identified as non-adherent if she attained a rate less than 95%. The 
three adherence rates were calculated in the following manner: First, dividing the actual number 
of cap openings by the prescribed number of opening during a designated 29-day period and 
multiplying by 100 for doses adherent. Second, days adherent was calculated computing the 
percent of days in which the subject opened the MEMS cap as prescribed. Third, a dose taken on 
schedule was calculated by computing the percent of days when the cap indicated removal of the 
medication at the correct time of day. For the ten women using the cap the following data were  
collected: doses adherent (M = 63.39%, SD = 27.60%, Range 6.60 to 90.00%), days adherent (M 
= 52.31%, SD = 28.85%. Range 2.70 – 90.00%), and doses taken on schedule (M = 42.63%, SD 
= 27.21%, Range 2.70 – 89.30%). 
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Table 14  Antiretroviral Medications and Self-reported adherence (n = 10). 
 
Medications 
prescribed 
and taken per 
day 
Schedule 
pill and 
doses per 
day 
Missed 
taking any 
in the last 4 
days 
Following 
dose 
instructions 
(i.e., 2 to 3 
times a day) 
 
Follow 
special 
instruction 
 
Missed 
pills on 
the 
weekend 
Last time 
you missed 
meds 
Sustiva 
Combivar 
 
1 pill x 1  
1 pill x 2 
0 
0 
 
All the time No 
instructions 
No 1-3 months 
Kaletra 
Zerit 
Epivir 
 
3 x 2 
2 x 2 
1 x 2 
0 
4 
0 
Most of the 
time  
No 
instructions 
Yes 1-2 weeks 
Combivar 
Viramune 
 
1 x 2 
1 x 2 
0 
0 
All of the 
time 
No 
instructions 
No > 3 months 
Reyataz 
Norvir 
Truvada 
 
2 x 1 
1 x 1 
1 x 1 
0 
0 
0 
All the time Yes - All 
the time 
No 
 
 
1 to 3 
months 
Epivir 
Viracept 
Ziagen 
 
2 x 2 
2 x 2 
1 x 2 
0 
0 
0 
All the time Yes - All 
the time 
No 1-2 weeks 
Sustiva 
Combivar 
 
1 x 1 
1 x 2 
0 
1 
All the time Yes - Some 
of the time 
Yes Within the 
past week 
Truvada 
Zerit 
Kaletra 
 
1 x 1 
1 x 2 
2 x 2 
0 
0 
0 
All the time Yes - All 
the time 
No Never skip 
Trizivir 
Reyataz 
Norvir 
 
1 x 2 
2 x 1 
1 x 1  
0 
0 
0 
All the time Yes - All 
the time 
No > 3 months 
Invirase 
Kaletra 
ZVD 
Viread 
Epivir 
5 x 2 
4 x 2 
1 x 2 
1 x 1 
1 x 1 
0 
0 
0 
0 
0 
All the time Yes - Some 
of the time 
No > 3 months 
Zerit 
Epzicon 
Reyataz 
Norvir 
1 x 1 
1 x 1 
2 x 1 
1 x 1 
0 
0 
0 
0 
All the time Yes- most 
of the time  
No > 3 months 
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Table 15  Cap Data for 29 Days (n = 10) 
Medication Information Cap Data 
Randomized 
Medication 
Frequency (dosing) 
of identified med 
 Percent of 
doses 
adherent  
Percent of 
days 
adherent 
Percent of days 
doses taken on 
schedule 
Sustiva 1 pill Once daily  100% 93.1% 89.3% 
Zerit 2 pills Twice daily  62.1% 44.8% 38.6% 
Viramune 1 pill Twice daily  100% 100% 31.6% 
Truvada 2 pills Once daily  83.0% 75.9% 82.1% 
Ziagen 1 pill Twice daily  84.5% 72.4% 63.2% 
Combivar 1 pill Twice daily  7.2%% 6.1% 4.7% 
Truvada 1 pill Once daily  82.8% 82.8% 71.4% 
Norvir 1 pill Once daily  86.2% 79.3% 57.1% 
ZVD 1 pill Twice daily  39.7% 3.4% 1.8% 
Zerit 1 pill Once daily  89.7% 89.7% 78.6% 
 
The ten women were equally divided between those that took a medication from the 
MEMS cap once or twice daily. When exploring the difference in means between taking a pill 
once vs. two times daily for percent of doses adherent, the women who took only one pill per day 
had a mean of 88.34% (SD = 7.1, Range = 82.80 – 100.00) vs. two pills per day with a mean of 
58.7% (SD =  36.7, Range = 7.20 – 100.00). The wide dispersion in standard deviation is 
reflected in the wide range of percentages adherent to one’s daily dose. Likewise for subjects 
taking a once daily drug verses those taking a twice daily drug there was a difference in percent 
of days adherent (M = 84.16 SD = 7.1, Range 75.90 - 93.10 vs. M = 45.4, SD = 41.96, Range 
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3.40 - 100.00) and percent of days following dosing schedule (M = 75.7, SD = 12.23, Range = 
57.10 - 89.30 vs. M = 27.98, SD = 25.46, Range = 1.80 - 63.20).  
Three women took only two medications with two of the women reporting perfect 
adherence in relation to doses for the last 4 days. One subject who took two medications daily 
was less than 10% adherent based on cap data. She also self-reported that she  (1) missed 
medications in the last four-day period, (2) missed her medications over the past week, (3) had 
difficulty taking her medications on the weekend, and (4) followed the special instructions for 
her medications “some of the time”. One subject who took five different antiretroviral 
medications reported perfect adherence, which was not reflected in the cap data. For this subject 
cap data reflect percent of doses adherent at 39.7%, percent of days adherent at 3.4% and percent 
of days doses taken on schedule at 1.8 percent. Five subjects who took three different 
antiretroviral medications all reported “perfect adherence” for the last 4 days on the ACTG self-
report measure; however, various percentages of doses adherent, number of days adherent, and 
on-time dosing of medications were reflected in the cap recording.  
The assessment of self-reported adherence is a retrospective recall of self-reported 
adherence 4 days prior to starting to use the MEMS cap.  These self-report data included the 
adherence patterns for all of the subject’s medications not just the medication included and used 
in the MEMS cap. Using the cap was prospective for the next 29 days. Using paired t-tests for 
doses adherent, days adherent, and doses taken on schedule and self-reported adherence 
suggested significant associations between the two measures. The self-reported adherence 
question “missed taking any of your doses in the last 4 days” was significantly associated with 
cap data: doses adherent (t = 6.89, (df 9) 95% CI; p = .000), days adherent (t = 5.498, (df 9) 95% 
CI; p = .000), and doses taken on schedule (t = 4.652, (df 9) 95% CI; p = .001). The self-report 
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adherence question “last time you missed meds.” was significantly associated with cap data: 
doses adherent (t = 7.134, (df 9) 95% CI; p = .000), days adherent (t = 5.363, (df 9), 95% CI; p = 
.000), and doses taken on schedule (t = 4.847, (df 9) 95% CI; p = .001). Using a chi-square 
procedure for the remaining self-report adherence items (2, 4, and 5) did not result in any 
significant associations.  
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5.0  CHAPTER FIVE 
5.1 SUMMARY OF FINDINGS 
This descriptive cross-sectional study had two overall purposes. The primary purpose was to 
describe the self-reported adherence patterns to antiretroviral medications for a sample of women 
with HIV/AIDS and factors that affected their self-reported adherence. In addition, the study 
examined the potential mediating effects of self-efficacy and the relationship this factor had on 
self-reported adherence for these women. The hypotheses were partially supported.  
Forty-four women were recruited as a convenience sample from western Pennsylvania 
and eastern Ohio. Seventy-five percent of the women lived in rural areas, small towns, or 
suburban areas. The mean age was 42.89 years. The women were almost equally divided 
between whites and non-whites; the latter group included three women of Latin descent.  
Approximately 80% of the women had a high school education or its equivalent; 18% had an 
education beyond high school.  Seventy percent of the women were single, divorced, widowed, 
or separated. Only five women were employed full-time; three were employed part-time. 
Twenty-eight women were identified as disabled.  Twenty-eight women did not report their 
income with 12 women reporting an income of less than $20,000 annually. Thirty-five women 
reported their insurance as coming from Medicare or Medicaid. Nearly all identified their 
exposure to HIV as being through heterosexual contact. 
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The findings showed that there was a significant relationship between race/ethnicity, 
marital status, and education and one’s self-reported adherence to antiretroviral medications. 
There were significant relationships between depressive symptomatology, perceived stigma, CD 
4, and HIV disease symptoms and self-reported adherence to antiretroviral medications. Social 
support and physical well-being failed to show a significant relationship with one’s self-reported 
adherence. The data suggested interrelationships among variables including social support; 
however, only two variables, depressive symptomatology and CD 4 contributed to one’s self-
reported adherence in the regression model. In addition, self-efficacy had a mediating effect 
between depressive symptomatology and self-reported adherence.  
Within the larger study, a small group of twelve women agreed to use an electronic event 
monitor (MEMS) cap for a period of 29 days. However, data were available for analysis for only 
ten subjects MEMS caps. One subject failed to return her MEMS cap despite attempts to contact 
her by telephone and mailing her an additional return envelope. Data were irretrievable from one 
cap and could not be downloaded into the file. Data from the caps were examined for rates of 
adherence. These data were compared to the self-reported adherence data. Based on the MEMS 
cap data, seven (70%) of the women achieved a dose adherence rate of 80% or better. Two of 
these seven women achieved a dose adherence rate of 95% or better in terms of dose adherence. 
Three women were less than 80% adherent; one subject achieved only 7% adherence.  For 
percent of days adherent, two women were adherent 93% or more of the days they used the 
MEMS cap. However, these two women only followed their dosing schedule 82% and 89% of 
the time respectively. Thus, 80% of the this subsample of women with HIV using the MEMS cap 
did not achieve the recommended 95% level of adherence for taking their medications as 
prescribed daily or taking their medications at the appropriate time intervals.  Another woman 
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with a dose adherence and percent of days adherent was only achieved percent of doses taken on 
schedule 32% of the time.  
5.2 DISCUSSION OF THE FINDINGS 
The sample of 44 women was approaching middle age with 9 (20%) of the women age 50 years 
or older. The white subjects represented HIV positive women in rural areas and small towns in 
western PA and eastern Ohio. These women obtained their HIV health care from rural clinics in 
their area. The majority of the non-white subjects were from a large urban inner city and 
receiving their HIV health care from a university-affiliated clinic.  
Although small towns have non-whites with HIV disease living in their communities, 
these women did not participate in the study or may have received their HIV care from the larger 
metropolitan area or local health care provider. The rural areas of western PA are predominately 
white, whereas the metropolitan/inner city area has a larger non-white population. There is very 
little racial/ethnic diversity throughout this section of western PA and eastern Ohio with less than 
1% of the population being of Asian or Latin ethnicity. Thus, this sample reflected the 
populations of the respective areas. 
Neither the subject’s age nor exposure risk category was significantly associated with 
self-reported adherence.  Non-white subjects were less adherent over the last 4 days then their 
white peers (r = .340, p = .021) with white subjects achieving 91% adherence.   Increased 
education was associated with better adherence; women with greater than a high school 
education reported adherence at 87.5% vs. women with less than a high school education who 
reported adherence of approximately 11% (r = .420, p = .025).  In addition, women who were no 
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longer married were adherent 48% of the time in following special medication instructions; their 
single or married peers were less adherent.  
The above findings reflect the variability of the effects of socio-demographic factors on 
self-reported adherence to antiretroviral medications as reported in the literature. Kalichman et 
al. (1999) reported that low literacy (education) was associated with decreased adherence, while 
Kleebeerger and colleagues (2001) reported African-Americans were less adherent to their 
antiretroviral medications than white subjects. There is a gap in the literature regarding the 
impact of marital status on adherence to antiretroviral medications. However, it may be that 
women no longer in a relationship strive for better adherence because if they become ill there 
may be limited availability of another person to care for them. Or, these women may be more 
focused on meeting their personal needs.  
Although Wilson et al. (2002) reported younger participants in their study were less 
adherent to antiretroviral medications, Murphy and colleagues (2004) reported the opposite with 
older subjects being less adherent.  For this study, age did not influence self-reported adherence 
to antiretroviral medications. The mean age of the women in this study were approximately 43 
years old. 
Self-reported adherence did not attain the desired 95% rate recommended in the literature 
(Paterson et al., 2002; Yeni et al., 2002; 2004). However, 34 (77%) of the women reported they 
had not missed taking any of their antiretroviral medications during the previous four-day period. 
It may be that these women were truly adherent to their medications, they were unable to 
adequately recall their patterns of medication taking for the previous four-day period, or there 
may have been some degree of subject bias to over-or-under reportiing their adherence. In the 
subsample of ten women who used the electronic cap (MEMS) dose adherence was 80% or 
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better for seven out of the ten subjects. These data may reflect an accurate account of adherence 
for this sample of women with HIV/AIDS. That said, when the sample of 10 women were 
divided between those taking medications once vs. twice daily, the once daily group (n = 5) was 
more adherent in the taking of medications daily, doses taken daily, and following their 
prescribed schedule. These data may suggest, at least for this small sample of five women that 
pill burden influenced adherence. 
Among the 34 women who reported missing their medications “last time you missed 
medications”, seven (20.6%) of these women, reported that they missed taking their medications 
during the last week and 28 (82.4%) reported that they missed taking their medications more 
than one week ago. Being involved with the day-to-day activities in their lives represented the 
most frequently identified reasons for missing antiretroviral medications. Weekend activities 
were not identified as a frequent reason for missing medications with only eight women 
reporting weekend activities as a problem.      
Adherence to one’s antiretroviral medications remains a pivotal issue for persons with 
HIV. The fact that there are medications to suppress the replication of the HIV virus is a 
blessing; however, taking these medications has been shown to be a burden for some people 
(Erlen & Mellors, 1999). The proactive status of pharmaceutical companies in continuing 
research on HIV medications and combining, simplifying, and decreasing the “pill burden” has 
the potential to increase adherence (Portsmouth et al., 2005; Yeni et al., 2004). In fact, in the last 
few months a new medication has been introduced that combines three antiretroviral medications 
into one pill with once daily dosing. However, these advances in management of HIV do not 
negate the importance of HIV education and prevention; nor, is there a cure for HIV on the 
horizon. Likewise, reinforcement of patient adherence to antiretroviral medications must be an 
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ongoing intervention strategy used by health care providers (Paterson et al., 2002; Yeni et al., 
2002; 2004). 
Using The Center for Epidemiologic Studies-Depression Scale (CES-D), the level of 
depressive symptomatology approached a moderately high level in this sample of women (M = 
22.42) (Radloff, 1977).  Although the score for depressive symptomatology was well beyond the 
cut-point of 16, there was only a weak association with depressive symptomatology and self-
reported adherence to antiretroviral medications and that was for “missed taking any of one’s 
medications” in the last four-day period.  
Depressive symptomatology was associated with perceived stigma and the presence of 
HIV disease symptoms.  Perhaps, the perception of increased stigma contributed to depressive 
symptomatology. Likewise, more HIV disease related symptoms and/or medication related 
physical symptoms may have contributed to depressive symptomatology. That said, it was 
surprising there was no significant association between depressive symptomatology and physical 
well-being. 
Catz et al. (2002) reported a mean CES-D score of 24.9 for the 100 women in their study 
with over 50% of the women having scores suggestive of severe depressive symptomatology. In 
their earlier study of men and women with HIV/AIDS, Catz and colleagues (2000) reported that 
subjects who were adherent to their antiretroviral therapy had a mean CES-D score of 17.39 
while non-adherent subjects had a mean score of 27.38.  Phillips and colleagues (2005) reported 
a mean CES-D score of 24.1. Ickovics and colleagues (2001) reported that increased depressive 
symptomatology was also associated with decreased adherence. Thus, the finding of a high level 
of depressive symptomatology in this sample of 44 women with HIV reflects the work of other 
researchers, which may suggest that one’s depressive state may influence one’s ability to achieve 
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adherence. In addition, in the regression model, the relationship between self-reported adherence 
and depressive symptomatology was mediated by self-efficacy beliefs. 
Considering that the mean score for depressive symptomatology was high, it may have 
been important to assess who was or was not taking antidepressant medications. These data were 
not assessed for the first 18 subjects. The remaining 26 women were questioned during the 
telephone screening process about the use of all medications, including any medications that may 
have affected their mood or any medications for depression. Three women reported taking 
antidepressant medications; however, these data did not change the depressive symptomatology 
mean for the sample as a whole or the latter 26 women. This finding may suggest that depressive 
symptomatology may not be appropriately assessed during a primary care visit. It is also possible 
that some women did not report a change in mood state to their health care providers and/or 
some of the women in the study did not accurately report their use of antidepressant medications 
to the researcher.  Perhaps some women taking antidepressant medications were embarrassed to 
admit they were experiencing a change or problem in their mood, sleep patterns, appetite, or 
other symptoms often associated with depressive symptomatology. Katon (2000) addressed the 
failure of health care providers to diagnose and effectively treat depressive symptomatology in 
more that 50% of persons in the USA. Thus, depression is a hidden health problem for many 
people, not only persons with HIV/AIDS.  
The finding that the regression model suggested self-efficacy beliefs mediated the 
relationship between depressive symptomatology and self-reported adherence is important. This 
finding suggests that people’s beliefs or level of confidence that they can be successful with their 
medication regimen does indeed affect their behaviors. These findings also fit with the 
theoretical framework as noted in Chapter Two. As Bandura (1977) explained, when individuals 
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learn and perceive that their behaviors will result in a favorable outcome, they will strive for that 
desired outcome. For this study, the desired outcome, improved self-reported adherence to 
antiretroviral medications, was attainable despite a moderately high self-reported appraisal of 
depressive symptomatology. In addition, these women may have been mindful that non-
adherence could have produced a negative result; an increase in HIV disease related symptoms, 
opportunistic diseases, medication failure, and/or “being sick”. The level of adherence education 
provided by their health care providers was not assessed. 
The literature review demonstrated the importance of social support for women with HIV 
(Bova, 2001; Hudson et al., 2001; Misener & Sowell, 1998; Simoni & Cooperman, 2000). 
Responses to the measure of social support, the Interpersonal Support Evaluation List (ISEL) 
(Cohen & Syme, 1985) suggested that these women had a limited amount of social support (M = 
79.33). However, despite the significant negative relationships with stigma and HIV disease 
symptoms, social support was not identified as contributing to self-reported adherence in the 
bivariate correlations with the self-reported adherence items or in the regression models.  
Catz and colleagues (2002) used the ISEL for their study, reporting a mean of 106.80. 
Thus, the women in this study had less social support than those in the study by Catz et al. This 
was the only identified study that used the ISEL for men or women with HIV.  Like adherence, 
there are numerous measures for the assessment of social support. The ISEL does not include 
specific subscale sores for family, friends, or health care provider support. Perhaps, being able to 
assess these factors would have better captured the issue of social support for these women. 
Erlen and Mellors (1999) addressed the importance of a supportive relationship with one’s health 
care provider. The women in this study receiving care from the rural clinics appeared to have a 
close working and friendship type relationship with the nurses and case managers. Because some 
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of the women often traveled a great distance (i.e., 30 miles or more) to their clinic appointments, 
they may have viewed this as a social outing. Some women that may have desired to participate 
in the study felt they could not because they had other family members with them or had made 
“other plans” after their appointment.  A similar relationship may have existed at the university 
clinic; however, that was not observed.  Given these observations, it is possible that the rural 
clinic and university setting met the need of this sample for understanding and social support.  
The hypothesis that perceived stigma influences self-reported adherence was supported in 
part; although, there was not a relationship with self-efficacy beliefs.  Despite these limited 
results, perceived stigma was significantly associated with depressive symptomatology and 
social support, and significantly negatively associated with CD 4 and physical well being.  
Most of the research reported on perceived stigma is qualitative. Anecdotally, many 
women in this study remarked how difficult it was to live with HIV and how people treat you; 
however, if a woman provided an example of being stigmatized this was shared in confidence. 
Several women, as in Black and Miles (2002) study concealed their HIV status from their 
children, as well as from younger family members, i.e., nieces, nephews, and grandchildren.  All 
of the rural women who met in public areas near their homes were very guarded about seeing 
someone they may have known. Rural women who met at their clinic were open, friendly, and 
very eager to share their negative HIV experiences. One woman, who lived approximately 150 
miles from Pittsburgh, was not concerned about other people knowing her HIV status. She had 
the attitude that it was other peoples’ ignorance that was the problem, not her having HIV 
disease. Another woman described living with HIV as being like a cancer survivor but no one 
wants to celebrate your living with the disease, your survival, or your success – people just want 
to judge you for getting the disease. Yet another woman made reference to that fact “no one 
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knows you are sick with HIV, I don’t look sick, I look like all the other women in this place” 
(meaning the researcher and the female health care providers at the rural clinic). 
When exploring the subscale scores for perceived stigma there were several significant 
relationships among other variables, including social support. It may be that the measure of 
perceived stigma failed to capture the type of perceived stigma most prevalent for these women 
with HIV. There was no literature to support the relationship of perceived stigma and self-
reported adherence. Therefore, this may be the first study to examine the possible relationships 
of these variables for women with HIV and also the potential mediating effect of self-efficacy.  
CD 4 data were available for only 26 of the women and was significantly negatively 
associated with self-reported adherence defined as “last time you missed your medications” and 
significantly associated with “following dose instructions”. CD 4 was negatively associated with 
perceived stigma and physical well-being. There was a strong trend for a relationship between 
CD 4 with HIV disease symptoms. These relationships are interesting, given that self-efficacy 
had a mediating effect for depressive symptomatology and self-reported adherence in the 
regression models but not CD 4 and HIV disease symptoms, or physical well-being. Although 
there was not a significant relationship between CD 4 and self-efficacy, it may be that awareness 
of one’s CD 4 increases one’s self-efficacy beliefs; thus, improving one’s self-reported 
adherence to antiretroviral medications. The caveat to these CD 4 data is their lack of 
completeness. Eighteen of the women did not know their CD 4. Fifteen (34%) of the women 
were aware of their viral load; these data were not associated with self-reported adherence. In 
addition, viral load was not associated with any other factor; there were no strong trends in the 
data.  
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CD 4 and viral load data were incomplete for several subjects.  This may have occurred 
because the women were only aware of their status as “undetectable” for viral load, that 
laboratory values were not collected on a monthly basis, or that they did not want to report less 
than favorable data for the study. In light of this absence of data, if CD 4 and viral load are used 
in future studies, a medical record review would be recommended for gathering these data.  
However, this would not have been possible for this study given that many rural subjects were 
not enrolled and recruited from the clinic setting. That said, subjects or their health care 
providers may not have consented to a medical record review; thus, adding an obstacle to 
recruitment and enrollment.  Also, at the time the proposal was written for this study, CD 4 and 
viral load were suggestive of one’s adherence. The issue of medication failure and resistance was 
just beginning to emerge in the literature. At the present time, these clinical markers are not 
always suggestive of the individual’s adherence, especially in the absence of symptoms (Yeni et 
al., 2004).  A future study would not include these data for analysis unless a medical record 
review was completed. However, including a response item for knowing one’s CD 4 or viral load 
might be an example of how well the women were aware of their disease status and self-
management of their disease.    
Although, HIV disease symptoms did not contribute to the regression analyses as 
affecting one’s adherence to antiretroviral medications, there were several significant 
associations between variables. There was a significant association between HIV disease 
symptoms and depressive symptomatology and a negative association with social support. There 
was a strong trend for a relationship with perceived stigma. There was also a negative association 
with the self-efficacy beliefs. Considering these trends it may be fruitful to continue exploration 
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of the effect of HIV disease symptoms on one’s adherence to antiretroviral medications in future 
studies of women with HIV.   
Holzemer and colleagues (1999, 2001, 2004) have done extensive research on the effects 
of HIV disease and medication related symptoms. These authors have explored HIV disease 
symptoms in relation to depressive symptomatology (Holzemer et al., 1999), one’s quality of life 
(Hudson, Kirksey, & Holzemer, 2004), and self-care (Holzemer et al., 1999; 2001). Likewise, 
the presence of HIV disease symptoms has been associated with lower CD 4 and increased viral 
loads and poor adherence (Fletcher et al., 2004). As identified, these data may or may not 
currently reflect the individual’s adherence due to long-term use of antiretroviral medications 
and disease resistance and/or viral mutation (Yeni et al., 2004).    
The possibility exists the wording on the HIV disease symptoms measure was confusing 
to subjects. One subject did not understand the wording “not present today”. Three subjects 
reported they did not have any HIV disease or medication related symptoms. It is interesting that 
these three women also had scores of less than 16 for depressive symptomatology.   This 
instrument was selected because including gynecological symptoms and addressing symptoms 
that may be bothersome to women with disease. However, few women reported the presence of 
gynecological symptoms. The most frequently reported symptoms were fatigue, fear, joint pain, 
muscle aches, and gastrointestinal problems, such as gas, bloating, diarrhea, and nausea.  Given 
the age of these women, it is possible that they had learned to function and live with the HIV 
disease related symptoms and symptoms no longer were an issue for them. It is also possible that 
since the measure only assessed the presence of the symptoms “today” that the true nature of 
their symptoms, if present in the past, were not captured. Perhaps, the measure needs to be 
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revised to follow the self-reported adherence measure and assess the presence of symptoms for 
the previous 4-day period.   
There were no associations for physical well-being and self-reported adherence with 
bivariate correlations or in the regression models. In addition, physical well-being was 
significantly negatively associated with perceived stigma, which has been addressed. The fact 
that the physical well-being subscale score of the MOS-HIV failed to demonstrate a relationship 
with self-reported adherence in this sample was surprising.  
The research by Liu and colleagues (2006) demonstrated extensive improvement in one’s 
physical well-being when adherent to medications. Simoni and Cooperman (2002) also reported 
improved physical well-being with better adherence. However, there remains limited research on 
the relationship of self-reported adherence and one’s physical well-being. It may be that since the 
women in this study had lived with this disease for several years, they had adapted to changes in 
their physical well-being and no longer felt it affected their lives.  It is also possible that the 
MOS-HIV subscale of physical well-being failed to capture the essence of issues of physical 
well-being for these women. Another measure may have been a better choice or use of selected 
items for the measure may have provided a better assessment.  
The MOS-HIV has been used extensively and is well documented as a valuable measure. 
In the future, using this measure to assess the overall health related quality of life for women 
with HIV may prove to be more reflective of their lives.  Exploring their quality of life may also 
add valuable insight for increasing self-reported adherence. 
The theoretical framework, self-efficacy theory, is partially supported. The person, 
identified through the socio-demographic variables (age, education, race/ethnicity, marital status, 
and exposure risk category) had a direct relationship to one’s behavior, self-reported adherence 
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to antiretroviral medications. The subscale of self-efficacy beliefs demonstrated significant 
relationships with two of the self-reported adherence items; “last time you missed your 
medications”, and “missed pills on the weekend”. Using bivariate correlations, there was a 
significant relationship between self-efficacy beliefs and social support. There was not a direct 
relationship between the physiological variables (CD 4, HIV symptoms, and physical well-
being). However, based upon the definition of self-efficacy, the subscales score for self-efficacy 
beliefs was used to further explore the potential mediating effect.    
Self-efficacy beliefs were fit into the step-wise regression model suggested by Barron and 
Kenny (1986). Regression of the mediator (self-efficacy beliefs) on the independent variables 
using a step-wise approach contributed to the model with a relationship between social support 
and self-reported adherence. Regression of the dependent variables, the five items of the ACTG, 
and seven independent variables resulted in significant associations being demonstrated when 
using a separate linear regression for each ACTG item “missed taking your doses in the last four 
days” and depressive symptomatology, and “following doses instructions” and “last time you 
missed your meds” and CD 4.  And finally in the last approach, “following dose instructions” 
and “last time you missed your meds” resulted in significant relationships with CD 4 and 
perceived stigma.  
As noted previously, there were a limited number of responses for CD 4 and viral load. 
Therefore, the last approach was repeated with these variables removed from the analysis. This 
resulted in the identification of self-efficacy beliefs mediating the relationship between self-
reported adherence “missed taking any of your doses in the last four days” and one’s depressive 
symptomatology. In addition, self-efficacy beliefs had a significant affect on the model with self-
reported adherence item “last time you missed your medications” and depressive 
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symptomatology as well as for social support. These findings suggest that self-efficacy beliefs 
greatly affect one’s adherence to antiretroviral medications. The contribution of strong self-
efficacy beliefs also had a mediating effect on self-reported adherence despite the moderately 
high scores for depressive symptomatology.  
The significance of self-efficacy beliefs mediating depressive symptomatology has been 
discussed. The fact that the model was supported, at least in part, has also been addressed. These 
findings suggest an implication that reinforcement of one’s self-efficacy beliefs may be pivotal 
in increasing adherence. This is not to say, thorough patient education regarding the importance 
of 95% adherence or better to antiretroviral medications can be overlooked and not re-evaluated 
on an ongoing basis. Perhaps, when poor adherence is identified the health care provider and 
patient should discuss their “belief in their ability to be adherent”, which could identify barriers 
to adherence. Perhaps, designing an intervention program that will sustain and/or increase one’s 
self-efficacy beliefs may be a key for future research. For the women in this study, self-efficacy 
beliefs for their use of antiretroviral medications appear to assist in the management of their HIV 
disease and medication adherence.   
Only two of the 10 women in this study who used the MEMS cap achieved the 
recommended level of adherence. There was a “super adherer” with 117% adherence; however, 
subtracting 17 from 100 resulted in an adherence rate of 83%, far less than desired. Also, one 
woman had less than 10% adherence, which possibly skewed the finding for doses adherent (M = 
63.39), days adherent (M = 52.31), and doses taken on schedule (M = 42.63). However, 
examining the individual data for each of the 10 women, five women had an adherence rate of 
83% or better; two women had an adherence rate of 100%. One subject self-reported near perfect 
adherence; however, her cap data reflected adherence at less than 10 percent. There w was no 
 145 
association between percentage of adherence and the number of different antiretroviral 
medications a subject took daily. In addition, most subjects accurately self-reported their 
adherence when this finding was compared to the MEMS data.   
Bova et al. (2005) reported numerous obstacles when using an electronic measure 
including cap failure for refrigerated medications. Researchers suggest use of a self-report 
measure of adherence may be as successful as using an electronic device such as the MEMS cap 
for assessment of adherence (Bova et al; Levine et al., 2006). The use of the MEMS cap or any 
electronic measure also increases the cost of assessment, measurement, and data analysis.   
Eleven women agreed to use the electronic measure with 10 caps available for data 
analysis. One cap was “frozen” and data were irretrievable. The instructions for use of the cap 
took approximately 10 additional minutes to explain to these subjects. None of the subjects 
required additional information for use. Two subjects required additional phone calls to return 
the cap following the 29-day period. It may have been beneficial to have the subjects make an 
appointment to return the caps and re-evaluate their self-reported adherence. This may have 
captured their adherence patterns more accurately. 
5.3 LIMITATIONS OF THE STUDY 
5.3.1 Sample and Recruitment 
The most notable limitations in this study were the small sample size and the lack of diversity; 
three Latina women were recruited and enrolled in the study. Western PA and eastern Ohio lack 
cultural diversity. Unique to the study is the percentage of women that resided in rural areas and 
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small towns of western PA. People in this area of the state, as a whole, have limited access to 
merchandise, food supplies, home materials, and public transportation, as well as health care, 
medications, and other social service. Obstacles in recruitment contributed to the size of the 
sample size.  
Each subject was provided a stipend of $15.00 for completing the study. There were no 
blatant attempts to complete the study quickly. However, the clinic staff may have used the 
stipend as an inducement for subjects to consider participation. Thus, the sample may have been 
biased due to the needs of the potential participant and/or a desire to please the clinic staff. The 
staff, case managers, and nurses approached potential subjects at the rural clinics and university 
setting. Although this was advantageous in providing the study literature and introducing the 
study, this literature may have been distributed to those women who had established patterns of 
appointment keeping adherence, could use the stipend, and/or those that had participated in other 
studies. To increase recruitment and enrollment the researcher was present at the clinics on as 
many specific HIV clinic days as possible. This had the benefit of increasing recruitment and 
enrollment but may also have contributed to bias in the selection of potential participants.  
The cross-sectional nature of the study may have increased subject participation but may 
not have reflected the true nature of the participant’s self-reported medication adherence or 
factors for women as a whole in the area of recruitment. It is also possible that the snapshot 
assessment of self-reported adherence did not truly reflect the individual’s self-reported 
adherence. Therefore, collecting data over a period of weeks may have more accurately captured 
the selected factors as well as self-reported adherence.  
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5.3.2 Measures 
Women in this study completed multiple measures requiring on average 60 minutes. Several 
women completed the instruments in the 60 minutes or less.  However, after completing and 
submitting the measures, two women wanted to chat or visit with someone interested in women 
with HIV. Many of the women freely contributed personal information about themselves, their 
families, their living situations, and their experiences of living with HIV. This would have been 
an excellent opportunity to collect qualitative data. 
The neuro-cognitive measure could probably have been eliminated because it was 
another measure for the subjects to complete.  Including a self-reported history of severe mental 
illness as an exclusion criterion was probably adequate. Although the clinic staff expected 
literacy to be an issue and recommended a measure be included, this was only a problem for one 
subject. All of the instruments were organized in a random order except the measure of self-
reported adherence, which required the interview format. Nevertheless, the randomization of the 
measures may not have been adequate to reduce subject bias for the multiple measures. Subjects 
may also have decided to complete the measures differently than presented possibly contributing 
to some response bias.  
Perhaps the measure that was most difficult for participants was the self-report measure 
of adherence. Some women were unclear regarding what was meant by 4 days ago. It may have 
been helpful to have had a calendar present for subjects while completing this measure. In 
addition, using fewer items of the measure may have been less confusing for subjects.    
The fact that the measures were self-report was in and of itself a limitation, as subjects 
may over-or-under-report not only their adherence but other issues, such as perceived stigma or 
their sense of physical well-being. However, there is no other way to collect these subjective data 
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than through self-report. Adherence can only be accurately measured when the medication is 
directly observed as the subject swallows each and every pill. This is not feasible for community 
dwelling persons. This approach would not only be costly but also extremely time consuming 
and potentially limit the recruitment of subjects into any study.    
The analysis of the self-report measure of adherence was problematic. Only two items 
could be considered continuous data. One item was not a measure of adherence. Each question 
required separate analyses for bivariate correlations and regression analysis. The use of the two 
continuous items or another measure of adherence may have better captured the overall patterns 
of self-reported adherence. The questions regarding the types of medications taken and rationale 
for missing one’s medication were interesting but did not factor into the data analyses. 
Many measures have been used to assess social support. Perhaps it may be worthwhile to 
re-evaluate the relationship of social support and self-reported adherence by adding a qualitative 
aspect to this study. Including a taped dialogue recording may have suggested areas for social 
support interventions. These recordings may also have provided themes for addressing the 
perceived stigma of living with HIV. As mentioned, the inability of all subjects to report their 
CD 4 and viral load was problematic. In addition, as addressed previously assessing the presence 
of HIV symptoms over the previous 4 days may have captured the problematic nature of 
symptoms. And, using only select items from the MOS-HIV, such as role and social function 
rather than a composite score would have been beneficial. Finally, using a cross sectional 
research design did not allow for true cause and effect it merely suggests the potential for a 
relationship between variables of interest. 
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5.4 CONCLUSIONS 
 
The study, although limited in the total number of subjects recruited, may be the first to explore 
the relationship between perceived stigma and self-reported adherence to antiretroviral 
medications. There has been limited quantitative research addressing the relationship between 
social support and self-reported adherence for women with HIV. Although, social support was 
not related to self-reported adherence for these women, and did not contribute to the model 
overall, further investigation is warranted. Certainly, depressive symptomatology remains a 
major issue for women with HIV and interventions to address their depressive symptomatology 
may be a key factor in the future.  This study identified the significance of one’s self-efficacy 
beliefs in mediating self-reported adherence to antiretroviral medications, especially for women 
with depressive symptomatology. Furthermore, the study contributed to the body of knowledge 
regarding psychological and physiological variables that may affect self-reported adherence. The 
sub-study of women that used the MEMS cap suggested that women with HIV may accurately 
report their adherence to antiretroviral medications. 
5.5    IMPLICATIONS FOR THE FUTURE 
There continues to be a gap in the literature regarding issues that affect self-reported adherence 
to antiretroviral medications for women with HIV. This study is unique in that it examines these 
phenomena for rural dwelling white women in the north central part of the United States. This 
study is however, just the beginning and should be expanded. In the future it may be worthwhile 
to pursue the relationship of marital status on one’s self-reported adherence to antiretroviral  
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medications. In addition, it may be important to investigate the issue of aging and self-reported 
adherence behaviors in a larger sample of older women, particularly women over the age of 50.   
Since depressive symptomatology was so prevalent in this sample of women future 
research may need to explore the use of antidepressant medications and a psychotherapy 
intervention to decrease depressive symptomatology. Increasing the overall sense of mental well-
being, may ultimately increase one’s self-reported adherence to antiretroviral medications. 
This sample size of the study was small. However, this study began to explore and 
explain multiple factors and their potential relationships on self reported adherence to 
antiretroviral medications for women with HIV. It may be well served for persons with HIV to 
continue this research with a larger more diverse sample of women. Future research might 
explore the relationship between years taking antiretroviral medications and living with the HIV 
disease as a possible covariate to self-reported adherence. Because of the maturity of this sample 
it may be salient to limit enrollment to women older than 40 years of age. This study is not an 
end but a step toward better understanding of these phenomena for women with HIV residing in 
western PA and eastern Ohio. It is also a beginning of a research program for women with 
chronic disease, particularly for women with HIV. 
 
 
 
 
 
 
 
 151 
  
 
 
 
 
APPENDICIES 
 
 152 
APPENDIX A 
ADDITONAL FINDINGS 
Possible relationships between the psychological (depressive symptomatology, social support, 
and perceived stigma) and physiological variables (CD 4, viral load, HIV disease symptoms, and 
physical well being) of interest were examined using Pearson r correlations. Depressive 
symptomatology was significantly associated with perceived stigma (r =. 482, p = .001) and HIV 
disease symptoms (r = .607, p = .000). Social support was significantly negatively associated 
with perceived stigma (r = -.497, p = .001) and HIV disease symptoms (r = -.310, p = .040). 
Perceived stigma was also significantly negatively associated with CD 4 (r = -.310, p = .041). 
HIV disease symptoms was significantly negatively associated with physical well-being (r = -
.350, p = .022). 
The measures of social support and stigma each have four subscale scores that were not 
considered as separate factors for these analyses. However, due to the relationships between 
these variables and depressive symptomatology the subscale scores were investigated.  The 
social support measure consists of subscales for appraisal support, belonging support, tangible 
support, and self-esteem support (Cohen & Syme, 1985). The perceived stigma measure consists 
of subscales for personalized stigma, disclosure, negative self-image, and public attitudes 
 153 
(Berger et al., 2001). The Pearson r was used to examine the possible association between 
depressive symptomatology and social support subscales and perceived stigma subscales.  There 
was a significant negative relationship between depressive symptomatology and social support 
subscale, self-esteem (r = -.306, p = .046).  There were significant associations between 
depressive symptomatology and personalized stigma (r = .512, p = .000), negative self-image (r 
= .482, p = .001), and public attitudes (r = .484, p = .001). 
The Pearson r was used to examine possible associations between social support 
subscales and perceived stigma subscales. Personalized stigma was negatively associated with 
appraisal support (r = -.392, p =. 008), belonging support (r = -.553, p = .000), tangible support 
(r = -.458, p = .002), and self-esteem (r = -.386, p = .014). Negative self-image was significantly 
negatively associated with appraisal support (r = -.345, p =. 022), belonging support (r = -.445, p 
= .002), tangible support (r = -.471, p = .001), and self-esteem (r = -.480, p = .001). Public 
attitudes were significantly negatively associated with appraisal support (r = -.359, p = .017), 
belonging support (r = -.470, p = .001), tangible support (r = -.445, p = .003), and self-esteem (r 
= -.392, p = .008).  
HIV disease symptoms were significantly negatively associated with appraisal support (r 
= -.304, p =. 044) and belonging support (r = -.363, p = .016). HIV disease symptoms were 
significantly associated with personalized stigma (r = .394, p = .008).  
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